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This thesis described the design and synthesis of macrocyclic pentamers 
and helical oligomers and their applications in stabilizing telomeric DNA and 
RNA G-quadruplex in both Na+ and K+ solutions. The G-quadruplex structure 
presents a novel structural feature where a planar G-tetrad comprises four 
in-plane guanine residues with an electron-rich π-surface. And the stabilization 
of telomeric DNA and RNA has a critical effect on the telomere related 
project such as anticancer drug discovery.  
In chapter 3, a series of H-bond-rigidified nearly planar macrocyclic 
aromatic pentamers 1-8 containing no exterior side chains were synthesized. 
These compounds have tunable interior functional groups and were tested for 
their ability to stabilize DNA or RNA G4 structures. In this thesis, circular 
dirchroism (CD) was used to exam the change in Tm value for various RNA 
or DNA sequences in the absence or presence of pentamers 1-8. Given that the 
pentamer ligand 4, which contains 3 interior hydroxyl groups, could 
specifically recognize telomeric G4 RNA consisting of  repeating 
(UUAGGG) segments and successfully discriminate G4 RNA from G4 DNA 
and double-stranded DNA and RNA, it is interesting that this observation has 
not been previously noted. And the molecular docking results suggest that the 
steric hindrance and weak H-bonding capacities from interior methyl groups 
as well as H-bonding abilities of the amide and aromatic protons in 4 account 
for its specific recognition of telomeric RNA vs DNA G4 structure. Changing 
the interior methyl group to ethyl or isopropgyl groups or increasing the 
number of interior hydroxyl groups did not produce measurable improvements 
in their ability to stabilize telomeric RNA G-quadruplex structure. Overall, 
pentamer 4 is the best ligand among the eight macrocyclic pentamers tested in 
terms of selective recognition of telomeric RNA G4 structures in Na+ solution. 
 viii
Since most of the reported small molecule ligands that bind and stabilize 
G4 structures rely on (1) the stacking interactions of the G-tetrads with 
aromatic surface of the ligands and (2) the ionic interactions between 
positively charged amine groups in the ligands and the negatively charged 
phosphate groups in the oligonucleotides.  
In chapter 4, two positively charged H-bond rigidified macrocyclic 
aromatic pentamers 2 and 3 adopting a nearly planar geometry were designed 
and synthesized. As the pyridone block has very similar binding behaviors as 
hydroxyl group, ligand 4 containing one pyridone building block was designed 
and synthesized. As discussed in chapter 3, the introduction of more hydroxyl 
groups could further strengthen the interaction between the ligand and 
telomeric G-quadruplex. Correspondingly, pyridine units are incorporated into 
the aromatic structure to find out whether the binding affinities of the ligands 
can be further increased or not. Inspired further by Ivn Huc's work in 2007, 
acyclic oligomers (L1-L5) from monomer to pentamer were also synthesized 
and tested.  
Our results show that both pentamers 2 and 3 could specifically recognize 
particular telomeric G4 RNA and successfully discriminate human telomeric 
G4 RNA from human telomeric G4 DNA and double-stranded RNA. Binding 
affinity increases in the order of 1 < 2 < 3 with incorporating exteriorly 
arrayed cationic side chains and with the longer linker. This suggests the 
efficient ionic interactions between the properly spaced ammonium cations 
from the ligands and those phosphate anions from RNA backbones to be the 
dominant driving force for the formation of stable ligand•RNA complexes. 
These two ligands also selectively bind with c-kit2 and pu27. And the helical 
structures especially L5 also have strong binding toward telomeric RNA 
G-quadruplex, and selectively binding with c-kit1 and c-kit2. As to 2 and 3, 
they both display very good preferential stabilizations of telomeric RNA  vs 
DNA G-quadruplexes, and exhibit different binding behaviors toward c-kit1 
c-kit2 and pu27.  
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Chapter 1 Introduction 
1.1 Telomere and Telomerase 
The end of the chromosomes in all eukaryotic species have specialized and 
non-coding DNA sequences, together with associated proteins, are known as 
telomeres.1 In 1991, Elizabeth H Blackburn had found that the telomeres 
(which contain G-rich sequences) have the ability to allow the end of the 
linear chromal DNA to be replicated completely without the loss of terminal 
bases at the 5' end of each strand of this DNA.2 As conventional 
semiconservative replication only starts from 5' end to the 3' end, every cycle 
of replication will lead to loss of some segment of telomeric DNA (Figure 1.1). 
Once the length of telomere reaches a critical level, the cell division will cease, 
leading to the apoptotic cell death. This is the classical process of cell's life. 
However, telomerase, which is an ribonucleotide protein, can catalyze 
telomere extension and alter the cell's fate. In other words, the existence of 
telomerase at high levels may make the cells immortal and divide without 
limitations. The expression levels of telomerase in normal cells and tumor 
cells, however, are quite different. 
From 1994 to 1997, Shay and coworkers published a series of works to 
show that the telomerase are active in over 90% human cancer cells. In 
contrast, the activity of telomerase in normal somatic cells is low or 
undetectable.3 Based on this result, Greider and Langford proposed that the 
activity of telomerase is a necessary factor for tumor cell proliferation in 1996 
and 1997, respectively.4 This property of telomerase leads that it is a potential 
target for designing the anticancer drugs.4a If small drug-like molecules can 
associate with telomerase and further inhibit its activity, they can serve as the 
potential hit molecules for anticancer drug discovery. 
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Figure 1. 1: Scheme of conventional semiconservative replication. a) DNA duplex. b) 
Leading strand synthesis starts from the 5'-to-3' end and the lagging strand also start from 
5'-to-3' end which need the RNA primer to induce. c) RNA primers were removed, and a 5' 
gap will produce shortening daughter chromosomes after every successive replication rounds.  
 
With this expectation, much effort has been paid on discovering the 
structures and functions of telomerase. Telomerase is one kind of 
RNA-dependent DNA polymerase which is comprised of a protein component 
and a RNA template. RNA template works as the hands to catch the telomeres, 
and protein component works as a catalysis factory. The terminal of RNA 
template is complementary with human telomere which is comprised of 
(TTAGGG)n segments. Once the RNA template interacts with telomeres, the 
protein component catalyzes the telomere extension. However, the crystal 
structure of telomerase is not available yet, making it very difficult to design a 
molecule which can directly interact with telomerase. Telomerase is a 
ribonucleoprotein enzyme, and its RNA component could complement to the 















was developed to inhibit the activity of telomerase by targeting its RNA 
component. 
1.2 Telomerase Inhibition  
Antisense strategy is a method of inhibiting the activity of a certain gene to 
affect its expression. For telomerase, some nucleotides or ligands which can 
directly bind or cleave the telomerase RNA or inhibiting reverse transcriptase 
were designed or discovered. Two possible means to inhibit telomerase 
activity will be discussed in this section. One approach focuses on telomerase 
RNA template while the other focuses on the telomere 3'-overhang sequences 
to interfere the telomere reverse transcription. In the following, I will briefly 
discuss the first approach and elaborate in a more detail for the second 
strategy. 
1.2.1 Antisense Strategy: Telomerase Inhibition by Target 
Human Telomerase RNA Template   
In 1994, Blackburn and Strahl found that some nucleoside analogs can 
efficiently inhibit telomerase activities leading to the telomeres shortening. For 
example, Ara-G an analog derived from Arabinofuranyl-guanosine 
triphosphate (Ara-GTP), not only efficiently inhibited the telomerase activity 
but also produced a rapid telomere shortening in vegetative growing 
hymenra.6 Even though the exact interaction mode that directly or indirectly 
effect the telomere length has not been demonstrated, these analogs indeed 
effect the telomere metabolism. After this seminal work, some other 
nucleotides triphosphate such as 7-deaza-2'deoxyguanosine-5'triphosphate 
(7-deaza-dGTP) and 7-deaza-2'deoxyadenosine-5'triphosphate (7-deaza-dATP) 
were also found to have the ability to inhibit human telomerase activity.7  
Based on these discoveries, the complementary sequences of telomerase 
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RNA template were cloned in 1995. Since the human telomerase RNA 
template is complementary to telomere DNA, addition of the RNA sequences 
that are complementary to telomerase RNA template and that are therefore 
able to compete with telomeres shall lead to cease of telomere extension.8 This 
work showed that binding with telomerase RNA template can inhibit the 
activity of telomerase and subsequently lead to the cell apoptosis. As the RNA 
segment can affect the telomerase activity and length of telomere, modified 
oligonucleotides called peptide nucleic acids (PNAs) were also tested.9 By 
hybridizing with the telomerase RNA template, the PNAs can efficiently 
inhibit the telomerase activity. Different PNAs were synthesized that contains 
from 6 to 20 bases. High inhibition activities were found for PNAs with the 
increasing number of based from 6 to 11, and no significant improvements in 
activity can be found beyond 11 bases.  
After RNAs and PNAs segments were analyzed, the DNA segments were 
also explored to examine their ability to inhibit telomerase activity. In 1997, a 
hexameric phosphorothioate oligonucleotide which had human telomeric DNA 
segments 5'-(TTAGGG)-3' was obtained. This hexanucleotides competed with 
telomeres and inhibitsed telomerase activity in cell lysates.10 Above are some 
published about telomerase inhibition by interacting with telomerase RNA 
template. In summary, nucleotide analogs, RNAs, PNAs and DNAs segments 
were developed to competent binding with telomerase RNA template to inhibit 
telomerase activity. From these results, one remarkable finding was found that 
by targeting the telomeric DNA G-quadruplex structure which was found in 
various regions of telomere, the telomerase activity could be affected.11 Next I 
will discuss the strategy on stabilizing telomeric DNA G-quadruplex to inhibit 
telomerase activity. Much attention has been paid in this area to find out an 
effective way to stabilize telomeric DNA G-quadruplex, and subsequentely to 
inhibit telomerase activity.  
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1.2.2 Stabilization of Telomeric DNA G-quadruplex Structure. 
As the telomerase can catalyze the extension of telomere, stabilizing 
telomere G-quadruplex could be an effective way to inhibit telomerase activity. 
By researching the structure and function of telomere, scientists found that the 
telomere is one kind of G-rich sequences which could form G-quadruplex by 
hydrogen bonding.11 And the formation of DNA G-quadruplex could affect the 
telomerase activity. So by stabilizing the telomeric DNA G-quadruplex 
structure, the activity of telomerase possibly can be inhibited.3b, 12 With this 
taken into consideration, telomeric DNA G-quadruplex is now considered as a 
new anticancer drug target. 
Over the past two decades, this topic has attracted much attention.  
Various compounds have been designed to stabilize the telomeric DNA 
G-quadruplex structures and affect the process of telomeres extension.  
In this section the background of G-quadruplexes will be discussed. Firstly, 
the structures and functions of G-quadruplex will be summaried. Secondly, 
given that the conformation of G-quadruplexes have a great effect on the 
activity of telomerase, the functions of G-quadruplexes will be further 
discussed. Since G-quadruplexes stabilizers presumably are able to stop the 
cell divisions of cancer cells, various small molecules which can stabilize 
G-quadruplexes will be discussed accordingly in details. 
1.2.2.1 Human telomeric DNA G-quadruplex structure  
In the past decade, there are many papers published, investigating the 
topology of oligonucleotides G-quadruplex structure as there are a large 
number of telomere-like sequences that can from different G-quadruplexes. 
More importantly, the same sequences could form different structures in 
different ionic solutions13 or the solution containing the same type of cations at 
different concentrations12c as the G-quadruplex structures are cation-dependent. 
Many methods have been used, such as NMR, X-ray crystallography, circular 
dichroism and UV absorption.  
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Figure 1.2: Schematic representations for structurally determined G-quadruplex 
topologies studied and reviewed herein. The 5’- end is indicated by the gray shaded circle. 
Guanosines in black are syn, and those in gray are anti. The topologies are described as 
pertaining to one of the three quadruplex structural groups.(taken from Karsisiotis, A. I.; 
Hessari, N. M. a.; Novellino, E.; Spada, G. P.; Randazzo, A.; Webba da Silva, M., Topological 
Characterization of Nucleic Acid G-Quadruplexes by UV Absorption and Circular Dichroism. 
Angew. Chem. Int. Ed. 2011, 50 (45), 10645-10648.) 
 
To facilitate a rapid assess to the solution structure, one kind inexpensive 
light absorption spectroscopic method such as circular dichroism (CD) was 
used as the primary method. This method replies on the facts that the different 
glycosine bond angles (GBA) show different CD spectra curves from which 
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solution structures can be derived. The G-quadruplex solution structures can 
be classified into three groups as shown in Figure 1.2.14  
 
Figure 1.3: CD spectra for a set of standard structurally characterized quadruplex 
topologies. a) CD Spectrum for parallel stranded quadruplexes (group I). b) CD spectrum 
for group II quadruplexes. c) and d) CD spectrum for group III quadruplexes. (taken from 
Karsisiotis, A. I.; Hessari, N. M. a.; Novellino, E.; Spada, G. P.; Randazzo, A.; Webba da Silva, 
M., Topological Characterization of Nucleic Acid G-Quadruplexes by UV Absorption and 
Circular Dichroism. Angew. Chem. Int. Ed. 2011, 50 (45), 10645-10648.) 
 
If all four guanosines have the same GBA, they form parallel-stranded 
G-quadruplex where the four strands have the same orientation and are 
classified as Group I. The typical peaks on the CD spectra include a negative 
peak around 240 nm and a positive peak around 265 nm (Figure 1.3a). For 
group II and group III, they are all anti-parallel stranded G-quadruplexes. The 
only difference is the orientation: in group II, three strands point up and one 
strand points down. The typical peaks on the CD spectra consist of a negative 
peak around 240 nm and a positive peak around 260-290 nm (Figure 1.3b). 
For Group III, two strands are up and two strands are down. The typical peaks 
on the CD spectra include a negative peak around 260 nm and a positive peak 
around 240 and 290 nm (Figure 1.3c).  
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By forming hydrogen bonds among the four guanosines, a planar structure 
called G-tetrad is formed that can be further stabilized by cation such as Na+ 
and K+. As will be summarized and discussed, a series of small molecules 
were synthesized which have a similar size with G-tetrad and have a planar 
aromatic surface.  
1.2.2.2 Telomerase inhibition by small molecules.   
As described at the beginning of section 1.2.2, telomeric DNA is comprise 
of guanine-rich sequences and human telomeric DNA is specially comprised 
of hexanucleotides segments (TTAGGG)n. These guanine-rich sequences can 
self-assemble to form G-quartets, via hydrogen bonds shown in Figure 1.4. 
Several G-quartets stack above each other to form the G-quadruplex structure. 
Unlike other DNA structures such as DNA duplex, telomeric DNA 
G-quadruplex could form a planar surface which allows for ligands to stabilize 
the G-quadruplex structure by aromatic π-π stacking forces. If some small 
molecules can selectively bind with the G-quadruplex structure, the telomeres 
could be stabilized, possibly hampering or inhibiting the telomere reverse 
transcription. And this provides the rational for us to design telomeric DNA 
G-quadruplex stabilizers. 
a)                             b) 
  
Figure 1.4: a)The structure of G-quartet. b) The structure of G-quadruplex.  
 
The first published compound which can target telomeric DNA 
G-quadruplex and work as telomerase inhibitor is 2,6-diamidoanthraquinone. 
It was designed by Stephen Neidle and Laurence H. Hurley in 1997.12a, 12c The 
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structure of 2,6-diamidoanthraquinone is shown in Figure 1.5. This compound 
has an aromatic planar surface which could stack with telomeric DNA 
G-quadruplex and the existence of positive charges, futher strengthens the 
interaction between ligands and telomeric G-quadruplex by ionic bonds. 
 





Figure 1.6: NMR spectra of DNA (d[T2AG3T]) and DNA in the presence of compound 
2,6-diamidoanthraquinone.(taken from Sun, D.; Thompson, B.; Cathers, B. E.; Salazar, M.; 
Kerwin, S. M.; Trent, J. O.; Jenkins, T. C.; Neidle, S.; Hurley, L. H., Inhibition of Human 




Sequence d[TTAGGGT]12c which can form parallel G-quadruplexes 
structure was tested and in the present of compound 2,6-diamidoanthraquinone 
the Tm value of this sequence was increased by about 20 degrees. In this paper, 
NMR titration was used and the imino proton signals of three guanine groups 
had a obviously shift from low to high fields (Figure 1.6). These results 
indicated that compound 2,6-diamidoanthraquinone indeed had a direct 
interaction with G-quadruplexes.  
The effect of compound 2,6-diamidoanthraquinone on the elongation of an 
18mer primer d[TTAGGGTTAGGGTTAGGG] was further investigate, 
proving that the G-quadruplexes structure was the target site that affected the 
activity of telomerase. 
In 1998, another important compound named TMPyP412b was reported 
and the structure was shown in Figure 1.5. This compound had an appropriate 
size to stack with DNA G-quadruplex structures. And the melting temperature 
of the DNA G-quadruplex increased when TMPyP4 interacted with it. The 
one dimensional NMR showed that there were apparent line broadening, and 
chemical shift of the imino signals indicated that the compound interacts with 
the G-quadruplex (Figure 1.7). From these NMR results, the author concluded 
that TMPyP4 targeted the G-quadruplexes which were formed by sequences 
d[TTAGGG], d[TTAGGGTT] and d[TTAGGGTTA].15 The IC50 of TMPyP4 
is 6.5 ± 1.4μM, suggesting a high efficiency for this compound to inhibit 
telomerase activity. 
And the binding mode between TMPyP4 and the other three telomeric 
DNAs d(G2T2G2TGTG2T2G2), d(AG3[T2AG3]3), and [d(T4G4)]4) might have  
an intercalative binding mode. This result was further improved by modeling 
which showed that this kind of intercalated complexes is possible.15 
In addition to TMPYP4, another cationic prophyrins TMPyP2 (Figure 1.5) 
was reported by Hurley in 1999.16 In this study, sequence 
5'-CATGGTGGTTTGGGTTAGGGTTA GGGTTAGGGTTACCAC-3' (G4A) 
was used. TMPyP2 has a very similar structure with TMPyP4, and the only 
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difference is that the N-methyl group on the pyridyl ring is closer to the 
prophine ring. Similar to TMPyP4, TMPyP2 also display a high ability to 
stabilize DNA G-quadruplex in Na+ and K+ solutions with the use of five 
equivalences of the compound. However, the IC50 value is almost 10 folder 
larger than TMPyP4. This implied that the ability of TMPyP2 to inhibit the 
telomerase activity was weaker than TMPyP4. This might be induced by the 
steric hindrance of TMPyP2. The N-methyl group of TMPyP2 not only 
makes the structure deviate from the coplanar structure but also decreases the 
likelihood of the ligands to stabilize G-tetrad via the π-π stacking interactions. 
 
Figure 1.7: 1H NMR spectra of TMPyP4 titrated into d(TTAGGGT) and compound TMPyP4 
marked as P. (taken from Wheelhouse, R. T.; Sun, D.; Han, H.; Han, F. X.; Hurley, L. H., 
Cationic Porphyrins as Telomerase Inhibitors:  The Interaction of 
Tetra-(N-Methyl-4-Pyridyl)Porphine with Quadruplex DNA. J. Am. Chem. Soc. 1998, 120 
(13), 3261-3262 ) 
 
In addition to TMPYP4, another cationic prophyrins TMPyP2 (Figure 1.5) 
was reported by Hurley in 1999.16 In this study, sequence 
5'-CATGGTGGTTTGGGTTAGGGTTA GGGTTAGGGTTACCAC-3' (G4A) 
was used. TMPyP2 has a very similar structure with TMPyP4, and the only 
difference is that the N-methyl group on the pyridyl ring is closer to the 
prophine ring. Similar to TMPyP4, TMPyP2 also display a high ability to 
stabilize DNA G-quadruplex in Na+ and K+ solutions with the use of five 
equivalences of the compound. However, the IC50 value is almost 10 folder 
larger than TMPyP4. This implied that the ability of TMPyP2 to inhibit the 
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telomerase activity was weaker than TMPyP4. This might be induced by the 
steric hindrance of TMPyP2. The N-methyl group of TMPyP2 not only 
makes the structure deviate from the coplanar structure but also decreases the 
likelihood of the ligands to stabilize G-tetrad via the π-π stacking interactions. 
 In 1998, Laurance H Hurley's group published a new compound named 
PIPER (N, N'-Bis[2-(1-piperidino)ethyl]-3,4,9,10-perlenetetracarboxylic 
diimide) as shown in Figure 1.5. 2D NOSEY NMR results showed that this 
ligand can bind with a human telomeric G-quadruplex which contain 
(TTAGGG)n segment by a threading intercalation mode. PIPER presented a 
good telomerase inhibition activity in a standard primer extension assay.17  
In 2001, another classical ligand called telomestatin containing 7 oxazole 
moieties was discovered by Kazuo Shi-ya (Figure 1.5). This compound is the 
metabolite of one kind of microorganism named as Streptomyces anulatus 
3533-SV4. It specifically inhibited the activity of telomerase (IC50 value is 
0.005 μM) but had weak affects on DNA polymerase activities and reverse 
transcriptase activities. Compared to TMPYP4 and 2,6-diamidoanthraquinone, 
telomestatin is the best compound for inhibiting telomerase with good 
selectivities.18 
In the same year, ethidium derivatives (Figure 1.5) were found to bind 
with the G-quadruplex especially antiparallel G-quadruplex structure with a 
high affinity (~107 M-1) and subsequently inhibited the activity of telomerase. 
The fluorescence results suggested that the florescence quantum yield of the 
oligomer was greatly increased when ethidium derivatives were added and the 
possible binding mode was intercalating or stacking. Native gel 
electrophoresis results showed that the existence of ethidium derivatives can 
help to form G-quadruplexes structure. The behavior of ethidium derivatives 
in a standard agarose gel proved that ethidium derivatives can be used as a 
DNA G-quadruplex formation probe.19  
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Figure 1.8: Structures of ligands which can stabilize the telomere G-quadruplex structures. 
 
Moreover, ligands 12459, BRACO-19 and Se2SAP (Figure 1.8) were 
reported. Ligand 12459 down regulates the telomerase activity in the human 
A549 lung carcinoma cell line.20 In contrast, the two other 
G-quadruplex-interacting reagents, telomestatin and BRACO-19, which had 
no effect on the hTERT splicing pattern in A549 cells, were cytotoxic against 
the A549-resistant clones and display a lower effect on stabilizing hTERT 
G-quadruplex.20 
The biological ability of BRACO-19 to stabilize G-quadruplex and inhibit 
telomerase activity was evaluated both in vitro and in vivo. The human utencs 
carcinoma cell line UXF 1138L was used to carry out the in vivo experiments. 
In vitro, BRACO-19 greatly decreased expression of the human telomerase 
reverse transcription. After 15 days, the length of telomere was shortened 
about 0.4 kb. In vivo, BRACO-19 also affected the expression of telomerase 
and led to telomere dyfunction. Both in vitro and in vivo results showed that 
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BRACO-19 indeed affect the copping and catalytic functions of telomerase.21 
As TMPyP4, compound Se2SAP was synthesized. In this paper, Taq 
polymerase stop assay was used and the results showed that Se2SAP greatly 
stabilized the single lateral-loop hybrid G-quadruplex which was 40 fold 
higher than TMPyP4. This is offered a possibility of selectively stabilizing 
different G-quadruplex.22  
The ligands discussed above are compounds with aromatic planar surface 
structures which have a very similars size as G-quadruplex or have strong π-π 
stacking with G-quadruplex. Most of them carrying positive charges can 
interact with phosphate groups from DNAs, producing strong interactions 
between ligand and G-quadruplex. However, the water solubility of these 
ligands was not very good. Below, I will discuss some ligands with aliphatic 
linkers and with their ends capped with amine groups. The existence of linker 
could strength the interaction with the loop and groove of G-quadruplex, and 
these kind ligands also present very good G-quadruplex stability and very 
good water solubility (Figure 1.8). 
In 2007, Ivn Huc and coworkers reported a series of macrocyclic and 
helical oligoamides which could greatly stabilize the telomeric DNA 
G-quadruplex. The new ligands selectively bind with G-quadruplex instead of 
DNA duplex. With the existence of terminated amine groups, all of these three 
compounds have good water solubility.23 Other ligands such as diarylethyl 
amides 24 and naphthalene diimide 25 containing amine groups at the end of the 
linker were also reported in 2008 and 2009, respectively. Both of them 
produced the telomerase inhibition. In 2010, Neidle and coworkers further 
modified the acridine structures by click chemistry.26 By click chemistry, a 
triazole group was introduced to connect acridine and alkyl-amine groups. 
Based on this design, a library of these compounds was generated. These 
compounds had selective effect on the cancer cell lines27 and led to the 
telomerase inhibition. Based on these reported results, it can be concluded that 
2 factors might greatly affect the interaction between ligands and 
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G-quadruplex structures. 
a. An aromatic planar surface in the ligands that can interact with the 
telomeric G-quadruplex by π-π stacking.  
b. Positive charges in the ligand that could help increase the strength of the 
interaction between ligands and telomeric G-quadruplex.  
After discussing DNA telomeric G-quadruplex, I will talk about the 
telomeric RNA and its G-quadruplex structure. 
1.3 Telomeric RNA and its G-quadruplex structure 
Recent findings demonstrate that telomere DNA was transcribed into 
telomeric repeat-containing RNA (TERRA) in mammalian cells.28 And these 
telomeric RNAs mostly containing (UUAGGG)n segments were present in 
various human and rodent cell lines mainly. In 2008, Julien Gros and 
coworkers found that in most vertebrates, there was a helix domain called P1 
helix which was located near to the telomerase RNA template.5 The sequence 
of P1 helix was a G-rich sequence and this sequence could form G-quadruplex. 
In this paper, the authors presented that the formation of G-quadruplex could 
inhibit the formation of P1 helix. And without the P1 helix, the activity of 
telomerase will be impaired.  
Based on these data, investigating the biology of telomeric RNA might 
lead to a new level of understanding the protection of chromosomes ends and 
discovering the secret of aging and cancer.29 As the human telomeric RNA has 
very similar sequences as human telomeric DNA, so discovery of the 
structures and functions of telomeric RNA could help to understand telomere 
and telomere-related biological significances and implications in drug 
discoveries. Until now, several methods such as NMR and X-ray crystallgraph 
have been used to discover the telomeric RNA structures and proved that the 
telomeric RNA could form G-quadruplex.30 The 2D NMR spectra of the 
solution structure of telomeric RNA G-quadruplex was obtained in 2002. The 
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structure was stabilized by base stacking and hydrogen bonds. The NMR 
results showed that this telomeric RNA G-quadruplex formed a parallel 
structure with sequence r(UGGGGU)4 in K+ solution.31 Subsequently, several 
other telomeric RNA sequences which can form G-quadruplex structure were 
discovered and two such sequences r(UAGGGUUAGGG) and 
r(AGGGUUAGGGUUAGGGUAGGG) attracted much more attention. Xu 
Yan30a and Anh Tuan Phan30b reported the solution structure of sequences r 
(UAGGGUUAGGG) and r (UUAGGGUUAGGGUUAGGGUAGGG) in Na+ 
and K+ solutions, respectively (Figure 1.9).  
 
Figure 1.9: Telomere RNA solution structure in Na+ and K+ solution.(taken from Xu, Y.; 
Kaminaga, K.; Komiyama, M., G-Quadruplex Formation by Human Telomeric 
Repeats-Containing RNA in Na+ Solution. J. Am. Chem. Soc. 2008, 130 (33), 11179-11184 ) 
 
Telomeric RNA G-quadruplex also followed the solution structure rule as 
shown in Figure 1.2. A lot of data showed that the telomere RNA preferred to 
form parallel G-quadruplex structures. And in solution, the telomeric RNA 
G-quadruplex could stack above each other. In 2009, Anh Tuan Phan30b and 
coworkers proposed that the loss of the terminated UUA structure led the 
telomeric RNA G-quadruplex stack together (Figure 1.10).  
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Figure 1.10: Scheme of telomeric RNA G-quadruplex stacking.(taken from Martadinata, H.; 
Phan, A. T. n., Structure of Propeller-Type Parallel-Stranded RNA G-Quadruplexes, Formed 
by Human Telomeric RNA Sequences in K+ Solution. J. Am. Chem. Soc. 2009, 131 (7), 
2570-2578 ) 
 
In 2010, Xu Yan and coworkers proved that human telomere RNA r 
(UAGGGUUAGGGU) can form a biomolecular G-quadruplex structure in the 
living cell, in this paper one light-switching probe was used.32 Next year, 
Neidle and coworkers reported that the telomeric RNA G-quadruplex and 
acridine form a stable complex and the crystal structure was also solved 
(Figure 1.11).33 From the crystal structure, it can be seen that a bimolecular 
G-quadruplex was formed and acridine was situated in the middle of these two 
telomeric RNA G-quadruplex structures.  
Recently, Xu Yan et al. reported that telomeric RNA and DNA can form a 
hybrid G-quadruplex structures.34 They suggested that this hybrid 
G-quadruplex structure play an important role in inhibiting cellular senescence 
as a telomere end protection, a piece of very valuable information for 
understanding the function and structure of human telomere RNA and DNA. 
These results might also lead to clinical relevances in the treatment of cancer, 
because the RNA molecules had obvious interactions with the telomeric 
DNA.34 Thus, telomeric G-quadruplex structure of RNA type may constitute a 
valuable drug target for researching new anticancer agents directly against 
telomeres. These data suggested that selective and directe targeting of 
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telomere RNAs by small molecules may help to clarify the role of telomere 
RNA molecules. However, there are few reports about ligands interacting with 
telomeric RNA G-quadruplex. So discovering the telomeric RNA 
G-quadruplex stabilizers is very important and interesting.  
 
Figure 1.11: Crystal structure of sequence r(UAGGGUUAGGGU) with ligand acridine. 
(taken from Collie, G. W.; Sparapani, S.; Parkinson, G. N.; Neidle, S., Structural Basis of 
Telomeric Rna Quadruplex−Acridine Ligand Recognition. J. Am. Chem. Soc. 2011, 133 (8), 
2721-2728.) 
 
It is well known that telomeric G4 DNAs represent a new class of 
molecular targets for designing DNA-interactive compounds.23, 35 A large 
number of G4 ligands have been reported to interact with telomeric G4 
DNAs23, 26, 36 and act as inhibitors of telomerase activity.26, 36b-d It is therefore 
important to discriminate between telomeric DNA and RNA G4 structures by 
small molecular ligands not only for discovering novel anticancer therapeutics 
with reduced clinical side effects and toxicity but also for discreening the 
biological roles of telomeric DNA and RNA G4 structures. In theory, the 
discrimination between telomeric DNA and RNA G4 structure could be 
achieved.25, 27, 37 In 2012, one in suit click chemistry was introduced to 
selectively bind with telomeric RNA or DNA telomeric G-quadruplex 
structures.38 In this paper, ligand selectively binds with telomeric RNA or 
DNA G-quadruplex and all the ligands presented no interaction with DNA 
 19
duplex. But until now, these kind of ligands which can selectively or 
preferrentially bind RNA telomeric G-quadruplex were rare. 
 Overall, the stability of RNA telomeric G-quadruplex by small ligands 
could be achieved and the discrimination between telomeric DNA and RNA 
G-quadruplex were very valuable in anticancer drug discovery.  
1.4 Aim of Study 
Ligands with macrocyclic aromatic ring have potential ability to stabilize 
telomeric DNA or RNA G-quadruplex structures. Here, we proposed to 
synthesize a series of hydrogen-bonding-mediated shape-persistent aromatic 
compounds as telomeric DNA or RNA G-quadruplex structure stabilizers. 
They have a similar size as G-quadruplex and the hydrogen bond is strong to 
fix the aromatic ring into a planar surface. These are the important factors to 
stabilize the G-quadruplex structure and subsequently inhibit the telomerase 
activity. 
In this regards, the aim of this thesis is to synthesize two series of ligands, 
both of which have the similar oligophenol-based backbond. For the first 
series, compounds were decorated with different interior functional groups and 
the second series of the compounds have two different exterior side chains 
with amine as terminal groups. Both series of these compounds take up an 
aromatic planar structure and all compounds are tested for their ability to 
stabilize the telomeric DNA and RNA G-quadruplex. Changes in Tm value are 
used to identify which compound is the best telomeric RNA G-quadruplex 
stabilizers in the terms of both binding affinity and selectivity.  
Inspirited by the results of Ivn Huc23, a serials of helical structures were 
also synthesized. With these compounds, we try to find out whether the 
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Chapter 2 Materials and Methods 
2.1 Materials 
All telomere DNA and RNA sequences are purchased from Sigma-Aldrich and the 
concentrations of all DNAs and RNAs were recalibrated by UV spectrophotometer at 
260 nm. All sequences are listed in Table 2.1. Buffer solutions (sodium phosphate, 
sodium chloride and potassium chloride) and water were all treated with 0.1% DEPC 
at room temperature for overnight and then autoclaved at 120 degree for 45 min. 
 
Table 2. 1: Telomere DNA and RNA sequences list. 
ID Sequences Note 
ORN1 r(UAGGGUUAGGGU) Bimolecular G41 
ORN2 r[AGGG(UUAGGG)3] Unimolecular G41a, 1c 
ORN3 r(UAUGCAUA) Duplex 
ORN4 r (UGUGGGAGGGGCGGGGUCUGGG) Unimolecular G42 
ORN5 r (GGGUGGGGGGGGCGGGGGAGGCCGGGG) Unimolecular G43  
ODN1 d[AGGG(TTAGGG)3] Unimolecular G44 
c-kit1 d (AGGGAGGGCGCTGGAGGAGGG) Unimolecular G45 
c-kit2 d(CGGGCGGGCGCGAGGGAGGGG) Unimolecular G46  
Pu27 d (TGGGGAGGGTGGGGAGGGTGGGGAAGG) Unimolecular G43  
Ds26 d(GTTAGCCTAGCTTAAGCTAGGCTAAC) Duplex 
2.2 CD Spectrophotometer 
CD spectra were measured using a Jasco model J-810 CD spectrophotometer. 
Samples were prepared by heating the oligonucleotides at 90 °C for 5 min and 
gradually cooling to room temperature. CD spectras were recorded at 25 degree using 
1cm path length quartz cuvette in a volume of 200 μL. The concentration of 
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oligonucletide is 5 μM. The wavelength of scanning is from 320 nm to 220 nm with 
100 nm/min scanning speed. Accumulated 3 times to derive average data, the 
background of blank sample was subtracted.  
In CD melting studies, diluted samples were equilibrated at room temperature for 
several hours to obtain equilibrium spectras. CD melting experiments were carried out 
at the same CD spectrophotometer using 1cm path length quartz cuvette in a volume 
of 200 μL and temperature range from 10 degree to 90 degree. The concentration of 
oligonucletide is 5 μM. The melting curves were obtained by monitoring the CD band 
at 260 nm or 290 nm. Except those specifically mentioned, all CD experiments were 
carried out under the same conditions containing 5 μM RNAs or DNAs and 5 μM 
ligands in buffered Na+ solution (200 mM NaCl, 10 mM Na-phosphate buffer, pH 6.8) 
or buffered K+ solution (5 mM KCl, 50 mM Tris buffer, pH 7.0). 
2.3 General Procedure for Isothermal Titration Calorimetry 
(ITC) 
Calorimetric titrations were set up in K+-tris or Na+-tris buffer (pH 7.0) with the 
use of 200 uL 30 μM of ORN2 in the sample cell and 40 uL 0.225 mM of pentamers 
in the syringe. For a typical titration, a total of 38.8 uL over 20 injections (1st 
injection at 0.8 uL and the remaining 19 injections at 2 uL) of ligand were titrated into 
the G-quadruplex solution (Stirring speed = 1000 rmp, initial delay = 60s, reference 
power = 5, spacing time = 400 s, temperature = 25 oC). The heat output per injection 
was obtained by integration and correction for the sample concentration and 
instrument characteristics. The corrected binding isotherms were fitted to obtain the 
Kb value, the number of binding sites (n) per G-quadruplex, and the enthalpy change 
(ΔH) associated with the interaction, using Origin 7.0 software (MicroCal Inc., 
Northampton, MA). A sequential fitting model using three binding sites gave the best 
fitting of the binding isotherms in almost all the cases studied. 
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2.4 Molecular Docking Studies  
2.4.1 Molecular Docking Studies on the Complexes Possibly Formed 
Between ORN1 and Pentamer 4 in Chapter 3. 
Each pentamer was first optimized at the level of B3LYP/6-31G* using Gaussian 
03 package and the minimized structure was used to calculate the HF/6-31G* 
electrostatic potential (ESP) from which the atomic charges used for molecular 
dynamics simulation were then derived using the RESP program implemented in the 
AMBER 9.0 package. For the pentamers we studied here, the possible binding 
orientations were first estimated using AutoDock 4.0. During the flexible docking, U1, 
U1', U12 and U12' flap tips are allowed to depart away to expose the binding sites for 
pentamer binding. Our docking simulations show that all the pentamers can occupy 
the spaces between flap tips and the neighbouring G-quartet. Next, explicit MD 
simulations were carried out to completely relax the binding complexes to determine 
the binding free energy. The one with the lowest binding free energy will be the most 
favorable binding structure. In the simulation, about 4400 TIP3P water molecules 
with 10 Å buffer were added around the complex. Na+ counterions were added to 
maintain the neutrality of the system. The simulations were carried out at 300 K with 
a time step of 2.0 fs. The non-bonded cutoff	was set to 12.0 Å and SHAKE algorithm 
was applied for all the bonds involving hydrogen atoms. After minimization with 
energy gradient less than 0.01 kcal/mol Å and equilibration for 200 ps, complex 
conformations were collected every 1 ps for the following 10 ns simulation. Finally, 
the last 5000 snapshots were collected for post-processing analysis and for free energy 
calculations. The free energy of pentamer binding to RNA is calculated by the 





interaction energy between the RNA and the ligand, Eelec, and the
differenceofthereactionfieldenergiesofthecomplex,thereceptorand
the isolated ligand, reacbindG , and the van derWaals interaction energy,
EvdW, and the change in themolecular surface area uponbinding, Δ
MBA. 
   89.20129.01048.0   MSAEGE CMSAEGEG vdWreacbindelec vdW
reac
bindelecbind               (1) 
The coefficients of these energy terms are calibratedby fitting to the
absolutebindingfreeenergiesforasetof99protein–ligandcomplexes.
The first two terms represent the electrostatic contribution to the
bindingfreeenergy,andthe lasttwotermsaccountforthenon-polar
contribution to thebinding freeenergy.Theenergy terms included in
thelinearequationareobtainedbyaveragingoveraseriesofsnapshots
fromMDtrajectorieswiththeprogramsietraj,andtheweightingterms
are fitted to experimental binding free energies. There is no explicit
entropictermintheequation;theentropiccontributiontothebinding
free energy is taken into account implicitly through the weighting
coefficientandtheconstant.)
2.4.2 Molecular Docking Studies on the Complexes Possibly Formed 
Between ORN1 and Pentamer 10 in Chapter 4. 
The crystal structure of RNA G-quadruplex of ORN1 was obtained from Protein 
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Data Bank (PDB ID: 3MIJ; J. Am. Chem. Soc. 2011, 133, 2721). Pentamer 3 was 
constructed with Schrodinger maestro. Docking was performed with Autodock 4.0 to 
make the pentamer have a favorable stacking of the macrocyclic aromatic 
coordination either on the top of G-quartet or in between the G-quartets. The 
relaxation of docking structures obtained was then implemented with molecular 
dynamics stimulations using PMEMD module of AMBER 10 program with ff03 force 
field to evaluate the binding affinity. TIP3P water molecules were added with the 
minimal distance between the complex and the edge of water box set as 10 Å. In order 
to maintain the neutrality of the system, K+ counterions were added. Non-bonded 
cutoff was set to 10.0 Å. SHAKE algorithm was applied with all bonds involving 
hydrogen atoms restrained. After minimization and heating up from 10 to 300 K for 
100 ps, productive MD was carried out at 300 K, with time step of 2.0 fs for 10 ns 
period, with complex conformations collected every 1 ps. For post-processing 
analysis and binding free energy calculation, all water molecules, counterions, and 
periodic boundary information were removed from the trajectory. Single-trajectory 
approach was used for all binding free energy calculations. 1000 regular snapshots 
from time interval with stable fluctuation (every 5 ps from 5001 to 10000 ps) were 
used for solvated interaction energy (SIE) using sietraj to calculate binding free 
energy. 
2.5 1H NMR Titration Spectra of ORN1 with pentamer 10 
NMR titration experiments were carried out on 500 MHz Bruker spectrometers at 
25 oC. A total of nine aliquots with first five aliquots at 0.5 uL and the remaining four 
at 1uL, 1.5uL, 2.5uL and 2.5uL of 5 mM solution of 3 in a 50 mM Tris buffer 
containing 90 mM KCl at pH 7.0 were titrated into 500 uL of ORN1 at 100 μM under 
the same buffer conditions. 
2.6 Native Gel Eectrophoresis 
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Native gel electrophoresis experiments were performed with 15% polyacrylamide 
(Acryaminde: Bis-acrylamide=37.5 :1) in TBE buffer (pH 8.3). At the experimental 
condition, all the telomere will form G-quadruplex and silver stain was choose to 
stained the gel. And sequence d(GGGTA) which could form G-quadruplex dimer was 
introduced as the marker. 
2.7 Binding and Kinetic Studies of SPR 
Binding events were monitored by surface plasmon resonance by using a 
BIACore X system with streptavidin-coated sensor chips (Sensor Chip SA). This chip 
consists of a gold platform and streptavidins immobilized carboxymethylated dextran 
layer at the surface. Sensor chips were treated with 1-min injection of 1 M NaCl in 50 
mM NaOH three times. Biotinylated 250 nM RNA (5’-Bio-r[UUU(UUAGGG)4] 
(ORN6), r[UUU(AUGCAUUUUUAUGCA)] (ORN7), or 250 nM [TTT(TTAGGG)4] 
(ODN2) in pH 6.8 Na-Phosphate buffer [500 mM NaCl]) was then flowed to 
immobilized on the surface of sensor chip through a biotin-streptavidin non-covalent 
coupling. Injection volume was 100 μM and a flow rate of it was 2 μl/min to achieve 
long contact times with the surface about 2500 resonance unit (RU). A 
non-G4-forming DNA was immobilized on the second channel to avoid non-specific 
interactions until sensorgram saturates. HBS-N (0.01 M HEPES, 0.15 M NaCl, 
BIACore) was used as running buffer. Samples dissolved in DMF were diluted as 
stock solution to 100 μM by water. After dilution by stock solution HBS-N to 0.5~10 
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Chapter 3 Neutral macrocyclic aromatic pentamers 
1-8 containing no exterior side chains for preferential 
stabilizations of telomeric RNA G-quadruplexes 
3.1 Introduction 
3.1.1 Background 
It was reported that the telomerase enzymes are active in 90% tumor cells. By 
discovering the structures and functions of telomere, scientists found that the telomere 
is one kind of G-rich sequences which could form G-quadruplex by hydrogen bond.1 
(Figure 1.4) And the formation of DNA G-quadruplex could affect the telomerase 
activity. While stabilizing the telomeric DNA G-quadruplex structure, the activity of 
telomerase can be inhibited.2 
Since 1997, the first compound 2,6-diamidoanthraquinon which can stabilize the 
telomeric DNA G-quadruplex structure and subsequently inhibit the activity of 
telomerase inhibition had been reported.2b During these 15 years, a lot of small 
molecular ligands were synthesized. Some of them are very potent in stabilizing 
telomeric DNA G-quadruplex structure and inhibiting telomerase activity. 
Recent milestone findings by Lingner and Blasco demonstrated the in vivo 
transcription of the telomere DNA into telomeric repeat-containing RNAs (TERRAs) 
in mammalian cells.3 The existence of TERRA RNAs may reveal a new level of 
regulation and protection of chromosome ends that could facilitate valuable insights 
into fundamental biological processes such as cancer and aging.4 Revealing the 
structure and function of telomere RNAs will be essential for understanding telomere 
biology and telomere-related diseases. In fact, some reports have shown by NMR and 
X-ray crystallography that human telomere RNA forms G-quadruplexes (G4).5 Xu 
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Yan and his coworkers demonstrated that human telomere RNA can form a 
bimolecular G4 structure in the living cells.6 (Figure 3.1) 
 
Figure 3. 1: Schematic structure of human TERRA RNA G4.( taken from Xu, Y.; Suzuki, Y.; Ito, K.; 
Komiyama, M., Telomeric Repeat-Containing Rna Structure in Living Cells. Proceedings of the 
National Academy of Sciences 2010, 107 (33), 14579-14584.) 
 
Recently, Neidle et al. reported a crystal structure of a telomere RNA G4 complex 
with an acridine ligand.7 (Figure 1.11) These data suggested that selective and direct 
targeting of telomere RNAs by small molecules may help to clarify the role of 
telomere RNA molecules. The proposed structures might also have clinical relevance 
in the treatment of cancer, as the RNA molecules may contribute to the telomeric 
alterations accompanying malignant transformation.3 Thus, telomeric G4 structures of 
RNA type may constitute a valuable target for researching new anticancer agents. 
It is well known that telomeric G4 DNAs represent a new class of molecular 
targets for designing DNA-interactive compounds.8 A large number of G4 ligands 
have been reported to interact with telomeric G4 DNAs9 and act as inhibitors of 
telomerase activity(Figure 3.2).9c-f  
It is therefore interesting to explore some ligands that can interact with telomeric 
G4 RNA and discriminate between telomeric DNA and RNA G4 structures. This kind 
of selectivity is important not only for discovering novel anticancer therapeutics with 
reducing clinical side effects and toxicities but also for discerning the biological roles 
of telomeric DNA and RNA G4 structures. Such highly-sought ligands specific for 
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RNA G4 structures, however, are hardly reported.8-9, 10 In principle, it is very possible 

































Figure 3. 2: Structures of the known telomeric DNA G4 stabilizers. 
3.1.2 Design Principle 
The G4 structure presents a novel structural feature where a planar G-tetrad 
comprises four in-plane guanine residues with an electron-rich π-surface. Most of the 
reported small molecule ligands that bind and stabilize G4 structures are based on the 
stacking interactions of the G-tetrads with aromatic surface of the ligands. Inspired by 
these findings, a series of H-bond-rigidified macrocyclic aromatic pentamers 1-8 
adopting a nearly planar geometry (Figure 3.3 and 3.4) were tested against DNA or 
RNA G4 structures. The G4 structure is cation dependent, especially for sodium and 
potassium ions. Based on our previous results, our compounds have a good binding 
affinity towards sodium and potassium cations by tuning the interior functional 
groups.12 With this consideration, up to 5 interior hydroxyl groups are included in 
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compounds 1-8. The existence of hydroxyl groups might help to stabilize the G4 as 
they could interact with cations. However, whether the more hydroxyl groups could 
lead to stronger stability of G-quadruplex and whether the existence of methyl groups 
are necessary or not are very clear to us. All these questions will be disscussed in 
results and discussion section. 
 
Figure 3. 3: Structures of macrocyclic aromatic pentamers 1-4 and schematic illustrations of steric 
bulkiness of interior methyl groups and protons as well as their roughly planar backbones. a, Chemical 
structures of pentamers 1‐4 rigidified by an intramolecular H‐bonding network. b, CPK representations 
that illustrate a progressively reduced steric hindrance imposed by the interior methyl groups as well as 
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a circular geometry contained within 1‐4 as revealed by the crystal structures of 1 and 2 as well as the 
ab initio optimized structures of 3 and 4 at the B3LYP/6‐31G* level. c, Distribution of steric bulkiness 
around the roughly planar backbones in 1‐4.  
All the experiments of CD, SPR were carried out in Na+ solution. Telomere can 
form the stable G-quadruplex structures in Na+ solution, however, not strong as in K+ 
solution. As the interaction between our pentamers and telomeric RNA or DNA was 
weak, the Na+ solution is suitable for our experiments which can show the obviousely 
change of the Tm value. The experiments in K+ solution were also carried out, but 
there is almost no change of the Tm value. 
 
 
Figure 3. 4: Structures of macrocyclic aromatic pentamers 5-8 and schematic illustrations of steric 






















































































3.2 Results and Discussion 
3.2.1 Synthesis of a series of Macrocyclic Pentamers 1-8 
To investigate the stabilization of G4 structures by our designed compounds, a 
series of macrocyclic pentamers were synthesized as shown in Scheme 3.1 to Scheme 
3.8. The monomer building block, methyl 2-hydroxy-3-nitrobenzoate, was 
commercial available. From the experimental results we found that the a stepwise 
synthetic scheme was a more efficient method to construct the backbone of most of 
the macrocyclic pentamers. For pentamers 1 and 8, one-pot reaction was used.   
For synthesis of pentamer 1, one-pot macrocyclization reaction was used.13 After 
reacting with dimethyl sulfide, monomer product 1a was obtained. After hydrolysis 
by NaOH and reduction by Pd/C in H2 atomsphere, 1a was charged into 1h (amino 
acid product). With the use of POCl3 and TEA in CH3CN, compound 1h underwent 
oligomerization reactions to form pentamer 1 with a yield of 46%. (Scheme 3.1)   
 
Scheme 3.1. Synthetic route of pentamer 1. 
After treating pentamer 1 with TBACl in CHCl3 solution at 60 degree around 12 
hours, the pure pentamer 2 was obtained with a yield of 83%. (Scheme 3.2) 
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Scheme 3.2. Synthetic route of pentamer 2. 






















































































1).Fe, AcOH, EtOH, reflux
2).1e,DIEA, CH2Cl2, r.t.




1).Fe, AcOH, EtOH, reflux
2).1M NaOH aqueous, dioxane, reflux
3).BOP, DIEA, CH2Cl2, N2, r.t.
Pd/C,H2, THF, 60 oC, 48 h
 
Scheme 3.4. Synthetic route of pentamer 4. 
In Scheme 3.3, two monomer building blocks 1a and 1b were used. Reduction of 
1a led to amine 1g, which underwent an amide coupling reaction with the acid 
chloride product 1f to form an oligoamide intermediate 2a. Following this kind of 
amide coupling reaction, the other three similar building blocks were added 
sequentially, producing the acyclic pentamer product 5a. By reduction of the nitro 
group and hydrolysis of the ester group, an amino acid intermediate was formed from 
5a. And this intermediate underwent an amide coupling reaction with the use of 
coupling reagent BOP to form cyclic pentamer 6a and subsequent de-benzylation to 
generate free hydroxyl groups that decorate the interior of pentamer 3 with a yield of 
81%. For Pentamer 4, 5, 6 and 7, the synthetic procedures are very similar with yields 
of 66%, 40%, 45% and 16%, respectively. (Scheme 3.4, 3.5, 3.6 and 3.7) 
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Scheme 3.5. Synthetic route of pentamer 5. 
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Scheme 3.6. Synthetic route of pentamer 6. 
 
Scheme 3.7. Synthetic route of pentamer 7. 
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As pentamer 1, pentamer 8 was synthesized following the one-pot reaction 
procedure. After reduction and hydrolysis, compound 1m was charged into amino 
acid 1o. With the use of macrocyclization regent POCl3 and TEA in CH3CN, 
compound 1o underwent a macrocyclization reaction to form pentamer 6f. In the 
presence of Pd/C and KOH in methanol solution, the allyl groups were removed to 
afford product 8 containing 5 hydroxyl groups in its interior with a yield of 12%. 
(Scheme 3.8)   
 
Scheme 3.8. Synthetic route of pentamer 8. 
3.2.2 Stabilizations of Telomeric RNA G4 structure by pentamers 1-8 
The G4 structure presents a novel structural feature where a planar G-tetrad 
comprises four in-plane guanine residues with an electron-rich π-surface. Most of the 
reported small molecule ligands that bind and stabilize G4 structures are based on the 
stacking interactions of the G-tetrads with aromatic surface of the ligands. Inspired by 
these findings, a series of H-bond-rigidified macrocyclic aromatic pentamers 1-8 
adopting a nearly planar geometry (Figure 3.3 and 3.4) were tested against telomeric 
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DNA or RNA G4 structures. A macrocyclic planarity in their aromatic backbones can 
be generally established by the crystal structures of 114 and 212 and the 
computationally optimized structures of 3 and 4 (Figure 3.3) at the B3LYP/6-31G* 
level that has consistently enabled us to accurately predict the 3D topography of 
oligomers of varying types that were later experimentally verified by crystal 
structures.15 Up to three hydroxyl groups were purposely introduced into the interior 
of 1-4 to examine the possible steric effects of interior methoxy methyl groups may 
have played on G4-ligand interactions. And two similar compounds 5 and 6 with 
more bigger functional groups such as ethyl or isopropyl groups were also synthesized 
to explore the steric effect between ligands and G-quadruplex. To find out the whether 
the cavity size of the compounds has a positive effect in stabilizing telomeric RNA 
G4, compounds 7 and 8 which have more than four hydroxyl groups were developed.  
As shown in Table 3.1, this is the RNAs and DNAs list which were used in this 
chapter. 
Table 3. 1: List of RNA and DNA sequences  
ID Sequences Note 
ORN1 r(UAGGGUUAGGGU) Bimolecular G4 
ORN2 r[AGGG(UUAGGG)3] Unimolecular G4 
ORN3 r(UAUGCAUA) Duplex 
ORN4 r (UGUGGGAGGGGCGGGGUCUGGG) Unimolecular G4 
ORN5 r (GGGUGGGGGGGGCGGGGGAGGCCGGGG) Unimolecular G4  
ORN6 biotin-r[UUU(UUAGGG)4] Unimolecular G4 
ORN7 biotin-r[UUU(AUGCAUUUUUAUGCA)] Duplex 
ODN1 d[AGGG(TTAGGG)3] Unimolecular G4 
ODN2 biotin-d[TTT(TTAGGG)4] Unimolecular G4 
c-kit1 d(AGGGAGGGCGCTGGAGGAGGG) Unimolecular G4 
c-kit2 d (CGGGCGGGCGCGAGGGAGGGG) Unimolecular G4  
Pu27 d (TGGGGAGGGTGGGGAGGGTGGGGAAGG) Unimolecular G4  
Ds26 d (GTTAGCCTAGCTTAAGCTAGGCTAAC) Duplex 
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3.2.2.1 CD Melting Experiment 
The ligands' ability to stabilize a telomeric RNA G4 structure was evaluated by 
CD melting experiments using the G4-forming RNA sequence r(UAGGGUUAGGGU) 
(ORN1, Table 3.1), which has been found to form a bimolecular RNA G4 structure.3a 
As shown in Figure 3.5 and Table 3.2, the pentamers progressively enhance the 
stabilization of RNA G4 structure with the increasing additions of hydroxyl groups 
into pentamers. The pentamer 4 appears as a remarkably strong G4 RNA stabilizer. 
 
Figure 3. 5: CD melting curves of bimolecular RNA G-quadruplex ORN1 20 μM with and without 1‐4 
at 10 μM monitored at 260 nm in the presence of 200 mM NaCl in 10 mM Na‐phosphate buffer at pH 
6.8. 
 
Table 3. 2: Ligand-mediated stabilizations of RNA G-quadruplex structure ORN1 by 1-4 using CD 
melting assays. 
Ligand –b 1 2 3 4 
Tm(°C) 41.5 42.7 44.0 46.8 47.4 
ΔTm(°C) – 1.2 2.5 5.3 6.2 
aTm and ΔTm ± 0.1 °C at 10 μM. bNo ligand is added. 
Of particular interest are ligands with high G4 structure affinity that exhibit the 
ability to discriminate RNA G4 structure from DNA G4 structure and RNA duplex. 
Toward this goal, we prepared 10 telomeric DNA and RNA substrates and elucidated 
ligand effects on the stabilization of these sequences. Firstly, ORN2, ORN3 and 
ODN1 were examined. The telomeric RNA substrate r[AGGG(UUAGGG)3] (ORN2, 
Table 3.1) and telomeric DNA d[AGGG(TTAGGG)3] (ODN1) form an 
intramolecular RNA G4 structure and an antiparallel DNA G4 structure in the 
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presence of Na+ ions, respectively. ORN3 [r(UAUGCAUA)] is a selfcomplementary 
RNA duplex substrate. As illustrated in Figure 3.5 and Figure 3.6, the CD melting 
curves of complexes of 4 with two G4 RNAs (ORN1 and ORN2), G4 DNA (ODN1) 
and the RNA duplex (ORN3) show that interaction of ligand 4 with the 
intramolecular G4 RNA (ORN2) is the strongest with respect to ORN1, ODN1 and 
ORN3. Indeed, ligand 4 gives a much higher ΔTm value with ORN2 than with 
ORN1 (9.9 °C vs. 6.2 °C at 10 μM, Table 3.3). To our surprise, no stabilization of 
either telomeric G4 DNA or duplex RNA by 4 was observed, even at high ligand 
concentration (50 μM, Figure 3.7); thus 4 is highly selective for telomeric RNA G4 
structure. 
Table 3. 3: Thermodynamical stabilizations of ORN2 the substrate by 4. 
RNA or DNA ORN 1 ORN 2 ORN 3 ODN 1 
ΔTm(°C) 6.2 9.9 0 0.5 
aTm and ΔTm ± 0.1 °C at 10 μM. 
 
Figure 3. 6: CD melting curves of (a) RNA r[AGGG(UUAGGG)3] (ORN2) 10 μM, (b) RNA 
r(UAGGGUUAGGGU) (ORN1) 20 μM, (c) DNA d[AGGG(TTAGGG)3] (ODN1) 10 μM, and (d) 
RNA r(UAUGCAUA) (ORN3) 10 μM in the presence of pentamer 4 (0 ~ 50 μM) monitored at 260 nm 
in the presence of 200 mM NaCl, 10 mM Na-phosphate buffer (pH 6.8), 5% DMF. 
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Figure 3. 7: CD melting assays for intramolecular RNA G-quadruplex ORN2 10 μM (●), bimolecular 
RNA G-quadruplex ORN1 20 μM (●), intramolecular DNA G-quadruplex ODN1 10 μM (●), and 
RNA duplex ORN3 10 μM (●) in the presence of 4 at varying concentrations (0 ~ 50 μM). The melting 
temperature of the structures without 4 is set at ΔTm = 0 °C 
 
As pentamer 4 is highly selective for telomeric RNA G4 structure, so the modified 
pentamer 5 and 6 were synthesized which were introduced bigger functional groups 
into the pentamers. Because pentamer 4 has good stability to ORN2 G4, here, 
pentamer 5 and 6 which have similar structures as pentamer 4 were used to exam their 
ORN2 G4 stability. As shown in Figure 3.8 and Table 3.4, the ligand 5 and 6 gave a 
ΔTm value around 2.9 °C and 1.6 °C with ORN2, respectively. With the increasing 
the size of the interior groups from methyl to isopropyl group, the ΔTm value has a 
greatly decrease from 9.9 °C to 1.6 °C. This means that the steric hindrance was 
increased and it will effect the stacking of ligand with RNA G4 structure.  
Based on the results showed in Table 3.4, it can be found that increase the size of 
interior functional groups will dramatically decrease the telomeric G4 stability of 
these aromatic macrocyclic pentamers. The exsitence of ethyl and isopropyl groups 
over the planar surface to affect the π-π stacking to the G-tetrad layer. To increase the 
size of interior groups gave negative effect on the stability of telomeric RNA 
G-quadruplex, then what will be occured when increasing the cavity size of these 
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compounds. To this question, pentamers 7 and 8 were synthesized and their stability 
towards ORN2 were also examined.  




















Figure 3. 8: CD melting assays for intramolecular RNA G-quadruplex ORN2 (5 μM) in the presence 
of pentamers 4, 5 and 6 at 5 μM monitored at 260 nm in the presence of 200 mM NaCl, 10 mM 
Na-phosphate buffer (pH 6.8), 5% DMF. 
Table 3. 4: Thermodynamical stabilizations of ORN2 the substrate by 4, 5 and 6. 
Ligand –b 4 5 6 
Tm(°C) 57.3 67.2 60.2 58.9 
ΔTm(°C) – 9.9 2.9 1.6 
bNo ligand is added 
  





















Figure 3. 9: CD melting assays for intramolecular RNA G-quadruplex ORN2 (5 μM) in the presence 
of pentamers 4, 7 and 8 at 5 μM monitored at 260 nm in the presence of 200 mM NaCl, 10 mM 
Na-phosphate buffer (pH 6.8), 5% DMF. 
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Table 3. 5: Thermodynamical stabilizations of ORN2 the substrate by 4, 7 and 8. 
Ligand –b 4 7 8 
Tm(°C) 57.3 67.2 57.6 48 
ΔTm(°C) – 9.9 0.3 -9.3 
bNo ligand is added 
 
As illustrated in Figure 3.9 and Table 3.5, the ΔTm value of ligand-G4 (ligand 7 
or 8) complex were decreased to 0.3 °C and -9.3 °C, respectively. With the increasing 
the cavity size of pentamers by changing methyl groups to hydroxyl groups, the ΔTm 
value has a greatly decrease from 9.9 °C to -9.3 °C. This means that increasing the 
number of hydroxyl groups could not increase the ability of stabilizing telomeric 
RNA G4. Apparently, the existence of methyl groups were necessary. However, 
without the crystal structure, we could not figure out what kind of reaction was 
included in this process.  
To investigate the selectivity of ligand 4, more telomeric RNA and DNA 
sequences which could form G4 were examined. As shown in Figure 3.10 and Table 
3.6, pentamer 4 has no stability to ORN4. As ORN5 could form very stable G4, the 
exactly Tm value were not collected. But from the CD curve, we can say that ligand 4 
could slightly stabilize the ORN4 sequence. 






























      
Figure 3. 10: CD melting assays for intramolecular RNA G-quadruplex ORN4 (5 μM) and ORN5 (5 
μM) in the presence of pentamer 4 at 5 μM monitored at 260 nm in the presence of 200 mM NaCl, 10 
mM Na-phosphate buffer (pH 6.8), 5% DMF. 
 
Moreover, sequences from the human c-kit1, c-kit2 and c-myc (pu27) promoters 
were also examined. As illustrated in Figure 3.11 and Table 3.6, no stabilization of 
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these three sequences was observed by ligand 4. At the same time, ligand 4 also could 
greatly discriminate the telomeric RNA G-quadruplex from DNA duplex (ds26) 
( Figure 3.11 and Table 3.6).  



































































Figure 3. 11: CD melting assays for intramolecular RNA G-quadruplex c-kit1 (5 μM), c-kit2 (5 μM), 
pu27 (5 μM) and ds26 (5 μM) in the presence of pentamer 4 5 μM monitored at 260 nm in the presence 
of 200 mM NaCl, 10 mM Na-phosphate buffer (pH 6.8), 5% DMF. 
 
Table 3. 6: Thermodynamical stabilizations of ORN4, ORN5, c-kit1, c-kit2, pu27 and ds26 by 4. 
DNA only 4  
Item 
Tm (oC) Tm (oC) ΔTm (oC) 
ORN4 67.7 67.9 0.2 
ORN5 >100 >100 - 
c-kit1 42.6 39.9 -2.7 
c-kit2 59.4 59.3 -0.1 
Pu27 57.6 58.8 1.2 
Ds26 52.8 52.0 -0.8 
 
From these data, we can conclude that pentamer 4 is the best compounds to 
stabilize the telomeric RNA G4 which containing (UUAGGG)n segments. It 
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presented very good stability to intramolecular telomeric RNA G4. In contrast, it 
almost had no binding to human telomeric DNA G4 which sequence is 
AGGG(TTAGGG)3 and other telomeric RNA and DNA sequences. Moreover, ligand 
4 could greatly discriminated telomeric RNA G-quadruple from RNA and DNA 
duplex. 
As ligand 4 is such good ligand, the discovery of binding affinity and binding 
mode of ligand 4 and telomeric RNA G4 were quite interesting. And SPR and 
molecular docking analysis were used to develop these relationships.   
3.2.2.2 SPR Binding Experiment 
Encouraged by these data, we further investigated the potential of ligand 4 as a 
selective telomeric RNA G4 ligand using surface plasmon resonance (SPR), which 
has proven to be a useful method to examine DNA/RNA-small molecule 
interactions.16 We prepared three different immobilized DNA or RNA targets: two 
G4es formed from either the telomeric RNA sequence biotin-r[UUU(UUAGGG)4] 
(ORN6) or the telomeric DNA sequence biotin-d[TTT(TTAGGG)4] (ODN2) and a 
double-stranded RNA biotin-r[UUU(AUGCAUUUUUAUGCA)] (ORN7) with a 
self-complementary sequence. The observed SPR binding curves are shown in Figure 
3.12 with their sensorgrams shown in Figure 3.13. Ligand 4 exhibits a significant 
response curve for telomeric RNA G4 structure (ORN6) at micro molar 
concentrations, whereas a response curve was not observed for telomeric G4 DNA 
(ODN2) and double-stranded RNA (ORN7). The dissociation constant (KD) of 4 for 
ORN6 was determined to be 1.8 μM. The SPR data shows a 1:1 stoichiometry for 
ligand-G4 binding, which is suggestive of a specific ligand-G4 interaction with a 
single guanine tetrad. The high affinity binding of 4 toward the telomeric RNA G4 
structure was consistent with the ΔTm values obtained by CD melting assay for 4, the 
ligand that induces the strongest thermal stabilization of intramolecular RNA G4 
structure (ORN2) with a ΔTm up to 9.9 oC (Table 3.3). 
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Figure 3. 12: SPR binding curves for the interactions between 4 and telomeric RNA G-quadruplex 
(ORN6, ■), telomeric DNA G-quadruplex (ODN2, ◆), and double‐stranded RNA (ORN7, ▲) using a 
running‐buffer containing 0.01 M HEPES and 0.20 M NaCl with the concentration of 4 varied from 0.5 
to 10 μM. The KD value calculated from SPR data was 1.8 μM for 4‐ORN6 complex with a 1:1 
binding stoichiometry. RU refers to response units at equilibrium. 
 
 
Figure 3. 13: SPR sensorgrams of the interaction of 4 with telomeric RNA G4 ORN6, telomeric DNA 
G4 ODN2, and double-stranded RNA ORN7 in the presence of 200 mM NaCl. The concentrations of 4 
were varied from 0.5 to 10 μM. 
 
3.2.2.3 Molecular Docking Analysis 
The additional inference on the binding stoichiometry between 4 and G4 RNA 
(ORN1) was achieved by carrying out molecular docking analyses (Figure 3.14).  
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Figure 3. 14: Structural optimization of complexes possibly formed between 4 (ball‐stick model 
mostly in green and red) and RNA G-quadruplex ORN1 containing two Na+ ions. a, 4 can attach from 
the top of RNA G-quadruplex, producing a stabilizing energy of 12.69 kcal/mol. b, 4 can attach 
alternatively from the bottom, producing a stabilizing energy of 11.62 kcal/mol. c, A 2:1 complex, (4) 
2:RNA, is also possible. 
 
During the flexible docking, U1, U1’, A2, and A2’ at the 5’ end are allowed to 
move freely. In the ligand-free RNA G4 structure, U1 and U1’ are pulled in toward 
the top G-quartet and adopt a closed conformation. When approached by 
RNA-binding ligand 4, three RNA-ligand binding modes may develop. Consistent 
with SPR data that reveal a 1:1 binding event, the calculated energies show that (1) 
attacking of 4 from the top of the RNA G4 structure (12.69 kcal/mol, Figure 3.14 a 
and 3.15 a) is energetically more favored than the attack from the bottom (11.62 
kcal/mol, Figure 3.14 b) by 1.07 kcal/mol and (2) a 1:1 binding stoichiometry 
between 4 and RNA (Figure 3.4a) is preferred over 2:1 binding mode (21.92 kcal/mol, 
Figure 3.14c) since the binding of the first molecule of 4 on the top of the RNA 
lowers the affinity of the bottom binding site in RNA toward the second molecule of 4. 
The latter can be clearly inferred from a difference of 9.22 kcal/mol in binding energy 
between 1:1 and 2:1 modes, a value that is 2.40 kcal/mol smaller than 11.62 kcal/mol 
for the attack from the bottom by 4 (Figure 3.14b). In the complex where 4 sits on the 
top of G-quartet (Figures 3.14a and 3.15a), our simulation shows that U1 and U1 ’ 
flap tips are departed away from the G-quartet to expose the binding site for 
recognition by 4 (Figure 3.15a). The 5’ hydroxyl proton H1 from the ribose of U1 
residue forms a strong intermolecular H-bond of 1.94 Ǻ with the amide O-atom O1 
from 4, which combines with another two additional H-bonds (H2•••O1 = 2.57 Ǻ and 
H3•••O1 = 2.45 Ǻ) to provide a strong anchor point. The RNA-4 complex is further 
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stabilized by a total of six weak H-bonds among H4-H10 and O2-O6 atoms (Figure 
3.15b) and by extensive aromatic π-π stacking interactions between aromatic 
backbone in 4 and the first G-quartet (Figure 3.15c). The comparable size between 4 
and G-quartet makes the G4 structure accommodate the ligand without a substantial 
steric clash, minimizing a distortion of the structure. 
 
Figure 3. 15: A 1:1 complex formed between 4 (green) and RNA G-quadruplex ORN-1 and the 
corresponding stabilizing forces. a, 4 sits on the top by molecular docking study; protons and oxygen 
atoms that participate in forming intermolecular H‐bonds are indicated by gray and red balls with the 
H‐bond distances shown in panel b. b, The distances of intermolecular H‐bond that stabilize the 1:1 
complex. A short contact between H5 and H6 is also observed in panel a. c, A top view illustrating a 
comparable size between 4 (green) and G‐quartet (yellow) and an occurrence of aromatic π‐π stacking 
interactions. 
3.3 Conclusion and Future Work 
Given that the pentamer 4 could specifically recognize telomeric G4 RNA which 
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containing (UUAGGG)n segments and successfully discriminate G4 RNA from G4 
DNA and double-stranded DNA and RNA, it is interesting that this observation has 
not been previously noted. Binding affinity increases with incorporating three 
hydroxyl groups into the pentamer ligand. This likely suggests a key role of steric 
hindrance and weak H-bonding capacities (Figure 3.15a-b) from interior methyl 
groups as well as H-bonding abilities of the amide and aromatic protons in 4 on its 
specific recognition of telomeric RNA G4 structure. Encouraged by these promising 
results, pentamer 5 and 6 which containing 3 interior hydroxyl groups were 
synthesized. The bigger size functional groups were introduced into the pentamer, and 
the steric hindrance lead to a great decrease of the Tm value. And circular pentamers 
containing 4 or 5 hydroxyl groups were also synthesized, as illustrated in Figure 3.9 
and Table 3.5, the increasing of interior hydroxyl groups could not further increase 
the stability of telomeric RNA G4. The existence of methyl groups are necessaries. 
Pentamer 4 could selectively recognize telomeric RNA G4 which containing 
(UUAGGG)n segments in Na+ solution. The experiments of CD were carried out in 
K+ solution, and there is almost no change of the Tm value. This might be due to that 
the interaction between pentamer 4 and telomeric RNA G-quadruplex structure is 
weak, and telomere could form very stable G-quadruplex strucuture in K+ solution. 
Prompted by the finding recently reported by Balasubramanian et al. on the design 
of a ligand capable of switching a parallel DNA G4 structure to an antiparallel one,17 
we reasoned that it might be possible to reversibly switch G4 conformation of RNA 
type by other pentameric ligands closely related to 4 in the future. And the water 
solubility of pentamer 4 is not good, some ligands which have good water solubility 
will be synthesized in future. These telomeric RNA sequences could form very stable 
G4 structure in K+ solution and the existence of pentamer 4 could not further increase 
their Tm value, in future we will try to synthesize pentamer 4 likely compounds to 
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Chapter 4 Cationic aromatic pentamers 9-11 as 
telomeric RNA and DNA G-quadruplex stabilizers 
4.1 Introduction 
4.1.1 Background 
As described in chapter 3, the activity of telomerase is an important factor that 
affects the apoptosis of tumor cells. Stabilization of telomeric G-quadruplex may 
inhibit the activity of telomerase and subsequently lead to the apoptosis of cancer 
cells.1 Many ligands have been designed and synthesized in the last 15 years and most 
of them exhibited good abilities of stabilizing telomeric DNA G-quadruplex and 
inhibiting telomerase activities. Recent findings by Lingner and Blasco demonstrated 
the in vivo transcription of the telomere DNA into TERRAs in mammalian cells.2 The 
existence of TERRA RNAs may reveal a new level of regulation and protection of 
chromosome ends that could facilitate valuable insights into fundamental biological 
processes such as cancer and aging.3,4,5,6,7 Revealing the structure and function of 
these telomere RNAs could be essential for the understanding of telomere biology and 
telomere-related diseases. In fact, the structure of human telomere RNA have been 
proven by NMR and X-ray crystallography and the results showed that human 
telomere RNA could form G4 structures (Figure 1.9 and 1.11).3 
Recently, Neidle et al. reported a crystal structure of telomeric RNA G4 complex 
with an acridine ligand.4b These data suggest that selectively and directly targeting of 
telomere RNAs by small molecules may help to clarify the role of telomere RNA 
molecules. The proposed structures might also have clinical relevance in the treatment 
of cancer, as the RNA molecules may contribute to the telomeric alterations 
accompanying malignant transformation.2,8 Thus, telomeric G4 structures of RNA 
type may constitute a valuable target for researching new anticancer agents directed 
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against telomeres. 
Xu Yan and his coworkers demonstrated that human telomere RNA9 can form a 
bimolecular G4 structure in the living cells (Figure 3.1).4a 
According to the knowledge of human telomeric DNAs and RNAs, many reports 
have been published to develop small ligands to stabilize the human telomeric DNA 
and RNA G-quadruplex. They presented very good stability to telomeric DNA 
G-quadruplex and discriminate particular telomeric DNA G-quadruplex from DNA 
duplex such as telomestatin10 and macrocyclic oligoamides5e.(Figure 4.1) 
a)                        b) 
 
Figure 4. 1: Structures of telomestatin and macrocyclic oligoamides. 
 
However, there are very few reports about selectively stabilizing telomeric RNA 
G-quadruplex or ligands showing a preferrence to stabilize telomeric RNA 
G-quadruplex. In 2008, compound 360 A was found to stabilize both telomeric DNA 
G-quadruplex and telomeric RNA G-quadruplex, however, 360A showed limited 
discrimination between these two kinds of G-quadruplex (Figure 4.2 a) even it had no 
stability towards DNA hairpin duplex.11 In this paper, sequences F21T 
(GGGTTA)3GGG (h-telo), FPf1T (GGGTTTA)3GGG, FPf8T (GGTTCA)3GGG, 
F21RT (GGGUUA)3GGG and hairpin duplex FdXT 
TATAGCTATAG8TATAGCTATA were used. F21T and FT21RT are human 
telomeric motifs.  
In 2010, a series of 24-membered polyoxazole compounds were synthesized and 
one of them which have a 5-(2-dimethylaminoethyl)- macrocyclic pyridyl 
polyoxazole had a very good stability to telomeric DNA G-quadruplex and telomeric 
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RNA G-quadruplex, especially for telomeric RNA G-quadruplex.12 (Figure 4.2 b)  
a)                                b) 
 
Figure 4. 2: The structures of a) 360 A, b) macrocyclic pyridyl polyoxazole. 
 
This compound could greatly increase the Tm value of hTel G-quadruplex DNA 
and AurA G-quadruplex RNA (r[AG4CG2CUG2UCG2AGUG2C] 5'-untrsanslated 
region of the mRNA) up to 20.5 degrees and 37 degrees, respectively. It prefers to 
stabilize RNA G-quadruplex, however, it has very cytotoxic to human breast cancer 
cells.  
Until now, there are no reports about ligands that could highly discriminate human 
telomeric RNA G-quadruplex rather than human telomeric DNA G-quadruplex. Even 
though the reports about discriminating human telomeric DNA and RNA 
G-quadruplex are rare, this is still a very important and challenging issue. Based on 
this, we analyzed a lot of previous works and designed a new series of side chain 
compounds. 
4.1.2 Design Principle 
It is well known that telomeric G4 DNAs represent a new class of molecular 
targets for designing DNA-interactive compounds.5 A large number of G4 ligands 
have been reported to interact with telomeric G4 DNAs5e, 6 and act as inhibitors of 
telomerase activity.6b-e It is therefore important to discriminate between telomeric 
DNA and RNA G4 structures by small molecule ligands not only for discovering 
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novel anticancer therapeutics with reduced clinical side effects and toxicity but also 
for discerning the biological roles of telomeric DNA and RNA G4 structures. Such 
highly-sought ligands that are specific to RNA G4 structures are not reported thus far. 
5,6,7 
As given in chapter 3, pentamer 4 was best compound which can lead to highesst 
Tm value of telomeric RNA G-quadruplex. However, when we tried to functionalize 
the exterior with linkers, we found that the benzyl groups was could remove. This is 
because when the existence of 5 linkers the steric hindrance was incrased and the 
reductive regent could not get into the benzyl group. As the G4 structure presents a 
novel structural feature where a planar G-tetrad comprises of four in-plane guanine 
residues with an electron-rich π-surface. Comparison of the molecular backbone of 
our recently reported pentamer 113 (Figure 4.3 a-c) with the G4 tetrad reveals a very 
similar dimensionality and molecular planarity between them, and a model of 
stabilization of the G4 tetrad and G-quadruplex structures by other closely related 
molecules derived from 1.14 Since most of the reported small molecule ligands that 
bind and stabilize G4 structures rely on (1) the stacking interactions of the G-tetrads 
with aromatic surface of the ligands and (2) the ionic interactions between positively 
charged amine groups in the ligands and the negatively charged phosphate groups in 
the oligonucleotides, two positively charged H-bond rigidified macrocyclic aromatic 
pentamers 9 and 10 (Figure 4.3) adopting a nearly planar geometry were designed and 
synthesized both in ~ 0.4 % after 11 steps (Scheme 4.1, 4.2).  
As discussed in last chapter, the increase in the number of hydroxyl groups could 
strengthen the interaction between ligand and telomeric G-quadruplex, in chapter 4 
ligand 11 which contains one pyridone block was synthesized (Scheme 4.3). The 
carbonyl group in the pyridone structure has stronger binding affinity to metal ions.  
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Figure 4. 3: (a) Chemical structure of pentamer 1 rigidified by an intramolecular H-bonding network. 
(b) and (c) describe the two hydrophobic caps made up of the interior methyl groups around the 
roughly planar backbones in 1 as revealed by its crystal structures.8a (d) illustrates a similarity in 
dimensionality and planarity between 1 (green) and a G4 tetrad (yellow). (e) Molecular design of 
cationic pentamers 9 and 10 derived from 1 for selective recognitions of RNA G-quadruplex structures. 
In (d), five interior methyl groups in 1 were removed for clarity of view, and the O-atoms from the 




Figure 4. 4: Chemical structures of ligand 11.  
4.2 Results and Discussion 
4.2.1 Synthesis of a series of Macrocyclic Pentamers 9-11  
 
 




To investigate the stabilization of G-quadruplex structures by our designed 
compounds, a series of macrocyclic pentamers were synthesized as shown in Scheme 
4.1-4.4.  
The starting material, 2,5-dihydroxylbenzoic acid, was commercially available. 
From the experimental results we found that a stepwise fashion was more efficient for 
constructing the aromatic backbones of all the macrocyclic pentamers.In Scheme 4.1, 
after the esterification of the starting material with sulfuric acid in methanol solution, 
ester product 1a was obtained. Then the alkyne group was attached to 1a to yield 
product 1b by a Williamson reaction. Followed by nitration and alkylation, monomer 
building block 1d was obtained and then treated with iron powder and acetic acid to 
afford amine product 1e, then this amine product underwent an amide coupling 
reaction with the acid chloride product 1f to form an oligoamide intermediate 1g. 
(Scheme 4.2) Following this kind of amide coupling reaction, the other three building 
blocks were added and the acyclic pentamer product 1j was formed. By reduction of 
the nitro group and hydrolysis of the ester group, an amino acid intermediate was 
formed. And this intermediate underwent an amide coupling reaction with the use of 
coupling reagent BOP to form cyclic Pentamer 1k, and subsequent by click chemistry 
two kinds of linkers 1m and 1o were introduced to the exterior of 1k to produce 
products 9a and 10a. Then the cyclic side chain products were treated with TFA and 
dichloromethane to generate the final products 9 and 10 .  
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Scheme 4.2: Synthetic route that affords pentamer 9 and 10 
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For the click chemistry, two commonly used conditions were tested. The first 
condition involves the use of copper(I) iodide as the catalyst in THF and triethyl 
amine as the base at room temperature for 12 h. The second set of conditions involves 
copper sulfate and sodium ascorbate as the catalyst in water/t-Butanol solution at 
room temperature for 24 h. By using the ESI mass to monitor the reaction, we found 
that the first condition led to the triazole product, and no deserved product was 
formed under second condition.  
For the first condition, even though the deserved product was formed, the starting 
material was not completely consumed. By increasing the reaction time to 2 days, the 
starting material was completely consuming. Purification of the reaction mixture led 
to a very low yield of around 11.5%. To improve the chemical yield, we tried different 
solvents and bases to identify the best reaction condition.  
Table 4. 1: Click chemistry with different solvents. 
Solvents Temperature Product 
THF r.t. Yes 
THF 35 oC Yes 
THF reflux Yes 
DMF r.t. Yes 
DMSO r.t. No product 
toluene r.t. No product 
Acetone r.t. Yes 
ACN r.t. Yes 
DCM r.t. Yes 
  
Table 4.1 lists the different solvents tested. In a typical procedure, compound 1k 
(2 mg, 2 μmol) was dispersed in 1 mL corresponding solvents. To this solution, 
triethylamine (40 μmol), copper(I) iodide (0.2μmol) and linker 1o (30 μmol) were 
added. The mixture was stirred for 2 days. After removal of the solvent, the residue 
was dissolved in CH2Cl2 (5 mL) and compared by using TLC method with ethyl 
acetate: CH2Cl2: MeOH=2:1:0.1 as the eluent. 
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By comparing the TLC plates, we found that in THF, DCM, acetone, ACN and 
DMF the product can be formed within 2 days. And THF and ACN seem to be good 
solvents for click chemistry with more intensive TLC spots. At different temperatures, 
40 oCis the best temperature for this reaction in THF. As the solubility of ligand 1k in 
ACN is not very good, THF was finally chosen as the reaction solvent for carrying out 
the click reaction. For DMSO and toluene, there is no product formed at room 
temperature and even at a temperature as high as 100 oC.  
Considering the above results, we chose THF as the solvent and subsequentely 
tried to find out the best base for this reaction. Totally 8 bases were used, which are 
listed in Table 2. Typically, compound 1k (2 mg, 2 μmol) was dispersed in 1 mL THF 
solvents. To this solution, corresponding bases (40 μmol), copper(I) iodide (0.2 μmol) 
and linker 1o (30 μmol) were adde. The mixture was stirred for 2 days. After removal 
of the solvent, the residue was dissolved in CH2Cl2 (5 mL) and all products were 
compared by using TLC method with the use of ethyl acetate: CH2Cl2: 
MeOH=2:1:0.1 as the eluent. 
 
Table 4. 2: Click chemistry with differnt bases. 
Bases Product Note 
TEA Yes  
NaH Yes Too much by-product 
DMAP+TEA Yes 
pyridine Yes 
Reaction was incomplete after 2 
days and much by-product was 
formed. 
NaOH Yes Too much by-product 
K2CO3 No  
DIEA Yes  
2.6-lutidine Yes Reaction was incomplete 
 
Comparing all these 8 bases, DIEA led to the most intensive spot for the product 
we are looking for on the TLC plate. K2CO3 couldn't produce any product, and NaH 
or NaOH lead to many byproducts. For DMAP/TEA or pyridine, most of the starting 
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material remained unreacted and many byproducts were also formed. 2,6-lutidine 
seems to be a good base for this click reaction, but long reaction time was needed. It 
takes 5 days to completely consume all of the starting materials. Overall, DIEA is the 







Figure 4. 5: The X-ray crystal structures of monomer 1w and its isomer allene product.  
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Table 4. 3: Crystal data and structure refinement for 1w. 
Identification code  b589a 
Empirical formula  C15 H18 N2 O5 
Formula weight  306.31 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pca2(1) 
Unit cell dimensions a = 15.734(2) Å = 90°. 
 b = 6.9369(9) Å = 90°. 
 c = 29.681(4) Å  = 90°. 
Volume 3239.6(7) Å3 
Z 8 
Density (calculated) 1.256 Mg/m3 
Absorption coefficient 0.095 mm-1 
F(000) 1296 
Crystal size 0.54 x 0.40 x 0.30 mm3 
Theta range for data collection 1.37 to 27.48°. 
Index ranges -20<=h<=20, -8<=k<=8, -38<=l<=27 
Reflections collected 21355 
Independent reflections 6170 [R(int) = 0.0671] 
Completeness to theta = 27.48° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9720 and 0.9504 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6170 / 3 / 411 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0715, wR2 = 0.1700 
R indices (all data) R1 = 0.0984, wR2 = 0.1893 
Absolute structure parameter -0.8(17) 









Table 4. 4: Crystal data and structure refinement for 1w isomer. 
Identification code  c094a 
Empirical formula  C16 H20 N2 O5 
Formula weight  320.34 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.463(3) Å   = 71.409(4)°. 
 b = 11.335(3) Å  = 78.343(6)°. 
 c = 17.528(6) Å   = 72.602(4)°. 
Volume 1688.4(9) Å3 
Z 4 
Density (calculated) 1.260 Mg/m3 
Absorption coefficient 0.094 mm-1 
F(000) 680 
Crystal size 0.46 x 0.27 x 0.10 mm3 
Theta range for data collection 1.96 to 27.50°. 
Index ranges -11<=h<=12, -14<=k<=14, -21<=l<=22 
Reflections collected 13896 
Independent reflections 7740 [R(int) = 0.0563] 
Completeness to theta = 27.50° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.3858 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7740 / 2 / 453 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0715, wR2 = 0.1748 
R indices (all data) R1 = 0.0997, wR2 = 0.1910 
Largest diff. peak and hole 0.724 and -0.547 e.Å-3 
 
As discussed in chapter 3, the existence of hydroxyl group can strengthen the 
interaction between ligands and telomeric G-quadruplex. And our previous study 
showed that the pyridone block had a very similar binding behavior as hydroxyl 
groups. And the pyridone is a better proton acceptor than hydroxyl group, so we 
introduce the pyridone into the macrocyclic pentamer structure. When preparing the 
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pyridone monomer which contains an alkyne group, we found that in DMF solution 
with K2CO3 as the base, the 1w isomer (allene product) was formed (Figure 4.5 b). In 
DMF, the base may trigger the rearrangement of alkyne to allene. But changing the 
solvent to acetone and controlling the reaction time to less than 6 hours, the pure 
product 1w is obtained (Figure 4.5a, Scheme 4.3). The crystal structures of these two 














































1) EtOCOCl, NMM, THF/DMF
2) NaN3, H2O
3) t-BuOH, toluene, 90oC, 50%
dioxane/HCl
Scheme 4.3: Synthetic route that affords pentamer 1w. 
The monomer 1w was treated with saturated dioxane HCl solution to afford the 
amine product 1y. As shown in Scheme 4.4, tetramer 1i was treated with KOH in 
dioxane solution. By hydrolysis of the ester group to carboxylic acids, 1p was 
obtained and then reacted with SOCl2 to produce the chloride product. And this 
chloride product reacts with 1y to form the acyclic pentamer 1za. By reduction of the 
nitro group and hydrolysis the ester group, an amino acid intermediate was formed. 
And this intermediate underwent an amide coupling reaction with the treatment of 
coupling reagent BOP to form cyclic pentamer 1zb. Subsequently by click chemistry 
linker 1o was connected with 1zb to produce side chain product 11a. As the product 
1za was hydrolyzed by NaOH, so the alkyne group on pyridone building block was 
rearranged to allene. The proton NMR of 1za was attached in appendix section. This 
results demonstrate that the click reaction could not occur at this position and product 
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11 might only have 4 linkers.(Scheme 4.4) The synthesis work of pentamer 11 is still 
in progress. 
 
Scheme 4.4: Synthetic route that affords pentamer 11 
4.2.2 Stabilizations of Telomeric G-quadruplex structure by 
pentamers 9 and 10 
The G4 structure presents a novel structural feature where a planar G-tetrad 
comprises of four in-plane guanine residues with electron-rich π-surfaces. Most of the 
reported small molecule ligands that binds and stabilizes G4 structures are based on 
the stacking interactions of the G-tetrads with aromatic surface of the ligands. And the 
existence of linker with positive charges could increase the strength of the interaction 
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between ligands and telomeric G-quadruples by ionic interaction. Inspired by these 
findings, two H-bond-rigidified macrocyclic aromatic pentamers 9 and 10 which 
adopt a nearly planar geometry (Figure 4.3) were tested against DNA or RNA G4 
structures. A macrocyclic planarity in their aromatic backbones can be generally 
established by the crystal structures of 113 and the computationally optimized 
structures of 9 and 10 (Figure 4.3) at the B3LYP/6-31G* level that had consistently 
enabled us to accurately predict the 3D topography of oligomers of varying types that 
were later experimentally verified by crystal structures.14d, 15  
In this chapter, 10 DNA and RNA sequences were examined (Table 4.5). 
Table 4. 5: RNA and DNA sequences studied. 
ID Sequences Note 
ORN1 r(UAGGGUUAGGGU) Bimolecular G4 
ORN2 r[AGGG(UUAGGG)3] Unimolecular G4 
ORN3 r(UAUGCAUA) Duplex 
ODN1 d[AGGG(TTAGGG)3] Unimolecular G4 
c-kit1 d (AGGGAGGGCGCTGGAGGAGGG) Unimolecular G4 
c-kit2 d (CGGGCGGGCGCGAGGGAGGGG) Unimolecular G4 
Pu27 d (TGGGGAGGGTGGGGAGGGTGGGGAAGG) Unimolecular G4 
Ds26 d (GTTAGCCTAGCTTAAGCTAGGCTAAC) Duplex 
4.2.2.1 CD Spectral and Melting Experiments 
The ligands’ ability of stabilizing a telomeric RNA G4 structure was evaluated by 
CD melting experiments using the G4-forming telomeric RNA sequence 
r(UAGGGUUAGGGU) (ORN1, Table 4.5), which has been found to form a 
bimolecular RNA G4 structure in Na+ solution.3a Although pentamer 1 carrying no 
exterior side chains produces no appreciable stabilization of ORN1 G4 structure at 5 
μM in Na+ solution (Figure 4.6 a and Table 4.6), 9 and 10 modified to have five 
exteriorly arrayed positively charged amine groups attained very significant 
stabilizations of the same RNA sequence at the same concentration by 14.1 and 21.3 
°C in ΔTm (Figure 4.6b, Table 4.6 and Figure 4.7), respectively. Pentamer 10 with a 
longer linker appears to be a stronger G4 RNA stabilizer for ORN1 than 9 in Na+ 
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solution. 
a)                              b) 













 ORN1 only 
 















Figure 4. 6: CD melting curves of bimolecular RNA G4 structure (ORN1; 10 μM) in the absence and 
presence of ligands 1, 9, 10 at 5 μM in a buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) 
monitored at 260 nm. In (a), the buffer solution additionally contains 5% DMF for complete dissolution 
of 1 at 5 μM. 
 
Table 4. 6: Stabilizations of RNA G-quadruplex structures ORN1 and ORN2 by 1, 9, 10 using CD 
melting assays in Na+ or K+ solutions. 
Na+ solution b K+ solution c 
ORN1 ORN2 ORN1 ORN2  
(42.3) d (48.5) d (60.9)d,e (62.0) d,f 
1 0.7 g 3.5 g N. D. N. D. 
9 14.1 19.6 14.6 e 8.0 f 
10 
ΔTm(°C)
21.3 24.1 15.4 e 11.5 f 
a RNA (5 μM) and ligand (5 μM) monitored at 260 nm in a buffer solution with Tm and ΔTm ± 0.1 °C. 
bIn 200 mM NaCl and 10 mM Naphosphate solution at pH 6.8. cIn 2 or 5 mM KCl and 50 mM Tris 
solution at pH 7.0. d Melting temperature in the absence of ligands. e In 2 mM KCl solution as the Tm 
values at higher concentrations are too large to allow ΔTm to be accurately determined. f In 5 mM KCl 
solution. g In the buffer solution contains 5% DMF in order to dissolve 1. N. D. = Not Determined. 
 
Of great interests are G4 structure stabilizers that exhibit the ability to 
discriminate RNA G4 structures from DNA G4 structures and RNA duplexes. 
Towards this goal, three RNA or DNA substrates were tested to elucidate the ligand 
effects on the selective stabilizations of these sequences (Table 4.5). Both telomeric 
RNA substrate ORN2 and its corresponding DNA version ODN1 are derived from 
ORN1, respectively forming a parallel RNA G4 structure (Figure 4.8c)3a and an 
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antiparallel DNA G4 structure1d in Na+ solutions. ORN3 forms a self-complementary 
RNA duplex structure. Remarkably as compiled in Table 4.6 using CD melting assays 
(Figures 4.8-4.10), 9 and 10 increase the Tm value of ORN2 by 19.6 and 24.1 °C in 
Na+ solution, respectively. To our delight, they both show negligible effects on either 
RNA duplex (ORN3) or DNA G4 structure (ODN1) with ΔTm values falling within 
the range of -1.1-1.0 °C (Table 4.7). Again, 10 was found to be a better G4 RNA 
stabilizer than 9 in Na+ solution. 
















Figure 4. 7: CD spectra of ORN1 (10 μM) in the absence and presence of pentamers 9 and 10 in a Na+ 
solution (200 mM NaCl and 10 mM Na-phosphate at pH 6.8 monitored at 260 nm. 
a)                       b)                      c)     













 ORN2 only 






























Figure 4. 8: (a) and (b) describe CD melting curves of unimolecular RNA G4 structure (ORN2; 5 μM) 
in the absence and presence of ligands 1,9,10 at 5 μM in a buffer solution (200 mM NaCl, 10 mM 
Na-phosphate, pH 6.8) monitored at 260 nm or 290 nm. (c) shows the corresponding CD spectra. In (a), 
the buffer solution additionally contains 5%. DMF for complete dissolution of 1 at 5 μM. 
In solutions containing biologically important K+ ions, ORN1 forms a 
bimolecular propeller-type parallel-stranded RNA G4 structure,3b and ORN2 
containing almost four (UUAGGG) repeats are likely to form a parallel-stranded 
RNA G4 structure in K+ solution (Figure 4.11b-4.12b).16 ODN1 forms an 
unimolecular propeller-type G4 structure17 in a crystal grown in the presence of K+ 
ions, but exists as a mixture of mixed-parallel/antiparallel and chair-type G4 structure 
in K+ solution.18 Significantly, the same degree of highly selective recognition of 
 75
RNA vs DNA G4 structures as observed in Na+ solution was similarly maintained in 
K+ solution with substantial structural stabilizations (Figures 4.11-4.14). This can be 
seen from the ΔTm values of 8.0–15.4 °C for the stabilizations of G4 structures 
(ORN1 and ORN2) by 9 and 10 (Tables 4.4) and those of 0.1–2.4 °C in ΔTm for 
RNA duplex (ORN3) and DNA G4 structure (ODN1) by the same two ligands (Table 
4.8). Because the Tm values of both ORN1 and ORN2 already exceed 60 °C at 
concentrations of as low as 2-5 mM KCl, the ΔTm values cannot be confidently 
determined at higher concentrations of KCl. Accordingly, the ΔTm values in K+ 
solution cannot be directly compared to those in Na+ solution in order to infer in 
which solution these RNA substrates can be better stabilized by the same ligands.  
  a)                                 b) 































Figure 4. 9: (a) CD melting curves of ORN3 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in a 
buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) monitored at 260 nm. (b) The 
corresponding CD spectra. 
  a)                                 b) 




































Figure 4. 10: (a) CD melting curves of ODN1 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in 
a buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) monitored at 290 nm. (b) The 
corresponding CD spectra. 
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Table 4.7: Thermodynamics stabilizations of the substrates by 9 and 10 in Na+ solution 
Oligonucleotide only 9 10 
 
Tm (ºC) Tm (ºC) ΔTm (ºC) Tm (ºC) ΔTm (ºC) 
RNA duplex 32.8 33.4 0.6 33.8 1.0 
Unimolecular 
ODN1 G4 
60.6 59.5 -1.1 60.6 0 
a RNA or DNA (5 μM) and ligand (5 μM) monitored at 260 nm in a buffer solution (200 mM NaCl, 10 
mM Na-phosphate, pH 6.8) with Tm and ΔTm ± 0.1 °C. 
 
Comparison of Table 4.6, 4.5 and 4.6 does allow us to conclude that (1) the 
bimolecular RNA G4 structure (ORN1) is better stabilized by both 9 and 10 in K+ 
than in Na+ solutions, (2) the unimolecular RNA G4 structure (ORN2), however, is 
noticeably stabilized more by both 9 and 10 in Na+ than in K+ solutions, and (3) 10 
consistently acts as a better G4 RNA stabilizer than 9 in both Na+ than K+ solutions, 
(4) Both 9 and 10 could discriminate particular human telomeric RNA G-quadruplex 
from human telomeric RNA G-quadruplex and RNA duplex. 
a)                                 b) 


































Figure 4. 11: (a) CD melting curves of ORN1 (10 μM) in the absence and presence of pentamers 9 and 
10 at 5 μM in K+ solution (2 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The 
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Figure 4. 12: (a) CD melting curves of ORN2 (5 μM) in the absence and presence of pentamers 9 and 
10 at 5 μM in K+ solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The 
corresponding CD spectra. 
 
a)                       b)                     c) 
























































Figure 4. 13: (a) CD melting curves of ORN3 (5 μM) in the presence of pentamer 9 (5 μM) in a buffer 
solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) CD melting curves of ORN3 at 5 
μM in the presence of pentamer 10 (5 μM) in a buffer solution (100 mM KCl, 50 mM Tris, pH 7.0) 
monitored at 260 nm. (c) The corresponding CD spectra. 
 
a)                                     b) 

































Figure 4. 14: (a) CD melting curves of ODN1 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in 





Table 4.8: Thermodynamics stabilizations of the substrates by 9 and 10 in K+ solution 
Oligonucleotide only 9 10 
 
Tm (ºC) Tm (ºC) ΔTm (ºC) Tm (ºC) ΔTm (ºC) 
RNA duplex 23.4 26.1 2.4 31.3b 1.3 
Unimolecular 
ODN1 G4 
47.3 48.5 1.2 47.4 0.1 
 
Our ligands show very good selectivity towards human telomeric RNA 
G-quadruplex rather than human telomeric DNA G-quadruplex and RNA duplex both 
in Na+ and K+ solutions. The CD spectra showed that the solution structure of ORN1 
and ORN2 are different from ODN1. Telomeric RNA formed parallel G4 structure, 
however, ODN1 formed antiparallel structure. To investigate structural-activity 
relationship towards selectivity, some of the more famous sequences (pu27, c-kit1 
and c-kit2) which could form parallel G4 structure were chosen. At the same time, the 
sequence of DNA duplex ds26 was choses as a control. 
All these four DNA sequences were treated with pentamer 9 and 10. In solutions 
containing Na+, pu27 formed a parallel intramolecular G-quadruplex, c-kit1 and 
c-kit2 formed a parallel/antiparallel  intramolecular G-quadruplex, ds26 forms a 
remarkable DNA duplex.  
    a)                                   b)  
  









































Figure 4. 15: (a) CD melting curves of ds26 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in a 
buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) monitored at 270 nm. (b) The 
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Figure 4. 16: (a) CD melting curves of pu27 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in a 
buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) monitored at 260 nm. (b) The 
corresponding CD spectra. 
 
    a)                               b) 
  

































Figure 4. 17: (a) CD melting curves of c-kit1 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in 
a buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) monitored at 260 nm. (b) The 
corresponding CD spectra. 
 
     a)                               b) 
  









































Figure 4. 18: (a) CD melting curves of c-kit2 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in 
a buffer solution (200 mM NaCl, 10 mM Na-phosphate, pH 6.8) monitored at 260 nm or 290 nm. (b) 





Table 4.9: Stabilizations of DNA G-quadruplex structures ds26, pu27, c-kit1 and c-kit2 by 9 and 10 
using CD melting assays in Na+ solutions. 
Na+ solution 
DNA only 9 10  
Tm (oC) Tm (oC) ΔTm (oC) Tm (oC) ΔTm (oC) 
Ds26 73.8 73.0 -0.8 71.4 -2.4 
Pu27 56.0 67.8 11.8 67.1 11.1 
C-kit1 56.2 56.1 -0.1 57.0 0.8 
C-kit2 59.9 80.3 20.4 >100 >40 
 
Surprisingly, compound 9 and 10 showed significant stability to c-kit2 in Na+ 
solution with ΔTm value up to 20.4 °C and more than 40 °C (Figure 4.18a and Table 
4.9), respectively. Pentamer 10 appeared to be a stronger c-kit2 G4 stabilizer than 9 in 
Na+ solution. And both of these two compounds led a conformation change of c-kit2 
G-quadruplex (Figure 4.18b). The existence of pentamer 9 and 10 led c-kit2 to form a 
favored conformation. From the Figure 4.18b, it can be concluded that the parallel 
structure is the preferred binding structure for our ligand. For pu27 which could form 
a parallel structure in Na+ solution, pentamer 9 and 10 can stabilize it with ΔTm value 
11.8 °C and 11.1°C (Figure 4.16a and Table 4.9), respectively. Interestingly, the Tm 
value of c-kit1 was not changed when the ligand 9 and 10 were used (Figure 4.17a 
and Table 4.9). And pentamer 9 and 10 consistently discriminated DNA duplex. 
    a)                               b) 
  





































Figure 4. 19: (a) CD melting curves of ds26 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in a 




    a)                               b) 
  






























Figure 4. 20: (a) CD melting curves of pu27 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in a 
buffer solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD 
spectra. 
 
    a)                               b) 
  









































Figure 4. 21: (a) CD melting curves of c-kit1 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in 
a buffer solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD 
spectra. 
     a)                               b) 
  

































Figure 4. 22: (a) CD melting curves of c-kit2 (5 μM) in the presence of pentamers 9 and 10 (5 μM) in 





Table 4.10: Stabilizations of DNA G-quadruplex structures ds26, pu27, c-kit1 and c-kit2 by 9 and 10 
using CD melting assays in K+ solutions. 
K+ solution 
DNA only 9 10  
Tm (oC) Tm (oC) ΔTm (oC) Tm (oC) ΔTm (oC) 
Ds26 76.1 74.4 -1.7 73.5 -2.6 
Pu27 68.2 73.5 5.3 77.3 9.1 
C-kit1 46.6 47.4 0.8 49.3 2.7 
C-kit2 53.9 57.7 3.8 61.2 7.3 
 
In solutions containing K+, pu27, c-kit1 and c-kit2 form parallel intramolecular 
G-quadruplex, ds26 forms a remarkable DNA duplex. As in Na+ solution, ligands 9 
and 10 had obviously binding to pu27 and c-kit2 in K+ solution with ΔTm values of 
3.8-9.1 °C (Figure 4.20, 4.22 and Table 4.10). And there were very weak binding with 
c-kit1 with a ΔTm value 0.8-2.7 °C (Figure 4.21 and Table 4.10). Accordingly, the 
ΔTm values in K+ solution cannot be directly compared to those in Na+ solution in 
order to infer in which solution these RNA substrates can be better stabilized by the 
same ligands. Comparison of Table 4.9 with Table 4.10 does allow us to conclude that 
(1) the intramolecular DNA G4 structure (c-kit2 and pu27) could be stabilized by 
ligand 9 and 10 in both Na+ and K+ solutions.(2) 10 consistently acts as a better G4 
DNA stabilizer than 9 in both Na+ than K+ solutions. (3) ligand 9 and 10 have greatly 
discriminated c-kit2 and pu27 from c-kit1 and DNA duplex in both Na+ and K+ 
solutions. (4) In K+ solution, pentamers 9 and 10 preferred to stabilize human 
telomeric RNA G-quadurplex.  
This kind of discrimination between G-quadruplex and pentmer 9 or 10 might due 
to the glucosidic bond angle (GBA) of G-quadruplex. For all syn or all anti type, the 
space of loop is bigger then the linker could easy insert into the loop and form the 
more stable strucuture by hydrogen-bond and other electrostatic interaction. In 
contrast, the loop was occupied by the sugear then the linker couldn't insert into it. 
There is only the interaction between amine and phophate parts. However, in aqueous 
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this kind electrostatic interaction is weak especially when temperature become higher. 
Combination the CD spectras of telomeric RNA or DNA with/without the present of 
pentamer 9 and 10, our ligand completely follow this GBA rules. 
Table 4.11: Stabilizationa,b of modified RNA G-quadruplex sequences by 9 using CD melting assays in 
K+ solution. 
RNA only RNA + 9 ΔTm 
ID Sequence 
(Tm, ºC) (Tm, ºC) (ºC) 
ORN1 r(UAG1G2G3UUAG4G5G6U) 60.9 75.5 14.6 
MU1 r(UAdGGGUUAGGGU) 49.3 60.5 11.2 
MU2 r(UAGdGGUUAGGGU) 54.6 71.3 16.8 
MU3 r(UAGGdGUUAGGGU) 55.8 68.3 12.6 
MU4 r(UAGGGUUAdGGGU) 55.4 70.1 14.7 
MU5 r(UAGGGUUAGdGGU) 55.0 67.7 12.8 
MU6 r(UAGGGUUAGGdGU) 56.4 70.6 14.2 
MU7 r(UAdGGGUUAdGGGU) __ 41.6 __ 
MU8 r(UAGdGGUUAGdGGU) __ 38.9 __ 
MU9 r(UAGGdGUUAGGdGU) __ 48.5 __ 
MU10 r[AAGG(UUAGGG)3] 44.8 47.0 2.2 
MU11 r[AGAG(UUAGGG)3] 41.2 42.7 1.5 
MU12 r[AGGA(UUAGGG)3] 39.7 38.5 -1.2 
a RNA (5 μM) and 9 (5 μM) monitored at 260 nm in a buffer solution (2 mM KCl, 50 mM Tris, pH 7.0) 
with Tm and ΔTm ± 0.1 °C. b Except for MU7, all the other modified RNA sequences seem to form a 
G4 structure in K+ solution (Figure 4.11b vs Figures 4.23-4.24). 
In our effort to possibly elucidate structural requirements for the observed 
stabilizations of RNA substrates by 9 and 10, a series of modified sequences 
containing a sequential replacement of six Gs at positions 1-6 in ORN1 with a dG 
base or with base A at various positions were tested (Table 4.11).  
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Figure 4. 23: CD spectra of modified RNAs (10 μM)in the absence and presence of pentamer 9 (5 μM) 
in a buffer solution (2 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (a) MU1, (b) MU2, (c) 




Figure 4. 24: CD spectra of modified RNAs (10 μM) in the absence and presence of pentamer 9 (5 μM) 
in a buffer solution (2 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. ((a) MU7, (b) MU8, (c) 






















































































































































MU9 ΔTm= 9.7 ºC  
 
        
Figure 4. 25: Scheme structures of MU1-MU9. 
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With respect to its parent ORN1, a G to dG replacement at all the positions 1-6 
invariably leads to a G4 structure less stable by 3.5-11.6 °C in Tm. It can be seen that 
the base G at the first position of ORN1 seems to be the most important for 
maintaining the high stability of the G4 structure and its stabilization by 9: a single G 
to dG replacement at this particular position as seen in MU1 not only destabilizes the 
G4 structure to the largest extent by 11.6 °C in Tm, but also results in the least 
stabilization effect by 9 (a ΔTm of 11.2 °C at position 1 vs 12.6-16.8 °C for positions 
2-6). On the other hand, G to dG replacements appears to be more tolerable at 
positions 2, 4, and 6 when compared to positions 3 and 5. Further, a mutation of an 
even single G to A at the first three positions is very detrimental, likely generating 
very weak G4 structures (MU7-9), which, however, can undergo favorable 
conformational re-organizations to reach higher stabilities. For the longer RNA 
sequence (ORN2), mutations of a single G to A also result in G4 structures of much 
lowered stabilities (MU10-12), for which ligand-mediated structural stabilizations by 
9 are very marginal (Figure 4.23, 4.24 and 4.25).  
4.2.2.2 ITC Binding isothermal Experiments 
To facilitate the evaluating of the solution binding profiles of 9 and 10 toward 
RNA substrates, isothermal titration calorimetry (ITC) were carried out. All the ITC 
binding isotherms show the exothermic behaviors (Figures 4.26-4.28), and the best 
fitting is achieved by using three sequential binding sites with the corresponding 
values for K1, K2, and K3 summarized in Table 4.12. Consistent with CD melting 
assays, ITC data similarly revealed 10 to be a better G4 RNA stabilizer than 9 in the 
Tris-buffered solutions containing 0-5 mM of Na+ or K+ ions. Interestingly, the 
binding behaviors in the Na+ buffer differ considerably from those in the K+ solutions. 
Specifically, while the G4 structure interacts with both 9 and 10 more strongly in 5 






Table 4. 12: Binding constants for the binding of ORN2 by 9 or 10 in Na+ or K+ solutions as 
determined by ITC at 25 °C. 
Na+ concentration K+ concentration 
 K c Tris only 
3 mM 5 mM 3 mM 5 mM 
K1 -- d -- e 2.1 5.8 1.4 
K2 -- d -- e 0.2 0.3 0.5 9 
K3 -- d -- e 4.8 1.9 1.0 
K1 4.2 1.6 6.7 7.8 4.0 
K2 1.6 0.2 0.6 0.3 0.4 10 
K3 0.5 4.1 6.8 4.9 0.8 
a 38.8 uL of 0.225 mM 9 or 10 in a buffered solution (50 mM Tris, 0-5 mM of Na+ or K+, pH 7.0) was 
titrated into 200 uL of 0.03 mM ORN2 in the same buffer at 25 °C. b All the ITC binding isotherms 
show an exothermic behavior with the best fitting achieved by using three sequential binding sites, and 
a 1:2 binding stoichiometry of ligand:ORN2 is generally observed. c For relative errors of K values in 
the unit of 105 M-1, see Table 4.13. d No binding. e No reliable curve fitting can be obtained (Figure 
4.27). 
 
Table 4. 13: Binding constants for the binding of ORN2 by 9 and 10 in Na+ or K+ solutions determined 
by ITC at 25 °C. 
Na+ concentration K+ concentration 
 K c Tris only 
3 mM 5 mM 3 mM 5 mM 
K1 -- d -- e 2.1 ± 1.0 5.8 ± 1.3 1.4 ± 0.5 
K2 -- d -- e 0.2 ± 0.1 0.3 ± 0.2 0.5 ± 0.2 9 
K3 -- d -- e 4.8 ± 3.7 1.9 ± 1.3 1.0 ± 0.4 
K1 4.2 ± 0.4 1.6 ± 0.3 6.7 ± 1.9 7.8 ± 3.5 4.0 ± 2.6 
K2 1.6 ± 0.3 0.2 ± 0.1 0.6 ± 0.3 0.3 ± 0.4 e 0.4 ± 0.5 e 3 
K3 0.5 ± 0.1 4.1 ± 1.8 6.8 ± 4.7 4.9 ± 5.2 e 0.8 ± 0.6 
a A total of 38.8 uL over 20 injections (1st injection at 0.8 uL and the remaining 19 injections at 2 uL) 
of 0.225 mM 9 or 10 in a buffered solution (50 mM Tris, 0-5 mM of Na+ or K+, pH 7.0) into 200 uL of 
0.03 mM ORN2 in the same buffer at 25 °C. b All the ITC binding isotherms show the exothermic 
behaviors with the best fitting achieved by using three sequential binding sites, and a 2:1 binding 
stoichiometry of ORN2:9 is generally observed. c Binding constants K in the unit of 105 M-1. d No 
binding was observed. e The obtained binding isotherm does not allow for a reliable curve fitting. 
From the ITC binding isotherms (Figures 4.26-4.28), a few other points can be 
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noted. (1) A ligand:tetraplex stoichiometry of 1:2 is generally observed for the 
binding of ORN2 by either 9 or 10. (2) Among the three sequential binding sites (K1, 
K2 and K3), both the 1st and 3rd binding sites are enthalpy-driven with the 2nd 
binding site, however, driven by entropy. (3) With respect to the 3rd binding site, the 
1st binding site is additionally characterized by a smaller enthalpic contribution as 
well as a much smaller entropic penalty. (4) The 1st and 3rd binding sites provide the 
primary driving forces for the formation of the 1:2 ligand:RNA complex (Table 4.6). 
 
Figure 4. 26: ITC binding isotherms involving titrating 38.8 uL of pentamer 9 or 10 (0.225 mM) into 
200 uL of ORN2 (30 μM) in a 50 mM tris buffer solution at 25 oC. 
 
These points unite to offer a possible binding scenario involving three binding 
sites that yields a 1:2 ligand: tetraplex complex with the ligand sandwiched between 
the two G4 structures as sketched in Figure 4.29: the 1st and 3rd binding sites may 
involve two and three ammonium cations from the pentamer ligand, respectively, and 
the 2nd binding site is presumably made up of the roughly planar macrocyclic 
pentameric backbone that at most moderately strongly binds to the planar G-tetrads 
with a net entropic gain.  
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Figure 4. 27: ITC binding isotherms involving titrating 38.8 uL of pentamer 9 (0.225 mM) into 200 uL 
of ORN2 (30 μM) in a 50 mM tris buffer solution (containing 3 mM or 5 mM NaCl, 3 mM or 5 mM 
KCl) at 25 oC. 
Consistent with this is our experimental observation, showing that 1, carrying no 
cationic exterior side chains, showed no detectable stabilizations of G4 structures 
(Table 4.6). This finding is indicative of weak or moderate binding between 
pentameric backbone and G-tetrad. Highly likely, a comparable size between the 
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ligand (9 or 10) and the G-tetrad structure favorably makes the G4 structure able to 
accommodate the ligand without a substantial steric clash, thereby minimizing 
ligand-induced distortions to the structure. To support the ITC results, docking 
modeling was also carried out which will discussed in next section. 
 
Figure 4. 28: ITC binding isotherms involving titrating 38.8 uL of pentamer 10 (0.225 mM) into 200 
uL of ORN2 (30 μM) in a 50 mM tris buffer solution  (containing 3 mM or 5 mM NaCl, 3 mM or 5 
mM KCl) at 25 oC. 
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Figure 4. 29: A speculative diagram illustrating a tentative assignment of three binding sites that 
account for the formation of a 1:2 ligand: tetraplex complex between the ligand (9 or 10) and two 
molecules of ORN2. Positive and negative charges refer to the ammonium cations from ligands and 
phosphate anions from RNA backbone, respectively. These oppositely charged ions can interact with 
each other not in a 1:1 ratio. Rather than the 1st and 3rd binding sites respectively consisting of two 
non-adjacent ammonium cations and the remaining three cations as shown, other possibly less stable 
alternative arrangements of these cations are also likely (Figure 4.31b-c). 
 
4.2.2.3 Docking Modeling 
Based on the ITC results, there was a 1:2 binding ratio between ligand and G4. A 
series of docking modeling experiments were carried out to further support this results. 
Computationally as illustrated in Figures 4.30 and 4.31, our molecular docking studies 
on the 1:1 or 1:2 ligand:tetraplex complexes using the recently determined crystal 
structure of ORN14b (For a sandwiched binding mode where an acridine ligand is 
sandwiched between two G4 structures formed from ORN1 recently shown by Neidle, 
see reference 4b. This kind of binding mode is probably applicable to both 9 and 10 
due to their macrocyclic planarity as seen from the crystal structure of 1. Ligand 10 
reveals a 1:2 binding stoichiometry of ligand:tetraplex for the most likely complex 
where three out of five ammonium cations in 10 efficiently interact via four ionic 
H-bonds (1.72, 1.74, 1.82 and 1.82 Å) with the three anionic phosphate groups 
located in the same tetraplex structure, and with the remaining two non-adjacent 
ammonium cations in 10 staying in close contacts via another three ionic H-bonds 
(1.73, 1.84 and 2.13 Å) with another tetraplex structure (Figure 4.31a). As a result of 
symmetry mismatch between the four-fold symmetric tetraplex structure and the 
five-fold symmetric 10 as well as a limited length of the partially rigidified linker in 
10, only three out of five ammonium cations can efficiently interact via ionic H-bonds 
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with the anionic O-atoms of the tetraplex phosphate groups for 1:1 complex (Figure 
4.30).  
 
Figure 4. 30: Molecular docking study on the possible 1:1 pentamer 10:tetraplex complex using the 




Figure 4. 31: Molecular docking studies on the possible 2:1 tetraplex:ligand 10 complexes using the 
recently determined crystal structure of ORN1 (J. Am. Chem. Soc. 2011, 133, 2721).  
 
With regards to the reason why pentamer 9 and 10 selectively recognize particular 
G-quadruplex structure, we believe that the binding ratio is 1:2. And increasing the 
amount of ligand, the G4 structure can stack together to produce oligomeric structures. 
This molecular docking model was further supported by Native gel electrophoresis 
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(Figure 4.32) and NMR spectra (Figure 4.33). 
4.2.2.4 Native gel electrophoresis 
Native gel electrophoresis was carried out with 15% polyacrylamide in TBE 
buffer (pH 8.3). The concentration of RNA (ORN1 and ORN2) is 5 μM, 
concentration of ligand was calculated depending on different ratios (0 to 4 equv.). 
The RNA sample was prepared in tris buffer 50 mM, NaCl (200 mM) or KCl (100 
mM). The total volume of each sample is 10 uL. Sequence d(GGGTA) which chould 
form the G-quadruplex dimer was used as the marker (labled as G). 
There was only one main band of ORN1 and ORN2 G-quadruplexes when 
ligands 9 and 10 were absent in both Na+ and K+ solutions. However, when the ligand 
9 and 10 were added, new bands with high molecular weight structures were formed. 
This native gel results indicated that ligand 9 and 10 could lead the formation of RNA 
G-quadruplex. As shown in Figure 4.32, high order structures were formed. With the 
increasing pentamer 9 and 10, this aggressive behavior became apparent. This result 
was corresponds to the ITC results and docking modeling results as shown in last two 
sections.  
 
                                                       
a)         ORN1 +9 +Na                        ORN1 + 9+K 
     G   0  0.5  1   2   4               G  0   0.5  1    2   4    
                  





b)        ORN1 + 10 + Na                           ORN1 + 10+ K 
 G   0   0.5   1    2    4             G   0   0.5   1   2   4 
        
c)        ORN2 +9+Na                            ORN2+9+K 
  0   0.5   1    2   4    G             0  0.5   1    2    4   G 
           
d)        ORN2+10+Na                             ORN2 +10+K 
 G   0  0.5  1    2   4                  G   0   0.5  1    2   4                
        
Figure 4. 32: Native gel electrophoresis results of ORN1 (10 μM), ORN2 (5 μM) with pentamer 10 





4.2.2.5 1H NMR of ORN1 with pentamer 10 
NMR experiments were carried out on 500 MHz Bruker spectrometers. At 25 oC, 
the concentration of NMR sample (ORN1) is 100 μM, and 5 mM pentamer 10 was 
used to titrate. All NMR experiments were carried out at the same condition Tris 












Figure 4. 33: NMR results of ORN1 (100 μM) with pentamer 10 in tris buffer (pH 7.0), 90 mM KCl 
solution. 
 
Inspired by the native gel electrophoresis results, the ORN1 and ligand 10 
titration experiment was performed. As shown in Figure 4.33, when increasing the 
amount of ligand 10 the signal peaks of ORN1 imino proton became boarder. The 
change of the imino peaks showed that a strong stacking occurred at the imino 
position. So our ligand might lead to the stacking of the telomeric RNA G-quadruplex. 
However, to clear this point, more experiments should be carried out such as 2D 
NMR. 
Moreover, we found that increasing of the ligand ratio could enhance the ΔTm of 
telomeric RNA G-quadruplex. When the ratio is up to 10 equivalents, the ΔTm could 
raise up to 31.2 ºC (Figure 4.34, 4.35 and Table 4.14). However, the increase of the 
ligand ratio couldn't infinitely enhance the ΔTm value (Table 4.14). 3 equivalents was 
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Figure 4. 34: CD melting curves of ORN2 r[AGGG(UUAGGG)3] (5 ~ 10 μM) in the present of 
pentamer 9 with different ratio monitored at 260 nm and 290 nm in the present of 200 mM NaCl, 10 
mM Na-phosphate buffer (pH 6.8) Na solution. 
 
Table 4. 14: Thermal dynamic results of ORN2 with pentamer 9 in different ratios in Na+ solution. 
 Ratio Tm (ºC) ΔTm (ºC) 
Only 48.5  
1 to 1 72.6 24.1 
1 to 2 74.5 26.0 
1 to 3 79.7 31.2 
Unimolecular 
RNA G4 (5 μM) 
1 to 4 77.0 28.5 
only 45.5  Unimolecular 
RNA G4 (10 μM) 2 to 1 67.3 21.8 
a)                                  b) 
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Figure 4. 35: a) CD spectra of ORN2 r[AGGG(UUAGGG)3] (5 μM) with pentamer 9 at different 
ratios (1:1, 1:2, 1:3 and 1:4) b) CD spectra of ORN2 r[AGGG(UUAGGG)3] (10 μM) with pentamer 9 
(2:1) monitored in the present of 200 mM NaCl, 10 mM Na-phosphate buffer (pH 6.8) Na+ solution 
monitored at 260 nm or 290 nm.  
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The job plot result was showed in Figure 4.36, which is the most accepted method 
for determining the binding stoichiometry. As shown in the job plot, the binding ratio 



















Figure 4. 36: Job plot of ORN2 with pentamer 9, this test was monitored the absorbance of the ORN2 
r[AGGG(UUAGGG)3] (10 μM) with pentamer 9 monitored in the present of 200 mM NaCl, 10 mM 
Na-phosphate buffer (pH 6.8) Na+ solution monitored at 260 nm.  
 
4.2.2.6 Effects of 10 on normal human prostate epithelial RWPE-1 cells and 
prostate cancer PC-3 cells 
Effects of 10 on viability of normal human prostate epithelial RWPE-1 cells and 
prostate cancer PC-3 cells were determined using the MTT assays. Result from the 
MTT assay showed that treatment of RWPE-1 and PC-3 cells with 10 resulted in a 
concentration-dependent decrease in the cell viability (Figure 4.37). As shown in 
Figure 4.37, 10 had a stronger cytotoxic effect on prostate cancer PC-3 cells than that 
on normal prostate epithelial RWPE-1 cells. At lower concentrations (2 and 5 µM), 10 
had very small cytotoxic effect on RWPE-1 cells while it had stronger effect on PC-3 
cells. 10 had a small to moderate toxicity to RWPE-1 cells at 10 µM but at same 
concentration this compound caused a much stronger toxicity to PC-3 cells. At a 
















20 μM5 μM 10 μM2 μM  
Figure 4. 37: Effects of 10 on normal human prostate epithelial RWPE-1 and prostate cancer PC-3 
cells. The cells were seeded at a density of 2 × 104 cells/ml of medium in 96-well plates (0.2 ml/well) 
and incubated for 24 h. The cells were then treated with various concentrations (2-20 μM) of 10 for 
72 h. Effects of 10 on the viability of RWPE-1 and PC-3 cells were determined by the MTT assay. Each 
value is the mean ± SE from three separate experiments. 
4.3 Conclusion and Future Work 
Given that both pentamers 9 and 10 could specifically recognize particular 
telomeric G4 RNA and successfully discriminate between human telomeric G4 RNA 
from G4 DNA and double-stranded RNA, it is interesting that this observation has not 
been previously reported. Binding affinity increases in the order of 1 < 9 < 10 with 
incorporating exteriorly arrayed cationic side chains and with the longer linker. This 
suggests that the efficient ionic interactions between the properly spaced ammonium 
cations from the ligands and those phosphate anions from RNA backbones to be the 
dominant driving force for the formation of stable ligand•RNA complexes. The length 
of the linker part in 9 and 10 also critically influences the binding affinity and 
possibly the binding modes. Although the macrocyclic pentameric backbone seems 
not to impart a significant binding affinity to 9 or 10, its modular nature does give rise 
to an accessible array of other closely related hybrid pentamers with tunable interior 
properties for fine-tuning the binding affinities and selectivity. These two compounds 
also selectively bind with c-kit2 and pu27. This kind of discrimination was followed 
the GBA rules. 
And the pentamers which are decorated with pyridone building block such as 
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pentamer 11 will be synthesized and their ability of stabilizing telomeric DNAs and 
RNAs will also be examined in the future. Further exquisite modifications in types of 
exteriorly arrayed linkers and organic cations should lead to a new generation of 
pentameric ligands for highly selective recognitions of RNA vs DNA G4 structures or 
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Chapter 5 Cationic acyclic molecules L1-L5 as 
telomeric RNA and DNA G-quadruplex stabilizers 
5.1 Introduction  
5.1.1 Background 
With the same research background of chapter 4, new styles of molecules should 
be designed. As cyclic planar molecules, some helical structures were also discovered 
could stabilize the telomeric DNA or RNA G-quadruplex structures. Inspired by Ivn 
Huc's work1 (Figure 5.1) which published in 2007 the uncyclic products (L1-L5) such 
as monomer, dimer, trimer, tetramer and pentamer were also obtained (Scheme 5.1, 
Figure 5.2).  
 
Figure 5. 1: Helical structures which published by Ivn Huc in 2007  
5.1.2 Design Principle 
There is a twist angle of G-quadruplex while each G-tetrad layer stacking with 
each other. This property of G-quadruple structure leads to that molecules which have 
helical structure could a better binding ligands. Based on this results, we designed and 
synthesized a series of helical compounds L1-L5 (Figure 5.2). In 2009, we published 
a series coupounds could could form helical strucures (Figure 5.3)3. The continuous 
internal hydrogen bonds lead to the helical comformation and these kind structures 
were further confirmed by 2D NMR and X-ray crystalgraphy. With the existence of 
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hydrogen bond, compounds L3 to L5 could form helical structures, too. 
 
Figure 5. 2 : Chemical structures of ligand L1-L5. 
 
Figure 5. 3: Crystal structure and chemical structure of compound published in reference 3.(taken from 
Yan, Y.; Qin, B.; Shu, Y.; Chen, X.; Yip, Y.; Zhang, D.; Su, H.; Zeng, H., Helical Organization in 








5.2 Results and Discussion 
5.2.1 Synthesis of a series of acyclic ligands L1-L5 
To investigate the stabilization of G-quadruplex structures by our designed 
compounds, a series of helical side chain compounds were synthesized as shown in 
Scheme 5.1. The starting material, 2,5-dihydroxylbenzoic acid, was commercially 
available. From the experimental results we found that a stepwise fashion was more 
efficient for constructing the aromatic backbones of all the helical compounds.  
These compounds can form helix structure by hydrogen bonding, the interaction 
between helical compounds and telomeric G-quadruplexes were also considered. We 
prepared compounds L1-L5 which were prepared starting from monomer into 
pentamer. By comparing the results of pentamers 2 and 3 (present in chapter 4), we 
found that the linker 1o was the better one. Subsequently in the preparation of 
compounds L1-L5, linker 1o was chosen.(Scheme 5.1) And each of these click 














































































































































































































Scheme: Synthetic route that affords pentamer L1-L5 
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5.2.2 Stabilizations of Telomeric G-quadruplex structure by L1-L5 
In this section, we were the first to examine the stability of telomeric RNA 
(ORN2) in K+ solution. These results showed that L1 and L2 led to the unstable of 
ORN2 G-quadruplex (Figure 5.4, Table 5.1), from L3 to L5 the stability of ORN2 
G-quadruplex were increased and the Tm values are 10.2 oC, 11.8 oC and 15.9 oC, 
respectively. As reported by our laboratory in 20102, the existence of hydrogen bond 
could lead the compound self-helix. From the trimer, the compound could form the 
helix structure. According to the change of Tm value, we can conclude that the helix 
structure can increase the stability of the ORN2 G-quadruplex and L5 was the best 
one which can increase the Tm value up to 15.9 oC.  
a)                                  b) 



















   























Figure 5. 4: (a) CD melting curves of ORN2 (5 μM) in the absence and presence of ligand L1-L5 5 
μM in K+ solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD 
spectra. 
 
Table 5. 1: Thermal dynamic results of ORN2 with compounds L1-L5 in K+ solution. 
ORN2 
Item only L1 L2 L3 L4 L5 
Tm (oC) 62.0 52.2 55.6 72.2 73.8 77.9 




As L5 was very good at stabilizing ORN2 G-quadruplex, we subsequently treated 
L5 with ORN1, ORN4, ORN5, ODN1, c-kit1, c-kit2, pu27 and ds26 in K+ solution. 
The results are shown in Figure 5.4-5.12 and Table 5.2. Similar to pentamer 2 and 3, 
ligand L5 also had strong stability of telomeric RNA G-quadruplex ORN1 withΔTm 
value 17.5 oC. L5 had similarly stability to c-kit1 and c-kit2 as theΔTm values were 
11.1 oC and 14.1 oC, respectively. In contrast, the interaction between L5 and pu27 
was very weak and there was only 1.4 oC increasing in Tm value. As expected, ligand 
L5 also had no stability towards telomeric DNA G-quadruplex (ODN1) which 
contains the segment (TTAGGG)n and DNA duplex (ds26).   
a)                                  b) 




























Figure 5. 5: (a) CD melting curves of ORN1 (10 μM) in the absence and presence of ligand L5 5 μM 
in K+ solution (2 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD 
spectra. 
 
a)                                  b) 




































Figure 5. 6: (a) CD melting curves of ORN4 (5 μM) in the absence and presence of ligand L5 5 μM in 






a)                                 b) 








































Figure 5. 7: (a) CD melting curves of ORN5 (5 μM) in the absence and presence of ligand L5 5 μM in 
K+ solution (2 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD spectra. 
 
a)                                  b) 


































Figure 5. 8: (a) CD melting curves of ODN1 (5 μM) in the absence and presence of ligand L5 5 μM in 
K+ solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD spectra. 
 
a)                                  b) 
































Figure 5. 9: (a) CD melting curves of c-kit1 (5 μM) in the absence and presence of ligand L5 5 μM in 







a)                                  b) 

































Figure 5. 10: (a) CD melting curves of c-kit2 (5 μM) in the absence and presence of ligand L5 5 μM in 
K+ solution (5 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD spectra. 
 
a)                                  b) 




































Figure 5. 11: (a) CD melting curves of pu27 (5 μM) in the absence and presence of ligand L5 5 μM in 
K+ solution (2 mM KCl, 50 mM Tris, pH 7.0) monitored at 260 nm. (b) The corresponding CD spectra. 
 
a)                                  b) 





































Figure 5. 12: (a) CD melting curves of ds26 (5 μM) in the absence and presence of ligand L5 5 μM in 







Table 5. 2: Thermal dynamic results of ORN1, ORN4, ORN5, ODN1, c-kit1, c-kit2, pu27 and ds26 
with compound L5 in K+ solution. 
ORN1 ORN4 ORN5 Ds26  
only L5 only L5 only L5 only L5 
Tm 
(oC) 60.9 78.4 66.9 75.5 67.4 76.3 76.1 76.9 
ΔTm 
(oC)  17.5  8.6  8.9  0.8 
ODN1 c-kit1 c-kit2 Pu27  
only L5 only L5 only L5 only L5 
Tm 
(oC) 47.3 48.7 46.6 57.7 53.9 68.0 68.2 67.5 
ΔTm 
(oC)  1.4  11.1  14.1  -0.3 
 
Based on these data, we can conclude that the helix structure increased the Tm 
value of telomeric RNA G-quadruplex. And L5 was the best ligand, and it greatly 
increased the stability of c-kit1 and c-kit2. However, ligand L5 has no binding 
towards pu27. This might be because the structure of ligand L5 is more suitable for 
c-kit1 and c-kit2 rather than pu27. Ligand L5 has the ability to selectively stabilize 
particular RNA and DNA G4 structures in K+ solution. Compared with pentamers 2 
and 3 (present in chapter 4), L5 prefers to stabilize human telomeric RNA 
G-quadruplex in K+ solution.   
5.3 Conclusion and Future work 
Inspired by the Ivn Huc's work which was published in 2007, the acyclic 
compounds L1-L5 were also developed. And the helical structures especially L5 have 
strong stability to telomeric RNA G-quadruplex, and selectively binds with c-kit1 and 
c-kit2. Compared 2 or 3 with L5, they all led to very good stability of telomeric RNA 
G-quadruplex and prefered to stabilize telomeric RNA G-quadruplex. However, they 
have different binding behaviors with c-kit1 and pu27. To figure out the different 
binding mode, the docking modeling will be performed in future. The docking 
modeling will also be finished in future to clear the binding mode between ligand 
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L1-L5 and telomeric RNA or DNA G-quadruplex strucutres.   
As the ΔTm value of ORN2 was increased in order L3<L4<L5, hexamer or even 
higher order ligand will be synthesized in future. Further exquisite modifications in 
types of exteriorly arrayed linkers and organic cations should lead to a new generation 
of pentameric ligands for highly selective recognitions of RNA vs DNA G4 structures 
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Chapter 6 Conclusion and Perspective  
Summary all results of chapter 3-5, we got some general conclusion. As shown in 
chapter 3, the pentamer 4 could specifically recognize telomeric G4 RNA which 
containing (UUAGGG)n segments and successfully discriminate G4 RNA from G4 
DNA and double-stranded DNA and RNA. This is an interesting results as it has not  
been previously noted. Except the π-π stacking interaction between macrocyclic 
pentamer and G-quadruplex sturcture, binding affinity increases with incorporating 
three hydroxyl groups into the pentamer ligand. This likely suggests a key role of 
steric hindrance and weak H-bonding capacities from interior methyl groups as well 
as H-bonding abilities of the amide and aromatic protons in 4 on its specific 
recognition of telomeric RNA G4 structure. The existence of methyl groups are 
necessaries. Pentamer 4 could selectively recognize telomeric RNA G4 which 
containing (UUAGGG)n segments in Na+ solution. 
In chapter 4, it is shown that pentamers 9 and 10 could specifically recognize 
particular telomeric G4 RNA and successfully discriminate between human telomeric 
G4 RNA from G4 DNA and double-stranded RNA. These two compounds have very 
good solubility in aqueous solution. Binding affinity increases in the order of 1 < 9 < 
10 with incorporating exteriorly arrayed cationic side chains and with the longer 
linker. This suggests that the efficient ionic interactions between the properly spaced 
ammonium cations from the ligands and those phosphate anions from RNA 
backbones to be the dominant driving force for the formation of stable ligand•RNA 
complexes. The length of the linker part in 9 and 10 also critically influences the 
binding affinity and possibly the binding modes. These two compounds also 
selectively bind with c-kit2 and pu27.  
Inspired by the Ivn Huc's work which was published in 2007, the acyclic 
compounds L1-L5 were also developed. And the helical structures especially L5 have 
strong stability to telomeric RNA G-quadruplex, and selectively binds with c-kit1 and 
 115
c-kit2.  
Although the macrocyclic pentameric backbone seems not to impart a significant 
binding affinity to 9 or 10, its modular nature does give rise to an accessible array of 
other closely related hybrid pentamers with tunable interior properties for fine-tuning 
the binding affinities and selectivity. Both 9 or 10 with L5, led to very good stability 
of telomeric RNA G-quadruplex and prefer to stabilize telomeric RNA G-quadruplex. 
However, they have different binding behaviors with c-kit1 and pu27. To figure out 
the different binding mode, the docking modeling will be performed in future.   
And the pentamers which are decorated with pyridone building block will be 
synthesized and their ability of stabilizing telomeric DNAs and RNAs will also be 
examined in the future. Further exquisite modifications in types of exteriorly arrayed 
linkers and organic cations should lead to a new generation of pentameric ligands for 
highly selective recognitions of RNA vs DNA G4 structures or for other interesting 
applications such as switching a parallel G4 structure to an antiparallel one. 
As the ΔTm value of ORN2 was increased in order L3<L4<L5, hexamer or even 
higher order ligand will be synthesized in future. Further exquisite modifications in 
types of exteriorly arrayed linkers and organic cations should lead to a new generation 
of pentameric ligands for highly selective recognitions of RNA vs DNA G4 structures 
or for other interesting applications such as switching a parallel G4 structure to an 
antiparallel one. 
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Chapter 7 Experimental Sections 
7.1 Experimental section for pentamers 1-8 containing no 
exterior side chains 
7.1.1 General remarks 
All the reagents were obtained from commercial suppliers and used as received 
unless otherwise noted. The organic solutions from all liquid extractions were dried 
over anhydrous Na2SO4 for a minimum of 15 minutes before filtration. Reactions 
were monitored by thin-layer chromatography (TLC) on silica gel pre-coated glass 
plate (0.225 mm thickness, 60F-254, E. Merck). Flash column chromatography was 
performed using pre-coated 0.2 mm silica plates from Selecto Scientific. Chemical 
yields refer to pure isolated substances. CD spectra were measured using a Jasco 
model J-810 CD spectrophotometer. ITC experiments were obtained using iTC200 
Microcalorimenter. Mass spectra were obtained using the Instrumentation includes 
Finnigan MAT95XL-T and Micromass VG7035. 1H NMR spectra were recorded on 
Bruker ACF-300 (300 MHz) and ACF500 (500 MHz) spectrometers. The solvent 
signal of CDCl3 was referenced at δ = 7.26 ppm, d6-DMSO was referenced at δ = 2.50 
ppm and d4-methanol was referenced at δ = 1.94 ppm. Coupling constants (J values) 
are reported in Hertz (Hz). 1H NMR data are recorded in the order: chemical shift 
value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), 
number of protons that gave rise to the signal and coupling constant, where applicable. 
13C spectra were proton-decoupled and recorded on Bruker ACF-300 (300 MHz) and 
ACF500 spectrometers (500 MHz). The solvent, CDCl3 was referenced at 77 ppm and 
d6-DMSO at 39.5 ppm. CDCl3 (99.8% deuterated) and d6-DMSO (99.8%-Deuterated) 
were purchased from Aldrich and used without further purification. d4-methanol 
(99.8% deuterated) was purchased from Cambridge Isotope Laboratories, Inc. and 
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used without further purification. 
7.1.2 Experimental Procedures and Compound Characterizations of 
pentamers 1-8 
Methyl 2-methoxy-3-nitrobenzoate (1a) 
Methyl 2-hydroxy-3-nitrobenzoate (30.00 g, 152.3 mmol) 
was dissolved in DMF (250 mL) to which anhydrous K2CO3 
(63 g, 456.9 mmol) and dimethyl sulfate (17.4 mL, 183 
mmol) were added to it. The mixture was heated under 
reflux for 4 hours. The reaction mixture was then filtered and the solvent was 
removed in vacuo. The residue was dissolved in CH2Cl2 (300 mL), washed with water 
(2 x 100 mL), and dried over anhydrous Na2SO4. Removal of CH2Cl2 gave a pure 
light yellow solid 1a. Yield: 27 g, 84 %; 1H NMR (300 MHz, CDCl3): δ 8.01 (dd, 1H, 
J = 7.9, 1.8 Hz), 7.90 (dd, 1H, J = 8.1, 1.8 Hz), 7.26 (m, 1H), 3.99 (s, 3H), 3.95 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ 164.4, 152.9, 145.17, 135.3, 128.0, 127.1, 123.5, 
63.9, 52.4. HRMS-ESI: calculated for [M]+ (C9H10NO5)+: m/z 211.0481, found: m/z 
211.0480.  
 
2-Methoxy-3-nitrobenzoic acid (1c) 
Compound 1a (4.00 g, 19.0 mmol) was dissolved in hot 
methanol (10 mL) to which 1 M NaOH (40 mL, 40 mmol) 
was added. The mixture was heated under reflux for 2 hours 
and then quenched with water (100 mL). The aqueous layer 
was neutralized by addition of 1 M HCl (80 mL) until the pH was at least 1. The 
precipitated crude product was collected by filtration, then the crude product was 
dissolved in CH2Cl2 and dried over anhydrous Na2SO4. Removal of CH2Cl2 gave a 
pure white solid 1c. Yield: 3.45 g, 92.0 %; 1H NMR (300 MHz, CDCl3):δ 8.28 (dd, 








3H). 13C NMR (75 MHz, CDCl3):δ 165.0, 151.9, 144.5, 134.7, 127.3, 126.8, 122.8, 
63.1. HRMS-ESI: calculated for [M]- (C8H6NO5)-: m/z 196.0251, found: m/z 
196.0252.  
 
2-benzyloxy-3-nitrobenzoic acid (1d) 
Compound methyl 2-benzyloxy-3-nitrobenzoate (14.35 g, 
50 mmol) was dissolved in hot methanol (30 mL) to which 1 
M NaOH (100 mL, 100 mmol) was added. The mixture was 
heated under reflux for 2 hours and then quenched with 
water (200 mL). The aqueous layer was neutralized by addition of 1 M HCl (200 mL) 
until the pH was at least 1. The precipitated crude product was collected by filtration, 
then the crude product was dissolved in CH2Cl2 and dried over anhydrous Na2SO4. 
Removal of CH2Cl2 gave a pure white solid 1d. Yield: 11.46 g, 84.0 %;1H NMR (500 
MHz, CDCl3): δ 8.28 (dd, 1H, J = 7.6, 1.9 Hz), 8.03 (dd, 1H, J = 7.6, 1.9 Hz), 7.48 (m, 
2H), 7.39 (m, 4H), 5.22 (s, 2H). 13C NMR (125 MHz, CDCl3): δ 167.9, 152.0, 145.6, 
136.8, 134.8, 129.9, 129.0, 129.0, 128.7, 126.3, 124.5, 79.2. HRMS-ESI: calculated 
for [M]- (C14H10NO5)-: m/z 272.0564, found: m/z 272.0567.  
 
Methyl 3-amino-2-methoxybenzoate (1g) 
Compound 1a (2.11 g, 10 mmol) was dissolved in EtOH 
(100 mL) to which iron powder (2.24 g, 40 mmol), acetic 
acid ( 10 mL) was added and refluxed 3 hours. After cooling, 
the reaction mixture was extraction by CH2Cl2, washed with 
water (2 x 100 mL), and dried over anhydrous Na2SO4. Removal of CH2Cl2 gave the 
pure brown liquid 1g. Yield: 1.72 g; 1H NMR (300 MHz, CDCl3): δ 6.92-7.14 (m, 
1H), 6.83-6.89 (m, 2H), 3.85 (s, 3H), 3.80 (s,3 H). 13C NMR (75 MHz, CDCl3): δ 
166.53, 146.63, 124.12, 123.92, 120.05, 119.29, 60.47, 51.80, HRMS-ESI: calculated 












3-amino-2-methoxybenzoic acid (1h) 
1c (3.94 g, 20.0 mmol) was reduced by catalytic 
hydrogenation in MeOH (100 mL) at 40 oC, using Pd/C 
(0.39 g, 10%) as the catalyst for 3 h. The reaction mixture 
was then filtered and the solvent was removed in vacuo to 
give the crude product, which was recrystallized from ether to give the pure product 
1h as a white solid. Yield: 3.14 g, 94 %. 1H NMR (500 MHz, CDCl3): δ 7.38 (dd, 1H, 
J = 7.4, 1.8 Hz), 7.03-6.93 (m, 1H), 6.18 (s, 1H), 3.88 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ 168.75, 146.89, 140.49, 124.84, 122.66, 121.64, 121.00, 60.89. HRMS-ESI: 
calculated for [M]+ (C8H9NO3) +: m/z 167.0582, found: m/z 167.0582. 
 
Methyl 2-ethoxy-3-nitrobenzoate(1i) 
Methyl 2-hydroxy-3-nitrobenzoate (10 g, 51 mmol) was 
dissolved in DMF (100 mL) to which anhydrous K2CO3 
(21.1g, 153 mmol) and bromoethane (6.4 g, 4.4 mL) were 
added to it. The mixture was heated under reflux for 4 hours. 
The reaction mixture was then filtered and the solvent was removed in vacuo. The 
residue was dissolved in CH2Cl2 (300 mL), washed with water (2 x 100 mL), and 
dried over anhydrous Na2SO4. Removal of CH2Cl2 gave a pure light yellow solid 1i. 
Yield: 9 g, 79%; 1H NMR (500 MHz, CDCl3): δ 8.00 (d, 1H, J = 7.6 Hz), 7.88 (d, 1H, 
J = 7.8 Hz), 7.26 (t, 1H, J = 7.6 Hz), 4.16 (dd, 2H, J = 6.5 Hz), 3.94 (s, 3H), 1.41 (t, 
3H, J = 6.5 Hz). 13C NMR (126 MHz, CDCl3): δ 164.96, 152.16, 145.74, 135.39, 
128.24, 127.68, 123.57, 73.23, 52.67, 15.31. HRMS-ESI: calculated for [M+Na]+ 
(C10H11NO5Na)+: m/z 248.0592, found: m/z 248.0528.  
 
2-ethoxy-3-nitrobenzoic acid(1j) 
Compound 1i (5 g, 22.2 mmol) was dissolved in hot 
methanol (11 mL) to which 1 M NaOH (45 mL, 45 mmol) 
was added. The mixture was heated under reflux for 2 hours 











was neutralized by addition of 1 M HCl until the pH was at least 1. The precipitated 
crude product was collected by filtration, then the crude product was dissolved in 
CH2Cl2 and dried over anhydrous Na2SO4. Removal of CH2Cl2 gave a pure white 
solid 1j. Yield: 4.2 g, 90%; 1H NMR (500 MHz, CDCl3): δ 8.29 (d, 1H, J = 7.7 Hz), 
8.07 (d, 1H, J = 7.7 Hz), 7.38 (t, 1H, J = 7.7 Hz), 4.38 (dd, 2H, J = 6.1 Hz), 1.51 (t, 
3H, J = 6.1 Hz). 13C NMR (126 MHz, CDCl3): δ 167.30, 152.54, 145.21, 136.76, 
129.84, 125.78, 124.19, 74.15, 15.37. HRMS-ESI: calculated for [M]- (C9H8NO5)-: 
m/z 210.0408, found: m/z 210.0400.  
 
Methyl 2-isopropoxy-3-nitrobenzoate (1k) 
Methyl 2-hydroxy-3-nitrobenzoate (10 g, 51 mmol) was 
dissolved in DMF (100 mL) to which anhydrous K2CO3 
(21.1 g, 153 mmol) and isopropyl bromide (9.4 g, 7.2 mL) 
were added to it. The mixture was heated under reflux for 4 
hours. The reaction mixture was then filtered and the solvent 
was removed in vacuo. The residue was dissolved in CH2Cl2 (300 mL), washed with 
water (2 x 100 mL), and dried over anhydrous Na2SO4. Removal of CH2Cl2 gave a 
pure light yellow oil 1k. Yield: 8.5 g, 70%; 1H NMR (500 MHz, CDCl3): δ 7.95 (d, 
1H, J = 7.1 Hz), 7.84 (d, 1H, J = 7.2 Hz), 7.23 (t, 1H, J = 7.3 Hz), 4.32 (dd, 1H, J = 
5.7 Hz), 3.93 (s, 3H), 1.28 (d, 6H, J = 5.8 Hz). 13C NMR (126 MHz, CDCl3): δ 165.50, 
162.55, 150.40, 146.26, 135.07, 127.94, 123.14, 80.29, 52.62, 22.01. HRMS-ESI: 
calculated for [M+Na]+ (C11H13NO5Na)+: m/z 262.0686, found: m/z 262.0699.  
2-isopropoxy-3-nitrobenzoic acid (1l) 
Compound 1k (5g, 21 mmol) was dissolved in hot methanol 
(10 mL) to which 1 M NaOH (42 mL, 42 mmol) was added. 
The mixture was heated under reflux for 2 hours and then 
quenched with water (100 mL). The aqueous layer was 
neutralized by addition of 1 M HCl until the pH was at least 1. The precipitated crude 
product was collected by filtration, then the crude product was dissolved in CH2Cl2 
and dried over anhydrous Na2SO4. Removal of CH2Cl2 gave a pure white solid 1l. 
Yield: 4.1 g, 87%; 1H NMR (500 MHz, CDCl3): δ 8.33 (d, 1H, J = 7.7 Hz), 8.04 (d, 
1H, J = 7.9 Hz), 7.38 (t, 1H, J = 7.7 Hz), 4.48 (m, 1H), 1.40 (d, 6H, J = 5.7 Hz). 13C 








82.25, 22.04. HRMS-ESI: calculated for [M]- (C10H10NO5): m/z 224.0554, found: m/z 
224.0559.  
 
Methyl 2-(allyloxy)-3-nitrobenzoate (1m) 
Methyl 2-hydroxy-3-nitrobenzoate (30.00 g, 152.3 mmol) 
was dissolved in DMF (250 mL) to which anhydrous K2CO3 
(63 g, 456.9 mmol) and dimethyl sulfate (15.8 mL, 183 
mmol) were added to it. The mixture was heated under 
reflux for 4 hours. The reaction mixture was then filtered 
and the solvent was removed in vacuo. The residue was dissolved in CH2Cl2 (300 
mL), washed with water (2 x 100 mL), and dried over anhydrous Na2SO4. Removal of 
CH2Cl2 gave a pure light yellow solid 1m. Yield: 26.7 g, 74%; 1H NMR (500 MHz, 
CDCl3): δ 8.04 (d, 1H, J = 7.0 Hz), 7.92 (d, 1H, J = 7.1 Hz), 7.30 (t, 1H, J = 7.0 Hz), 
6.16 – 6.02 (m, 1H), 5.40 (d, 1H, J = 17.2 Hz), 5.31 (d, 1H, J = 10.1 Hz), 4.66 (d, 2H, 
J = 4.4 Hz), 3.96 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 164.93, 151.71, 145.87, 
135.47, 132.56, 128.34, 127.92, 123.86, 119.27, 77.72, 52.77. HRMS-ESI: calculated 
for [M+Na]+ (C11H11NO5Na)+: m/z 260.0529, found: m/z 260.0531.  
 
Methyl 2-(allyloxy)-3-aminobenzoate (1n) 
Compound 1m (5 g, 21.1 mmol) was dissolved in EtOH 
(220 mL) to which iron powder (4.73 g, 84.4 mmol), acetic 
acid (22 mL) was added and refluxed 3 hours. After cooling, 
the reaction mixture was extraction by CH2Cl2, washed with 
water (2 x 150 mL), and dried over anhydrous Na2SO4. 
Removal of CH2Cl2 gave the pure brown liquid 1n. Yield: 3.8 g, 87%; HRMS-ESI: 
calculated for [M+Na]+(C11H13NO3Na)+: m/z 230.0788, found: m/z 230.0791. 
 
Methyl 3-(2-(benzyloxy)-3-nitrobenzamido)-2-methoxybenzoate (2a) 
Acid 1d (3.77 g, 13.8 mmol) was dissolved in CH2Cl2 















27.6 mmol) was added at room temperature. The reaction mixture was stirred for 5 
hours then the excess (COCl)2 was removed in vacuo to produce the compound 1f. A 
solution of amine 1g (2.08, 11.5 mmol) and DIEA (5.9 mL, 34.5 mmol) in CH2Cl2 (75 
mL) was added. The reaction mixture was allowed to stir continuously overnight at 
room temperature. The reaction mixture was washed with 1 M HCl (50 mL), followed 
by NaCl (100 mL). Drying over Na2SO4 and removal of solvent in vacuo gave the 
crude product, which was recrystallized from methanol to give the pure product 2a as 
a white solid. Yield: 5.65 g, 85.0 %.1H NMR (500 MHz, CDCl3): δ 9.80 (s, 1H), 8.69 
(dd, 1H, J = 8.2, 1.6 Hz), 8.29 (dd, 1H, J = 7.9, 1.8 Hz), 7.98 (dd, 1H, J = 8.0, 1.8 
Hz), 7.58 (dd, 1H, J = 7.9, 1.6 Hz), 7.40 (t, 1H, J = 7.9 Hz), 7.27 – 7.24 (m, 3H), 7.19 
(dd, 1H , J = 15.3, 7.4 Hz), 5.17 (s, 2H), 3.92 (s, 3H), 3.56 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 166.0, 161.8, 149.3, 149.2, 144.9, 135.9, 133.9, 132.3, 131.1, 129.4, 
129.1, 128.5, 128.3, 126.4, 124.9, 124.3, 123.8, 123.3, 79.8, 62.1, 52.2; HRMS-ESI: 





To a solution of 2a (4.05 g, 9.25 mmol) and iron 
(2.07 g, 37 mmol) in EtOH (37 mL) was added 
acetate acid (9.3 mL). The reaction was refluxed 
for 2 hours. After cooling, the solvent was 
evaporated and the residue was dissolved with 
CH2Cl2 and washed with water and Brine. The 
organic layer was dried over Na2SO4. 
Evaporation of the solvent gave the amine product used for the next step reaction 
without purification. Acid 1d (5.08 g, 18.6 mmol) was dissolved in CH2Cl2 (50 mL) 
to which DMF (0.34 mL), (COCl)2 (3.33 mL, 27.2 mmol) was added at room 
temperature. The reaction mixture was stirred for 5 hours then the excess (COCl)2 was 












and DIEA (4.76 mL, 27.8 mmol) in dry CH2Cl2 (150 mL) were added to the residue. 
The reaction was allowed to proceed for 4 h. After washing with HCl solution, 
aqueous sat. NaHCO3 and Brine, the organic layer was dried over Na2SO4. The 
residue was recrystallized from methanol to give the pure product 3a as a white solid. 
Yield: 4.34 g, 71%; 1H NMR (500 MHz, CDCl3): δ 9.83 (s, 1H), 9.39 (s, 1H), 8.78 
(dd, 1H, J = 8.1, 1.1 Hz), 8.61 (dd, 1H, J = 8.1, 1.2 Hz), 8.12 (dd, 1H, J = 7.8, 1.5 Hz), 
7.96 (dd, 1H, J = 8.0, 1.6 Hz), 7.87 (dd, 1H, J = 7.1, 1.2 Hz), 7.58 (dd, 1H, J = 7.7, 
1.2 Hz), 7.39-7.33 (m, 3H), 7.22-7.00 (m, 10 m), 5.05 (s, 2H), 4.81 (s, 2H), 3.93 (s, 
3H), 3.61 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 166.0, 163.2, 161.4, 149.2, 146.0, 
144.9, 135.7, 134.4, 134.0, 132.7, 132.1, 130.8, 129.3, 129.2, 128.9, 128.8, 128.5, 
128.3, 128.1, 127.5, 126.6, 126.1, 125.5, 124.9, 124.5, 124.3, 124.0, 123.4, 80.0, 78.9, 





nzamido)-2- methoxybenzoate (4a) 
To a solution of 3a (4.38 g, 6.63 mmol) and 
iron (1.49 g, 27 mmol) in EtOH (30 mL) was 
added acetate acid (7 mL). The reaction was 
refluxed for 2 hours. After cooling, the solvent 
was evaporated and the residue was dissolved 
with CH2Cl2 and washed with water and Brine. 
The organic layer was dried over Na2SO4. 
Evaporation of the solvent gave the amine product used for the next step reaction 
without purification. Acid 1c (2.6 g, 13.3 mmol) was dissolved in CH2Cl2 (50 mL) to 
which DMF (0.24 mL), (COCl)2 (2.38 mL, 26.6 mmol) was added at room 
temperature. The reaction mixture was stirred for 5 hours then the excess (COCl)2 was 
removed in vacuo to prodce the compound 1e. The amine product (4.18 g, 6.63 mmol) 















The reaction was allowed to proceed for 4 h. After washing with HCl solution, 
aqueous sat. NaHCO3 and Brine, the organic layer was dried over Na2SO4. The 
residue was recrystallized from methanol to give the pure product 4a as a white solid. 
Yield: 3.5 g, 65 %.1H NMR (500 MHz, CDCl3): δ 9.82 (s, 1H), 9.80 (s, 1H), 9.53 (s, 
1H), 8.85 – 8.73 (m, 3H), 8.32 (dd, 1H, J = 7.9, 1.7 Hz), 8.02 (dd, 1H, J = 8.0, 1.7 Hz), 
7.86 (dd, 1H, J = 7.8, 1.5 Hz), 7.75 (dd, 1H, J = 7.8, 1.5 Hz), 7.62 (dd, 1H, J = 7.9, 
1.5 Hz), 7.48 - 7.35 (m, 3H), 7.24 (t, 1H, J = 8.0 Hz), 7.20-7.07 (m, 9H), 7.04 (t, 2H, 
J = 7.3 Hz), 4.95 (s, 2H), 4.94 (s, 2H), 3.97 (s, 3H), 3.81 (s, 3H), 3.65 (s, 3H).13C 
NMR (125 MHz, CDCl3): δ 165.9, 163.4, 163.2, 161.3, 151.0, 149.2, 145.8, 144.3, 
136.1, 134.5, 134.3, 132.8, 132.5, 132.3, 129.3, 129.1, 129.1, 128.9, 128.9, 128.5, 
128.4, 127.7, 126.3, 126.1, 125.7, 125.6, 124.8, 124.5, 124.3, 124.1, 123.4, 79.2, 78.9, 






To a solution of 3a (4.38 g, 6.63 mmol) and iron 
(1.49 g, 27 mmol) in EtOH (30 mL) was added 
acetate acid (7 mL). The reaction was refluxed 
for 2 hours. After cooling, the solvent was 
evaporated and the residue was dissolved with 
CH2Cl2 and washed with water and Brine. The 
organic layer was dried over Na2SO4. Evaporation of the solvent gave the amine 
product used for the next step reaction without purification. Acid 1j (3 g, 13.3 mmol) 
was dissolved in CH2Cl2 (50 mL) to which DMF (0.24 mL), (COCl)2 (2.38 mL, 26.6 
mmol) was added at room temperature. The reaction mixture was stirred for 5 hours 
then the excess (COCl)2 was removed in vacuo to produce the chloride compound, 
which was dissolved in dry CH2Cl2. The amine product (4.18 g, 6.63 mmol) and 















reaction was allowed to proceed for 4 h. After washing with HCl solution, aqueous sat. 
NaHCO3 and Brine, the organic layer was dried over Na2SO4. The residue was 
recrystallized from methanol to give the pure product 4c as a white solid. Yield: 3 g, 
55 %. 1H NMR (500 MHz, CDCl3): δ 9.82 (s, 1H), 9.76 (s, 1H), 9.45 (s, 1H), 8.80 – 
8.59 (m, 3H), 8.24 (dd, 1H, J = 7.9, 1.5 Hz), 7.97 (dd, 1H, J = 8.0, 1.6 Hz), 7.83 (d, 
1H, J = 7.8 Hz), 7.74 – 7.67 (m, 1H), 7.58 (dd, 1H, J = 7.9, 1.3 Hz), 7.44 – 7.31 (m, 
3H), 7.20 (t, 1H, J = 8.0 Hz), 7.14 (d, 2H, J = 6.2 Hz), 7.11 – 7.00 (m, 5H), 6.97 (t, 
2H, J = 7.6 Hz), 4.92 (s, 2H), 4.91 (s, 2H), 4.09 (t, 2H, J = 7.0 Hz), 3.94 (s, 3H), 3.64 
(s, 3H), 1.27 (t, 3H, J = 7.0 Hz). 13C NMR (126 MHz, CDCl3): δ 166.00, 163.45, 
163.31, 161.73, 149.92, 149.24, 145.84, 145.80, 144.82, 135.82, 134.29, 134.24, 
132.84, 132.53, 132.33, 129.96, 129.45, 129.20, 129.18, 129.09, 128.53, 128.50, 
128.36, 127.82, 126.48, 126.31, 126.18, 125.73, 125.69, 124.72, 124.58, 124.51, 
124.40, 124.19, 123.45, 79.27, 79.00, 74.11, 62.17, 52.32, 50.71, 15.23. HRMS-ESI: 





To a solution of 3a (4.38 g, 6.63 mmol) and iron 
(1.49 g, 27 mmol) in EtOH (30 mL) was added 
acetate acid (7 mL). The reaction was refluxed 
for 2 hours. After cooling, the solvent was 
evaporated and the residue was dissolved with 
CH2Cl2 and washed with water and Brine. The 
organic layer was dried over Na2SO4. Evaporation of the solvent gave the amine 
product used for the next step reaction without purification. Acid 1l (3 g, 13.3 mmol) 
was dissolved in CH2Cl2 (50 mL) to which DMF (0.24 mL), (COCl)2 (2.38 mL, 26.6 
mmol) was added at room temperature. The reaction mixture was stirred for 5 hours 
then the excess (COCl)2 was removed in vacuo to produce the chloride compound 















(3.4 mL, 19.9 mmol) in dry CH2Cl2 (150 mL) were added to the residue. The reaction 
was allowed to proceed for 4 h. After washing with HCl solution, aqueous sat. 
NaHCO3 and Brine, the organic layer was dried over Na2SO4. The residue was 
recrystallized from methanol to give the pure product 4d as a white solid. Yield: 2.9 g, 
53 %. 1H NMR (500 MHz, CDCl3): δ 9.85 (s, 1H), 9.76 (s, 1H), 9.46 (s, 1H), 8.77 
(ddd, 2H, J = 7.9, 6.2, 1.4 Hz), 8.71 (dd, 1H, J = 8.1, 1.4 Hz), 8.25 (dd, 1H, J = 7.9, 
1.7 Hz), 7.99 (dd, 1H, J = 8.0, 1.7 Hz), 7.85 (dd, 1H, J = 7.9, 1.5 Hz), 7.71 (dd, 1H, J 
= 7.9, 1.5 Hz), 7.59 (dd, 1H, J = 7.9, 1.5 Hz), 7.46 – 7.31 (m, 3H), 7.23 – 7.15 (m, 
3H), 7.07 (dt, 5H, J = 15.1, 5.5 Hz), 6.96 (t, 2H, J = 7.6 Hz), 4.91 (s, 4H), 4.31 (hept, 
1H, J = 6.1 Hz), 3.95 (s, 3H), 3.64 (s, 3H), 1.25 (s, 3H), 1.25 (s, 3H). 13C NMR (126 
MHz, CDCl3): δ 165.90, 163.31, 163.14, 162.04, 149.16, 148.42, 145.66, 145.60, 
145.13, 135.61, 134.13, 134.07, 132.84, 132.51, 132.19, 131.03, 129.64, 129.20, 
129.12, 129.10, 128.50, 128.43, 128.41, 127.72, 126.45, 126.33, 126.05, 125.65, 
124.57, 124.40, 124.38, 124.19, 124.13, 123.37, 81.91, 79.14, 78.99, 62.12, 52.26, 






To a solution of 3a (1 g, 1.5 mmol) and iron 
(0.34 g, 6.05 mmol) in EtOH (15 mL) was added 
acetate acid (1.5 mL). The reaction was refluxed 
for 2 hours. After cooling, the solvent was 
evaporated and the residue was dissolved with 
CH2Cl2 and washed with water and Brine. The 
organic layer was dried over Na2SO4. Evaporation of the solvent gave the amine 
product used for the next step reaction without purification. Acid 1d (0.49 g, 1.8 
mmol) was dissolved in CH2Cl2 (50 mL) to which DMF (0.03 mL), (COCl)2 (0.322 















hours then the excess (COCl)2 was removed in vacuo to produce the chloride 
compound which was dissolved in dryCH2Cl2. The amine product and DIEA (0.64 
mL, 3.75 mmol) in dry CH2Cl2 (50 mL) were added to the residue. The reaction was 
allowed to proceed for 4 h. After washing with HCl solution, aqueous sat. NaHCO3 
and Brine, the organic layer was dried over Na2SO4. The residue was recrystallized 
from methanol to give the pure product 4e as a white solid. Yield: 0.9 g, 67 %.1H 
NMR (500 MHz, CDCl3): δ 9.73 (s, 1H), 9.54 (s, 1H), 9.19 (s, 1H), 8.78 (d, 1H, J = 
8.0 Hz), 8.73 (d, 1H, J = 8.0 Hz), 8.66 (d, 1H, J = 8.0 Hz), 8.16 (d, 1H, J = 7.6 Hz), 
8.03 (d, 1H, J = 7.9 Hz), 7.83 (d, 1H, J = 7.6 Hz), 7.80 (d, 1H, J = 7.8 Hz), 7.61 (d, 
1H, J = 7.6 Hz), 7.44 (t, 1H, J = 7.6 Hz), 7.39 (b, 2H), 7.26 – 7.11 (m, 6H), 7.11 – 
6.91 (m, 10H), 5.06 (s, 2H), 4.84 (s, 2H), 4.69 (s, 2H), 3.95 (s, 3H), 3.58 (s, 3H). 13C 
NMR (126 MHz, CDCl3): δ 165.98, 163.49, 163.21, 161.83, 149.20, 146.07, 145.77, 
145.06, 135.66, 134.43, 134.23, 133.95, 132.81, 132.53, 132.03, 131.28, 129.57, 
129.31, 129.20, 129.02, 128.97, 128.65, 128.49, 128.45, 128.13, 128.04, 127.50, 
126.72, 126.24, 126.16, 125.67, 125.56, 125.06, 124.65, 124.53, 124.46, 124.14, 
123.43, 80.07, 78.91, 78.86, 62.14, 52.29. HRMS-ESI: calculated for [M]- 





To a solution of 4a (3.4 g, 4.2 mmol) and iron 
(0.94 g, 16.8 mmol) in EtOH (20 mL) was added 
acetate acid (5 mL). The reaction was refluxed 
for 2 hours. After cooling, the solvent was 
evaporated and the residue was dissolved with 
CH2Cl2 and washed with water and Brine. The 
organic layer was dried over Na2SO4. 
Evaporation of the solvent gave the amine product used for the next step reaction 

















heated at reflux for 2 h. After removal the SOCl2, the amine product (3.3 g, 4.2 mmol) 
and DIEA (1.7 mL, 10.5 mmol) in dry CH2Cl2 (60 mL) were added to the residue. 
The reaction was allowed to proceed for 4 h. After washing with HCl solution, 
aqueous sat. NaHCO3 and Brine, the organic layer was dried over Na2SO4. The 
residue was recrystallized from methanol to give the pure product 5a as a white solid. 
Yield: 2.5g, 62%. 1H NMR (500 MHz, CDCl3): δ 9.97 (s, 1H), 9.85 (s, 1H), 9.64 (s, 
1H), 9.30 (s, 1H), 8.83-8.79 (m, 3H), 8.73 (d, 1H, J = 7.9 Hz), 8.48 (dd, 1H, J = 7.9, 
1.5 Hz), 8.05 (dd, 1H, J = 8.0, 1.5 Hz), 7.87-7.84 (m, 1H), 7.81 (d, 1H, J = 7.8 Hz), 
7.68-7.64 (m, 1H), 7.62 (dd, 1H, J = 7.8, 1.2 Hz), 7.49 (t, 1H, J = 7.9 Hz), 7.42-7.35 
(m, 3H), 7.26-7.18 (m, 3H), 7.15-7.08 (m, 5H), 7.06-6.96 (m, 3H), 4.97 (s, 2H), 4.90 
(s, 2H), 3.98 (s, 3H), 3.92 (s, 3H), 3.80 (s, 3H), 3.69 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 165.7, 163.4, 163.3, 163.0, 161.4, 151.1, 149.2, 147.0, 145.9, 145.6, 144.3, 
136.4, 134.7, 134.6, 132.8, 132.5, 132.4, 131.8, 129.2, 129.0, 128.9, 128.9, 128.8, 
128.5, 128.4, 128.4, 127.9, 127.5, 126.8, 126.4, 126.1, 125.8, 125.6, 125.6, 125.5, 
125.1, 124.6, 124.6, 124.4, 124.3, 124.1, 123.3, 78.7, 78.7, 64.4, 62.9, 62.1, 52.1; 




ido)benzamido) benzamido)benzamido)-2- methoxybenzoate (5b) 
To a solution of 4a (1.5 g, 1.9 mmol) and iron 
(410 mg, 7.4 mmol) in EtOH (20 mL) was added 
acetate acid (2 mL). The reaction was refluxed 
for 2 hours. After cooling, the solvent was 
evaporated and the residue was dissolved with 
CH2Cl2 and washed with water and Brine. The 
organic layer was dried over Na2SO4. 
Evaporation of the solvent gave the amine product used for the next step reaction 
without purification. Acid 1d (628 mg, 2.3 mmol) was dissolved in CH2Cl2 (20 mL) to 

















The reaction mixture was stirred for 5 hours then the excess (COCl)2 was removed in 
vacuo to produce the compound 1f. The amine product (1.53 g, 1.9 mmol) and DIEA 
(1.0 mL, 5.7 mmol) in dry CH2Cl2 (60 mL) were added to the residue. The reaction 
was allowed to proceed for 4 h. After washing with HCl solution, aqueous sat. 
NaHCO3 and Brine, the organic layer was dried over Na2SO4. The residue was 
recrystallized from methanol to give the pure product 5b as a white solid. Yield: 1.05 
g, 55 %. 1H NMR (500 MHz, CDCl3): δ 9.81 (s, 1H), 9.67 (s, 1H), 9.33 (s, 1H), 9.20 
(s, 1H), 8.79 - 8.76 (m, 2H), 8.70 (d, 2H, J = 8.2 Hz), 8.35 (dd, 1H, J = 8.2, 1.9 Hz), 
8.06 (dd, 1H, J = 8.2, 1.9 Hz), 7.86 - 7.82 (m, 2H), 7.62 - 7.58 (m, 2H), 7.5 (t, 1H, J = 
8.2 Hz), 7.39 - 7.32 (m, 3H), 7.21 - 7.13 (m, 6H), 7.12 - 7.01 (m, 7H), 6.95 - 6.89 (m, 
3H), 5.11 (s, 2H), 4.83 (s, 2H), 4.79 (s, 2H), 3.90 (s, 3H), 3.60 (s, 3H), 3.27 (s, 3H);  
13C NMR (125 MHz, CDCl3): δ 165.8, 163.5, 163.3, 162.9, 161.9, 149.4, 149.2, 147.2, 
146.0, 145.6, 144.9, 136.0, 134.5, 133.9, 132.8, 132.4, 131.4, 131.1, 130.8, 129.5, 
129.3, 128.9, 128.9, 128.8, 128.8, 128.6, 128.5, 128.4, 128.4, 128.0, 127.5, 126.8, 
126.4, 126.2, 126.1, 125.8, 125.6, 125.5, 125.4, 125.4, 124.8, 124.6, 124.5, 124.4, 
124.1, 123.4, 80.3, 78.8, 78.6, 65.8, 62.4, 62.0; HRMS-ESI: calculated for [M]- 





To a solution of 4c (210 mg, 0.26 mmol) and 
iron (72 mg, 1.27 mmol) in EtOH (5 mL) was 
added acetate acid (0.3 mL). The reaction was 
refluxed for 2 hours. After cooling, the solvent 
was evaporated and the residue was dissolved 
with CH2Cl2 and washed with water and Brine. 
The organic layer was dried over Na2SO4. 
Evaporation of the solvent gave the amine product used for the next step reaction 

















which DMF (0.05 mL), (COCl)2 (0.5 mL, 3.8 mmol) was added at room temperature. 
The reaction mixture was stirred for 5 hours then the excess (COCl)2 was removed in 
vacuo to produce the compound 1f. The amine product and DIEA (0.13 mL, 0.78 
mmol) in dry CH2Cl2 (10 mL) were added to the residue. The reaction was allowed to 
proceed for 4 h. After washing with HCl solution, aqueous sat. NaHCO3 and Brine, 
the organic layer was dried over Na2SO4. The residue was recrystallized from 
methanol to give the pure product 5c as a white solid. Yield: 193 mg, 71 %. 1H NMR 
(500 MHz, CDCl3): δ 9.85 (s, 1H), 9.65 (s, 1H), 9.29 (s, 1H), 9.21 (s, 1H), 8.78 (dd, 
2H, J = 8.0, 1.9 Hz), 8.69 (dd, 1H, J = 8.0, 1.0 Hz), 8.65 (d, 1H, J = 7.3 Hz), 8.30 (dt, 
1H, J = 9.5, 4.8 Hz), 8.07 – 8.02 (m, 1H), 7.83 (ddd, 2H, J = 16.8, 7.8, 1.2 Hz), 7.66 – 
7.55 (m, 2H), 7.48 (t, 1H, J = 7.9 Hz), 7.34 (dd, 3H, J = 14.5, 6.8 Hz), 7.24 – 7.09 (m, 
6H), 7.02 (dd, 4H, J = 6.8, 4.3 Hz), 6.99 – 6.86 (m, 6H), 5.10 (s, 2H), 4.86 (s, 2H), 
4.81 (s, 2H), 3.92 (s, 2H), 3.61 (s, 3H), 3.53 (q, 2H, J = 7.0 Hz), 0.97 (t, 3H, J = 7.0 
Hz). 13C NMR (126 MHz, CDCl3) δ 165.87, 163.45, 163.35, 163.29, 162.04, 159.47, 
152.48, 149.28, 146.07, 145.96, 145.60, 145.04, 136.48, 135.84, 135.03, 134.48, 
134.36, 133.87, 132.89, 132.55, 132.44, 131.75, 131.47, 130.23, 129.65, 129.42, 
129.22, 129.12, 128.96, 128.88, 128.77, 128.75, 128.69, 128.55, 128.44, 128.41, 
128.37, 128.04, 127.62, 127.15, 126.59, 126.33, 126.13, 125.91, 125.66, 125.61, 
125.39, 125.33, 124.72, 124.58, 124.46, 124.39, 124.19, 123.45, 80.35, 78.91, 78.65, 
72.22, 62.17, 52.21, 15.10. HRMS-ESI: calculated for [M]-(C60H50N5O13-): m/z 





To a solution of 4d (200 mg, 0.24 mmol) and iron (67 mg, 1.19 mmol) in EtOH (5 mL) 
was added acetate acid (0.3 mL). The reaction was refluxed for 2 hours. After cooling, 
the solvent was evaporated and the residue was dissolved with CH2Cl2 and washed 
with water and Brine. The organic layer was dried over Na2SO4. Evaporation of the 
solvent gave the amine product used for the next step reaction without purification. 
 131
Acid 1d (86 mg, 0.3 mmol) was dissolved in 
CH2Cl2 (5 mL) to which DMF (0.01 mL), 
(COCl)2 (0.08 mL, 0.6 mmol) was added at 
room temperature. The reaction mixture was 
stirred for 5 hours then the excess (COCl)2 was 
removed in vacuo to produce the compound 1f. 
The amine product and DIEA (0.12 mL, 0.72 
mmol) in dry CH2Cl2 (10 mL) were added to the residue. The reaction was allowed to 
proceed for 4 h. After washing with HCl solution, aqueous sat. NaHCO3 and Brine, 
the organic layer was dried over Na2SO4. The residue was recrystallized from 
methanol to give the pure product 5d as a white solid. Yield: 170 mg, 67 %. 1H NMR 
(500 MHz, CDCl3): δ 9.89 (s, 1H), 9.51 (s, 1H), 9.21 (s, 1H), 9.19 (s, 1H), 8.82 – 8.74 
(m, 2H), 8.69 – 8.56 (m, 2H), 8.28 (dd, 1H, J = 7.8, 1.7 Hz), 8.03 (dd, 1H, J = 8.0, 1.7 
Hz), 7.84 (dd, 1H, J = 7.9, 1.5 Hz), 7.79 (d, 1H d, J = 7.9, 1.5 Hz), 7.64 – 7.56 (m, 
2H), 7.47 (t, , 1H J = 7.9 Hz), 7.39 – 7.29 (m, 3H), 7.24 – 7.10 (m, 6H), 7.05 – 6.99 
(m, 4H), 6.99 – 6.86 (m, 6H), 5.11 (s, 2H), 4.94 (s, 2H), 4.80 (s, 2H), 4.00 (dt, 1H, J = 
12.3, 6.1 Hz), 3.92 (s, 3H), 3.65 (s, 3H), 1.03 (s, 2H), 1.02 (s, 3H). 13C NMR (126 
MHz, CDCl3): δ 165.83, 163.81, 163.34, 163.32, 162.00, 149.24, 149.16, 145.80, 
145.61, 145.00, 144.69, 135.63, 134.46, 134.22, 133.75, 132.85, 132.43, 132.34, 
132.17, 131.49, 129.59, 129.33, 129.20, 129.12, 129.03, 128.87, 128.77, 128.64, 
128.49, 128.39, 128.36, 127.97, 127.61, 126.53, 126.35, 126.08, 125.91, 125.59, 
125.30, 125.03, 124.78, 124.75, 124.52, 124.36, 124.14, 123.35, 80.18, 79.39, 78.91, 
78.55, 62.14, 52.19, 21.72. HRMS-ESI: calculated for [M]-(C61H52N5O13)-: m/z 





To a solution of 4e (800 mg, 0.903 mmol) and iron (202 mg, 3.16 mmol) in EtOH (9 

















cooling, the solvent was evaporated and the 
residue was dissolved with CH2Cl2 and 
washed with water and Brine. The organic 
layer was dried over Na2SO4. Evaporation of 
the solvent gave the amine product used for 
the next step reaction without purification. 
Acid 1d (296 mg, 1.08 mmol) was dissolved in 
CH2Cl2 (5 mL) to which DMF (0.02 mL), 
(COCl)2 (0.29 mL, 2.2 mmol) was added at room temperature. The reaction mixture 
was stirred for 5 hours then the excess (COCl)2 was removed in vacuo to produce the 
compound 1f. The amine product and DIEA (0.46 mL, 2.71 mmol) in dry CH2Cl2 (10 
mL) were added to the residue. The reaction was allowed to proceed for 4 h. After 
washing with HCl solution, aqueous sat. NaHCO3 and Brine, the organic layer was 
dried over Na2SO4. The residue was recrystallized from methanol to give the pure 
product 5e as a white solid. Yield: 724 mg, 72 %. 1H NMR (500 MHz, CDCl3): δ 9.78 
(s, 1H), 9.39 (s, 1H), 9.20 (s, 1H), 9.12 (s, 1H), 8.77 (t, 2H, J = 6.9 Hz), 8.67 (t, 2H, J 
= 8.5 Hz), 8.11 (d, 1H, J = 7.6 Hz), 8.01 (d, 1H, J = 7.8 Hz), 7.85 (d, 1H, J = 7.3 Hz), 
7.81 (d, 1H, J = 7.6 Hz), 7.68 (d, 1H, J = 7.0 Hz), 7.59 (d, 1H, J = 7.8 Hz), 7.46 – 
7.32 (m, 5H), 7.26 – 7.06 (m, 8H), 7.06 – 6.90 (m, 10H), 6.88 (m, 2H), 5.02 (s, 2H), 
4.79 (s, 2H), 4.73 (s, 2H), 4.62 (s, 2H), 3.91 (s, 3H), 3.55 (s, 3H). 13C NMR (126 MHz, 
CDCl3): δ 165.97, 163.53, 163.45, 163.38, 161.70, 149.20, 149.10, 146.03, 145.87, 
145.79, 145.09, 135.59, 134.59, 134.39, 133.85, 132.79, 132.41, 132.38, 132.18, 
131.29, 129.71, 129.28, 129.11, 129.09, 129.05, 128.92, 128.86, 128.73, 128.61, 
128.55, 128.48, 128.38, 128.08, 128.03, 127.70, 126.54, 126.32, 126.15, 126.06, 
125.63, 125.56, 125.01, 124.78, 124.70, 124.60, 124.35, 124.14, 123.45, 80.10, 79.09, 
78.75, 78.57, 62.10, 52.21. HRMS-ESI: calculated for [M+Na]+(C65H53N5O13Na)+: 





















To a solution of 5a (465 mg, 0.50 mmol) and 
iron (112 mg, 2.0 mmol) in EtOH (5 mL) was 
added acetate acid (1.0 mL). The reaction was 
refluxed for 3 hours. After cooling, the solvent 
was evaporated and the residue was dissolved 
with CH2Cl2 and washed with water and Brine. 
The organic layer was dried over Na2SO4. 
After removal of the solvent, the residue was 
not purified, but used directly in the next step. To the solution of residue in hot 
methanol (1.5 mL) was added 1 M KOH (1.0 mL). The reaction was heated under 
reflux for 4 hours. After quenching with water (15 ml), the aqueous layer was 
neutralized by addition 1 M HCl (1.5 mL). The mixture was extracted with CHCl3 
(3x15 mL). The organic extracts were dried over Na2SO4 and concentrated under 
reduced pressure. To the solution of the residue in dry CH2Cl2 (10 mL) was added 
BOP (0.55 g, 1.25 mmol) and DIEA (0.34 mL, 2 mmol). The reaction was stirred in 
room temperature for 6 hours. The reaction was washed with HCl solution, aqueous 
sat. NaHCO3 and Brine. After removal of the solvent, the residue was purified by 
flash column chromatography on silica gel using CH2Cl2/Ethyl Acetate (20/1 v/v) as 
the eluent to give the product 6a, three-step total yield: 210 mg, 47%.1H NMR (300 
MHz, CDCl3): δ 10.76 (s, 1H), 10.64 (s, 1H), 10.49 (s, 1H), 10.22 (s, 1H), 10.03 (s, 
1H), 8.93-8.86 (m, 4H), 8.71 (d, 1H, J = 8.1 Hz), 8.00 (dd, 2H, J = 14.0, 8.0 Hz), 
7.93-7.84 (m, 2H), 7.78 (d, 1H, J = 7.8 Hz), 7.47-7.34 (m, 5H), 7.11 (m, 4H), 
7.03-6.86 (m, 6H), 5.12 -4.93 (m, 4H), 3.95 (s, 3H), 3.88 (s, 6H); 13C NMR (75 MHz, 
CDCl3): δ 162.9, 162.5, 162.4, 162.2, 146.5, 146.4, 144.9, 133.7, 133.0, 132.9, 132.7, 
132.6, 132.4, 129.3, 129.2, 129.1, 128.5, 127.4, 127.1, 126.4, 126.2, 126.2, 126.0, 
125.8, 125.7, 124.2, 124.1, 124.0, 123.6, 79.7, 79.6, 63.6, 63.2, 63.1. HRMS-ESI: 





















To a solution of 5b (600 mg, 0.58 mmol) and 
iron (130 mg, 2.32 mmol) in EtOH (6 mL) was 
added acetate acid (0.6 mL). The reaction was 
refluxed for 2 hours. The reaction was 
dissolved with CH2Cl2 and washed with water 
and Brine. The organic layer was dried over 
Na2SO4. After removal of the solvent, the 
residue was not purified, but used directly in 
the next step. To the solution of residue in hot methanol (10 mL) was added 1 M 
NaOH (1.2 mL). The reaction was heated under reflux for 2 hours. After quenching 
with water (10 mL), the aqueous layer was neutralized by addition 1 M HCl (1.2 mL). 
The mixture were extracted with CH2Cl2. The organic extracts were dried over 
Na2SO4 and concentrated under reduced pressure. To the solution of the residue in dry 
CH2Cl2 (25 mL) was added BOP (0.65 g, 1.8 mmol) and DIEA (0.40 mL, 2.3 mmol). 
The reaction was stirred in room temperature for 6 hours. The reaction was washed 
with HCl solution, aqueous sat. NaHCO3 and brine. After removal of the solvent, the 
residue was purified by flash column chromatography on silica gel using Ethyl acetate 
/ CH2Cl2 (1/10 v/v) as the eluent to give the product 6b, three-step total yield: 104 mg, 
18 %. 13C NMR (125 MHz, CDCl3): δ 163.3, 162.9, 162.8, 162.6, 162.5, 162.4, 162.4, 
162.3, 162.2, 162.2, 146.5, 146.3, 146.2, 146.1, 145.1, 144.9, 144.9, 144.5, 144.5, 
144.3, 134.1, 133.7, 133.6, 133.4, 133.4, 133.3, 133.1, 133.1, 133.1, 133.0, 132.8, 
132.8, 132.7, 132.7, 132.4, 132.4, 130.1, 129.7, 129.6, 129.4, 129.3, 129.2, 129.2, 
129.1, 128.6, 128.5, 128.5, 128.2, 127.9, 127.9, 127.6, 127.5, 126.7, 126.4, 126.2, 
126.2, 126.2, 126.1, 126.1, 126.1, 126.0, 125.9, 125.9, 125.8, 125.8, 125.7, 125.6, 
124.1, 124.0, 123.8, 123.6, 123.5, 123.4, 79.9, 79.7, 79.7, 79.7, 79.7, 79.4, 63.6, 63.4, 






















To a solution of 5c (200 mg, 0.19 mmol) and 
iron (54 mg, 0.95 mmol) in EtOH (2 mL) was 
added acetate acid (0.2 mL). The reaction was 
refluxed for 2 hours. The reaction was dissolved 
with CH2Cl2 and washed with water and Brine. 
The organic layer was dried over Na2SO4. After 
removal of the solvent, the residue was not 
purified, but used directly in the next step. To the 
solution of residue in hot methanol (10 mL) was added 1 M NaOH (0.4 mL). The 
reaction was heated under reflux for 2 hours. After quenching with water (10 mL), the 
aqueous layer was neutralized by addition 1 M HCl to pH 7. The mixture were 
extracted with CH2Cl2. The organic extracts were dried over Na2SO4 and concentrated 
under reduced pressure. To the solution of the residue in dry CH2Cl2 (10 mL) was 
added BOP (210 mg, 0.48 mmol) and DIEA (0.13 mL, 0.76 mmol). The reaction was 
stirred in room temperature for 6 hours. The reaction was washed with HCl solution, 
aqueous sat. NaHCO3 and brine. After removal of the solvent, the residue was purified 
by flash column chromatography on silica gel using Ethyl acetate / CH2Cl2 (1/10 v/v) 
as the eluent to give the product 6c, three-step total yield: 38 mg, 20 %. 13C NMR 
(126 MHz, CDCl3): δ 163.13, 163.06, 163.00, 162.96, 162.85, 162.77, 162.74, 162.59, 
162.47, 162.45, 162.39, 162.36, 146.67, 146.52, 146.43, 145.63, 145.18, 145.10, 
144.80, 144.65, 144.56, 144.53, 144.49, 144.43, 144.37, 144.22, 133.64, 133.49, 
133.39, 133.27, 133.22, 133.15, 133.11, 133.01, 132.97, 132.92, 132.74, 132.59, 
132.48, 129.85, 129.81, 129.78, 129.75, 129.70, 129.64, 129.54, 129.51, 129.32, 
129.28, 128.62, 128.55, 128.47, 128.44, 128.33, 128.26, 128.17, 127.45, 127.42, 
127.19, 126.39, 126.35, 126.27, 126.19, 126.10, 126.04, 126.01, 125.89, 125.82, 
125.57, 124.07, 123.90, 123.85, 123.66, 123.60, 123.50, 123.39, 79.88, 79.57, 79.48, 
79.24, 72.05, 71.76, 63.90, 62.56, 15.85, 15.34.; HRMS-ESI: calculated for 




















To a solution of 5d (250 mg, 0.24 mmol) and 
iron (92 mg, 1.65 mmol) in EtOH (3 mL) was 
added acetate acid (0.3 mL). The reaction was 
refluxed for 2 hours. The reaction was dissolved 
with CH2Cl2 and washed with water and Brine. 
The organic layer was dried over Na2SO4. After 
removal of the solvent, the residue was not 
purified, but used directly in the next step. To the 
solution of residue in hot methanol (10 mL) was added 1 M NaOH (0.6 mL). The 
reaction was heated under reflux for 2 hours. After quenching with water (10 mL), the 
aqueous layer was neutralized by addition 1 M HCl to pH 7. The mixture were 
extracted with CH2Cl2. The organic extracts were dried over Na2SO4 and concentrated 
under reduced pressure. To the solution of the residue in dry CH2Cl2 (10 mL) was 
added BOP (270 mg, 0.6 mmol) and DIEA (0.17 mL, 0.96 mmol). The reaction was 
stirred in room temperature for 6 hours. The reaction was washed with HCl solution, 
aqueous sat. NaHCO3 and brine. After removal of the solvent, the residue was purified 
by flash column chromatography on silica gel using Ethyl acetate / CH2Cl2 (1/10 v/v) 
as the eluent to give the product 6c, three-step total yield: 38 mg, 13 %. 1H NMR (500 
MHz, CDCl3): δ 10.48 (s, 1H), 10.31 (s, 1H), 10.15 (s, 2H), 9.42 (s, 1H), 8.94 (m, 4H), 
8.47 (d, J = 8.0 Hz, 1H), 7.85 (m, 5H), 7.64 (d, J = 7.8 Hz, 1H), 7.38 (m, 6H), 7.18 (t, 
J = 7.3 Hz, 1H), 6.92 (m, 16H), 5.22 (d, 2H, J = 11.5 Hz), 5.08 – 4.92 (m, 3H), 4.88 
(d, 2H, J = 11.6 Hz), 4.43 (dt, J = 12.1, 6.0 Hz, 1H), 3.90 (d, J = 10.3 Hz, 3H), 1.53 (d, 
J = 6.0 Hz, 3H), 1.48 (d, J = 6.1 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 163.12, 
162.49, 162.47, 162.38, 146.68, 145.42, 144.87, 144.45, 144.39, 144.11, 144.03, 
143.61, 143.48, 133.57, 133.52, 133.41, 133.29, 133.18, 132.94, 132.78, 132.57, 
132.49, 131.63, 130.90, 130.69, 129.98, 129.87, 129.72, 129.43, 129.24, 129.03, 
128.61, 128.46, 128.42, 128.17, 127.87, 127.51, 127.37, 127.08, 126.26, 126.18, 
126.10, 126.03, 125.97, 125.84, 125.71, 125.52, 124.32, 123.79, 123.66, 123.41, 


















[M]-(C60H51N5O10) -: m/z 1000.3563, found: m/z 1000.3527. 
 
Pentamer 6e 
To a solution of 5e (600 mg, 0.54mmol) and 
iron (121 mg, 2.16 mmol) in EtOH (6 mL) was 
added acetate acid (0.6 mL). The reaction was 
refluxed for 2 hours. The reaction was 
dissolved with CH2Cl2 and washed with water 
and Brine. The organic layer was dried over 
Na2SO4. After removal of the solvent, the 
residue was not purified, but used directly in 
the next step. To the solution of residue in hot 
methanol (10 mL) was added 1 M NaOH (1.08 mL). The reaction was heated under 
reflux for 2 hours. After quenching with water (10 mL), the aqueous layer was 
neutralized by addition 1 M HCl to pH 7. The mixture were extracted with CH2Cl2. 
The organic extracts were dried over Na2SO4 and concentrated under reduced 
pressure. To the solution of the residue in dry CH2Cl2 (10 mL) was added BOP (600 
mg, 1.35 mmol) and DIEA (0.37 mL, 2.16 mmol). The reaction was stirred in room 
temperature for 6 hours. The reaction was washed with HCl solution, aqueous sat. 
NaHCO3 and brine. After removal of the solvent, the residue was purified by flash 
column chromatography on silica gel using Ethyl acetate / CH2Cl2 (1/10 v/v) as the 
eluent to give the product 6e, three-step total yield: 89 mg, 16%. 13C NMR (126 MHz, 
CDCl3): δ 163.58, 163.16, 162.83, 162.61, 162.55, 162.43, 162.36, 162.28, 146.41, 
146.22, 144.96, 144.94, 144.81, 144.63, 144.44, 144.32, 144.08, 133.82, 133.70, 
133.54, 133.50, 133.29, 133.22, 133.14, 133.02, 132.99, 132.78, 132.75, 132.60, 
132.47, 130.28, 129.73, 129.64, 129.60, 129.47, 129.42, 129.40, 129.33, 129.28, 
129.19, 129.09, 128.97, 128.62, 128.55, 128.50, 128.47, 128.42, 128.39, 128.19, 
128.05, 128.01, 127.86, 127.75, 127.02, 126.73, 126.40, 126.18, 126.09, 125.97, 
125.92, 125.86, 125.68, 125.59, 125.46, 124.23, 124.00, 123.92, 123.66, 123.51, 






















To a solution of amino acid 1o (1.36 g, 7 
mmol) in CH3CN (250 mL) was added POCl3 
(1.33 mL, 14 mmol) at room temperature. The 
solution was vigorously stirred. After 10 min, 
Et3N (3.03 mL, 21 mmol) was added into the 
reaction mixture. The solution was stirred for 
12 h. The reaction was concentrated in vacuo. 
The residue was purified by flash column 
chromatography (ethyl 
acetate:dichloromethane = 1:10) to afford circular pentamer 8 as a white solid. Yield: 
273 mg, 33%.1H NMR (500 MHz, CDCl3): δ 10.34 (s, 5H), 8.93 (s, 5H), 7.92 (s, 5H), 
7.42 (s, 5H), 6.03 (dd, 5H, J = 13.3, 7.7 Hz), 5.18 (d, 10H, J = 13.5 Hz), 4.63 (s, 10H). 
13C NMR (126 MHz, CDCl3): δ 162.97, 144.44, 133.03, 130.80, 127.42, 126.28, 
125.89, 123.82, 122.27. HRMS-ESI: calculated for [M+Na]+ (C50H45N5NaO10)+: m/z 
898.3059, found: m/z 898.3064. 
 
Pentamer 1 
To a solution of amino acid 1h (33.4 mg, 0.2 mmol) 
in CH3CN (2.0 mL) was added POCl3 (38 uL, 0.4 
mmol) at room temperature. The solution was 
vigorously stirred. After 10 min, Et3N (84 uL, 0.6 
mmol) was added into the reaction mixture. The 
solution was stirred for 12 h. The reaction was 
concentrated in vacuo. The residue was purified by 
flash column chromatography (ethyl 


































pentamer 1 as a white solid. Yield: 13.7 mg, 46%. 1H NMR (500 MHz, CDCl3): δ 
10.91 (s, 5H), 9.02 (d, 5H, J = 7.9 Hz), 8.04 (d, 5H, J = 7.7 Hz), 7.46 (t, 5H, J = 8.0 
Hz), 4.12 (s, 15H). 13C NMR (125 MHz, CDCl3): δ 162.27, 146.50, 132.85, 126.56, 
126.18, 125.62, 124.33, 63.32. HRMS-ESI: exact mass calculated for [M]- 
(C40H35N5O10) -: m/z 744.2311, found: m/z 744.2314. 
 
Pentamer 2 
Pentamer 1 (3.7 mg, 0.005 mmol) was dissolved 
in 1.0 mL of CHCl3. To this solution, TBACl 
(27.7 mg, 0.1 mmol, 20 equiv.) was added. The 
temperature of the solution was then increased to 
60 oC and the reaction was allowed to proceed at 
60 oC for 12h. As the reaction progressed, the 
solution gradually became green. 12 h later, 10 
mL water was added to stop the reaction. The 
organic phase was separated and aqueous layer 
was washed twice with CHCl3 (2 x 10 mL). The combined organic layer (CHCl3) was 
dried with sodium sulfate. The solvent is removed under reduced pressure to produce 
the Pentamer 2. Yield: 358 mg, 83%. 1H NMR (500 MHz, CDCl3): δ 11.16 (s, 1H), 
11.15 (s, 1H), 11.11 (s, 1H), 11.01 (s, 1H), 10.61 (s, 1H), 8.64 (d, 2H, J = 3.0 Hz), 
8.53 (d, 1H, J = 3.0 Hz), 8.37 (d, 1H, J = 7.0 Hz), 8.29 (s, 1H), 8.04 (s, 1H), 7.54 (d, 
1H, J = 3.0 Hz), 7.51 (d, 1H, J = 3.0 Hz), 7.48-7.46 (m, 1H), 7.37 (dd, 2H, J = 7.5, 2.5 
Hz), 6,94 (t, 1H, J = 8.0 Hz), 4.20 (s, 3H), 4.14 (s, 3H), 4.11 (s, 3H), 4.10-4.08 (m, 
4H), 4.08 (s, 3H), 4.02 (t, 2H, J = 6.5 Hz), 3.93 (t, 2H, J = 6.5 Hz), 1.88-1.81 (m, 6H), 
1.76-1.72 (m, 2H), 1.51-1.47 (m, 8H), 1.38-1.21 (m, 32H), 0.93-0.87 (m, 12H). 13C 
NMR (125 MHz, CDCl3): δ 165.9, 162.6, 162.3, 162.2, 162.01, 156.8, 156.5, 156.1, 
140.1, 140.4, 140.4, 133.6, 133.5, 132.2, 125.7, 125.4, 125.3, 124.7, 124.1, 111.9, 
111.1, 111.0, 110.6, 111.5, 110.3, 110.1, 111.1, 108.8, 108.8, 68.7, 63.2, 63.2, 62.7, 
31.8, 29.3, 29.3, 29.2, 29.2, 29.0, 26.0, 26.0, 25.9, 25.8, 22.7, 14.1. HRMS-FAB: 



















Pentamer 6a (89.7 mg, 0.10 mmol) was reduced 
by catalytic hydrogenation in THF (20 mL) at 50 
oC, using 10% Pd/C (18.0 mg, 20%) as the catalyst 
for 3 h. The reaction mixture was then filtered and 
the solvent removed in vacuo and washed with 
ether to give the green solid Pentamer 3. Yield: 
58 mg, 81%. 1H NMR (500 MHz, d6-DMSO): δ 
11.72 (s, 1H), 11.18 (s, 1H), 11.05 (s, 1H), 10.91 
(s, 1H), 10.19 (s, 1H), 8.93 – 8.79 (m, 3H), 8.70 
(dd, 1H, J = 8.0, 1.4 Hz), 8.61 (d, 1H, J = 7.9 Hz), 7.95 – 7.86 (m, 3H), 7.81-7.80 (m, 
2H), 7.60 (d, 1H, J = 6.9 Hz), 7.38 – 7.28 (m, 3H), 7.16 (dd, 2H, J = 17.7, 8.0 Hz), 
4.08 (s, 6H), 4.03 (s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 163.9, 163.5, 162.3, 
162.2, 162.1, 147.2, 146.9, 146.9, 133.4, 133.2, 133.0, 132.1, 131.9, 131.8, 126.3, 
125.9, 125.8, 125.7, 125.6, 125.6, 125.5, 125.3, 125.3, 124.9, 124.5, 124.5, 124.2, 
123.9, 123.4, 123.2, 122.6, 122.5, 63.3, 63.1; HRMS-ESI: calculated for [M]- 
(C38H31N5O10) -：m/z 716.1998, found: m/z 716.2019 
 
Pentamer 4 
Pentamer 6b (130.0 mg, 0.13 mmol) was 
reduced by catalytic hydrogenation in THF (25 
mL) at 60 oC, using 10% Pd/C (39 mg, 30%) as 
the catalyst for 48 hours. The reaction mixture 
was then filtered and the solvent removed in 
vacuo and washed with ether to give the green 
solid pentamer 4. Yield: 66%. 1H NMR (500 
MHz, d6-DMSO:CDCl3 = 10:1): δ 11.86 (b, 1H), 
11.23 (b, 1H), 11.07 (s, 3H), 8.86 - 8.84 (m, 2H), 
8.70 – 8.66 (m, 3H), 7.88 – 7.75 (m, 5H), 7.42 (t, 2H, J = 7.6 Hz), 7.22 – 7.21 (m, 3H); 


































146.8, 133.2, 132.4, 132.2, 132.0, 126.0, 125.9, 125.5, 125.5, 124.8, 124.8, 124.7, 
124.6, 124.5, 124.3, 123.7, 123.3, 123.2, 123.1, 122.8, 122.3, 122.1, 63.1, 63.0; 




Pentamer 6c (200 mg, 0.2 mmol) was reduced 
by catalytic hydrogenation in THF (30 mL) at 60 
oC, using 10% Pd/C (60 mg, 30 %) as the 
catalyst for 48 hours. The reaction mixture was 
then filtered and the solvent removed in vacuo 
and washed with ether to give the green solid 
pentamer 5. Yield: 57 mg, 40 %. 1H NMR (500 
MHz, d6-DMSO:CDCl3 = 10:1): δ 11.66 (s, 1H), 
11.44 (b, 1H), 10.95 (b, 1H), 10.89 (s, 2H), 8.81 
(d, 1H, J = 8.80 Hz), 8.73 (m, 3H), 8.57 (t, 1H, J = 7.83 Hz), 7.92 (t, 1H, J = 8.80 Hz), 
7.84 (d, 1H, J = 7.83 Hz), 7.75 (m, 4H), 7.29 (m, 2H), 7.13 (m, 3H), 4.13 (q, 2H, J = 
4.12 Hz), 4.01 (s, 3H), 1.57 (t, 3H, J = 4.12 Hz). 13C NMR (126 MHz, 
d6-DMSO:CDCl3 = 10:1): δ 163.46, 162.77, 162.74, 162.38, 147.33, 146.20, 144.57, 
143.94, 143.84, 133.52, 133.47, 133.34, 133.32, 132.54, 132.05, 132.01, 127.16, 
126.38, 125.61, 125.42, 125.25, 124.93, 124.59, 124.53, 124.45, 124.38, 123.92, 
123.88, 123.80, 123.29, 122.84, 122.76, 122.45, 72.32, 63.12, 15.45. HRMS-ESI: 
calculated for [M]- (C38H30N5O10)-: m/z 716.1998, found: m/z 716.1970. 
 
Pentamer 6 
Pentamer 6d (200 mg, 0.2 mmol) was reduced by catalytic hydrogenation in THF 
(30 mL) at 60 oC, using 10% Pd/C (60 mg, 30%) as the catalyst for 48 hours. The 
reaction mixture was then filtered and the solvent removed in vacuo and washed with 
ether to give the green solid pentamer 6. Yield: 65 mg, 45%.  1H NMR (500 MHz, 


















10.36 (b, 1H), 8.78 (d, 1H, J = 7.3 Hz), 8.70 (t, 2H, 
J = 6.5 Hz), 8.61 (b, 1H), 8.51 (m, 1H), 7.92 (d, 
1H, J = 6.6 Hz), 7.77 (m, 5H), 7.29 (d, 2H, J = 5.2 
Hz), 7.14 (m, 3H), 4.32 (m, 1H), 3.99 (s, 3H), 1.37 
(s, 6H). 13C NMR (126 MHz, d6-DMSO): δ 164.56, 
164.07, 163.43, 163.22, 162.33, 147.46, 145.19, 
145.04, 144.26, 144.19, 133.92, 133.38, 132.35, 
131.63, 128.68, 126.46, 125.84, 125.56, 125.43, 
125.18, 125.05, 124.62, 124.43, 124.34, 124.12, 
123.78, 123.11, 122.55, 122.08, 79.15, 63.16, 21.85. HRMS-ESI: calculated for [M]- 
(C39H32N5O10)-: m/z 730.2155, found: m/z 730.2137. 
 
Pentamer 7 
Pentamer 6e (82 mg, 78 umol) was reduced by 
catalytic hydrogenation in THF (10 mL) at 60 oC, 
using 10% Pd/C (40 mg, 40%) as the catalyst for 
48 hours. The reaction mixture was then filtered 
and the solvent removed in vacuo and washed 
with ether to give the green solid pentamer 7. 
Yield: 30 mg, 56%. 1H NMR (500 MHz, 
d6-DMSO): δ 11.70 (s, 1H), 11.41 (s, 1H), 11.23 
(s, 1H), 11.02 (s, 1H), 10.99 (s, 1H), 10.39 – 
10.24 (m, 4H), 8.80 (d, 1H, J = 6.5 Hz), 8.65 (d, 1H, J = 6.5 Hz), 8.62 (d, 1H, J = 6.5 
Hz), 8.52 (t, 2H, J = 6.5 Hz), 7.90 (d, 1H, J = 6.5 Hz), 7.84 (d, 1H, J = 6.5 Hz), 7.79 
(b, 2H), 7.75 (d, 1H, J = 6.5 Hz), 7.29 (b, 1H), 7.12 (m, 4H), 4.06 (s, 3H). 13C NMR 
(126 MHz, CDCl3): δ 163.74, 163.69, 163.42, 162.17, 147.44, 144.88, 144.85, 144.54, 
144.50, 133.67, 132.86, 132.80, 132.53, 132.39, 126.49, 125.89, 125.32, 125.14, 
124.82, 124.60, 124.56, 123.80, 123.61, 123.56, 123.00, 122.95, 122.83, 122.60, 
122.56, 122.50, 63.63. HRMS-ESI: calculated for [M+Na]+ (C36H26N5O10Na)+: m/z 



































Pentamer 6f (200 mg, 229 umol) was reduced 
by catalytic hydrogenation in THF (30 mL) at 60 
oC, using 10% Pd/C (100 mg, 50%) as the 
catalyst for 48 hours. The reaction mixture was 
then filtered and the solvent removed in vacuo 
and washed with ether to give the green solid 
pentamer 8. Yield: 70 mg, 45%. 1H NMR (500 
MHz, d6-DMSO): δ 11.16 (s, 5H), 10.32 (s, 5H), 
8.51 (d, 5H, J = 7.5 Hz), 7.79 (d, 5H, J = 7.9 Hz), 
7.60 (s, 5H), 7.10 (t, 5H, J = 7.9 Hz). 13C NMR 
(126 MHz, d6-DMSO): δ 164.28, 145.11, 131.62, 125.00, 124.06, 123.97, 122.07. 
HRMS-ESI: calculated for [M]- (C35H24N5O10) - : m/z 674.1529, found: m/z 674.1536. 
7.2 Experimental section of side chain macrocyclic 
pentamers 9-11  
7.2.1 General remarks 
All the reagents were obtained from commercial suppliers and used as received 
unless otherwise noted. The organic solutions from all liquid extractions were dried 
over anhydrous Na2SO4 for a minimum of 15 minutes before filtration. Reactions 
were monitored by thin-layer chromatography (TLC) on silica gel pre-coated glass 
plate (0.225 mm thickness, 60F-254, E. Merck). Flash column chromatography was 
performed using pre-coated 0.2 mm silica plates from Selecto Scientific. Chemical 
yields refer to pure isolated substances. CD spectra were measured using a Jasco 
model J-810 CD spectrophotometer. ITC experiments were obtained using iTC200 
Microcalorimenter. Mass spectra were obtained using the Instrumentation includes 
Finnigan MAT95XL-T and Micromass VG7035. 1H NMR spectra were recorded on 


















signal of CDCl3 was referenced at δ = 7.26 ppm, d6-DMSO was referenced at δ = 2.50 
ppm and d4-methanol was referenced at δ = 1.94 ppm. Coupling constants (J values) 
are reported in Hertz (Hz). 1H NMR data are recorded in the order: chemical shift 
value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), 
number of protons that gave rise to the signal and coupling constant, where applicable. 
13C spectra were proton-decoupled and recorded on Bruker ACF-300 (300 MHz) and 
ACF500 spectrometers (500 MHz). The solvent, CDCl3 was referenced at 77 ppm and 
d6-DMSO at 39.5 ppm. CDCl3 (99.8% deuterated) and d6-DMSO (99.8%-Deuterated) 
were purchased from Aldrich and used without further purification. d4-methanol 
(99.8% deuterated) was purchased from Cambridge Isotope Laboratories, Inc. and 
used without further purification. 
7.2.2 Experimental Procedures and Compound Characterizations of 
pentamers 9-11  
Methyl 2,5-dihydroxybenzoate (1a) 
2,5-dihydroxybenzoic acid (4.62 g, 30.0 mmol) was dissolved in 
MeOH (60 mL), to which concentrated H2SO4 (5 mL) was added. 
The mixture was heated under reflux for 48 hours. The solvent 
was then removed in vacuo and the residue was dissolved in 
CH2Cl2 (100 mL), washed with water (2 x 50 mL) and dried over 
anhydrous Na2SO4. Removal of CH2Cl2 gave the pure product 1a as a light brown 
solid. Yield: 4.89 g, 97 %. 1H NMR (300 MHz, CDCl3): δ 10.33 (s, 1H), 7.28 (d, 1H, 
J = 3.1 Hz), 7.01 (d, 1H, J = 8.9 Hz), 6.88 (d, 1H, J = 8.9 Hz), 4.76 (s, 1H), 3.93 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ 170. 9, 156.1, 148.5, 124.9, 119.1, 115.6, 112.9, 








Methyl 2-hydroxy-5-(prop-2-yn-1-yloxy)benzoate (1b) 
 Compound 1a (2 g, 12 mmol) was dissolved in anhydrous 
acetone (25 mL), to which anhydrous K2CO3 (6.63 g, 48 mmol) 
and 3-bromoprop-1-yne (0.54 mL, 6 mmol) were added. The 
mixture was heated under reflux for 12 hours. The reaction 
mixture was then filtered and the solvent was removed in 
vacuo. The concentrate was dissolved in CH2Cl2 (60 mL), 
washed with water (2 x 30 mL) and dried over anhydrous 
Na2SO4. Removal of CH2Cl2 gave the crude product, which was further purified by 
gradient flash column chromatography on silica gel using hexane/ethyl acetate (1:10) 
as the eluent to give pure product 1b as a white solid and the excesses compound 1a 
can be recycled. Yield: 1 g, 80 %.1H NMR (500 MHz, CDCl3): δ 10.40 (s, 1H), 7.39 
(d, 1H, J = 3.2 Hz), 7.15 (dd, 1H, J = 8.8, 3.2 Hz), 6.93 (d, 1H, J = 8.8 Hz), 4.64 (d, 
2H, J = 2.6 Hz), 3.94 (s, 3H), 2.52 (t, 1H, J = 2.6 Hz). 13C NMR (125 MHz, CDCl3): δ 
170.1, 156.7, 149.8, 124.9, 118.6, 114.1, 111.9, 78.4, 75.6, 56.8, 52.3. HRMS-ESI: 
calculated for [M]- (C11H9O4)-: m/z 205.0506, found: m/z 205.0513. 
 
Methyl 2-hydroxy-3-nitro-5-(prop-2-yn-1-yloxy)benzoate (1c)  
Compound 1b (5g, 24 mmol) was dissolved in 
dichloromethane (200 mL) and placed in an ice bath. 2.5 mL 
(1.3 eqv.) of concentrated nitric acid and 3.3 mL (2.2 eqv.) 
of concentrated sulphuric acid were then added drop wise to 
the solution. The reaction was allowed to proceed for 
10minutes, after which the mixture was washed with water, 
extracted with dichloromethane and dried over anhydrous Na2SO4. Removal of 
CH2Cl2 gave the crude product. The solid obtained was recrystallized in methanol to 
produce the product 1c as a yellow solid. Yield: 4g, 66%. 1H NMR (500 MHz, CDCl3): 










Hz), 4.01 (s, 3H), 2.57 (t, 1H, J = 2.5 Hz). 13C NMR (125 MHz, CDCl3): δ 168.5, 
150.6, 148.4, 137.6, 123.2, 118.2, 116.4, 77.2, 76.9, 57.0, 53.2. HRMS-ESI: 
calculated for [M]- (C11H8NO6)-: m/z 250.0357, found: m/z 250.0352. 
 
Methyl 2-methoxy-3-nitro-5-(prop-2-yn-1-yloxy) benzoate (1d)  
Compound 1c ( 1 g, 4 mmol) was dissolved in 
dimethylformamide (14 mL), to which anhydrous K2CO3 
(2.2 g, 16 mmol) and dimethylsulphate (0.75 mL, 8 mmol) 
were added. The mixture was heated under reflux for 5 
hours. The reaction mixture was then filtered and the filtrate 
was removed in vacuo. The concentrate was dissolved in 
CH2Cl2 (60 mL), washed with water (2 x 30 mL) and dried over anhydrous Na2SO4. 
Removal of CH2Cl2 gave the crude product, which was recrystallized in methanol to 
yield the product 1d as a yellow solid. Yield: 0.8g, 75%. 1H NMR (500 MHz, CDCl3) : 
δ 7.63 (d, 1H, J = 3.3 Hz), 7.54 (d, 1H, J = 3.3 Hz), 4.74 (d, 2H, J = 2.4 Hz), 3.96 (s, 
6H), 2.58 (t, 1H, J = 2.4 Hz). 13C NMR (125 MHz, CDCl3): δ 164.5, 152.5, 147.5, 
145.6, 128.2, 122.2, 114.9, 77.2, 77.0, 64.4, 56.8, 52.9. HRMS-ESI: calculated for 
[M]+ (C12H11NO6)+: m/z 265.0586, found: m/z 265.0584. 
 
2-metyoxy-3-nitro-5-(prop-2-yn-1-yloxy)benzoic acid (1f) 
Compound 1d (3 g, 11.3 mmol) was dissolved in hot 
methanol (20 mL) to which 1 M NaOH (22.6 mL, 22.6 
mmol) was added. The mixture was heated under reflux for 
2 hours and then quenched with water (200 mL). The 
aqueous layer was neutralized by addition of 1 M HCl until 
the pH was at least 1. The precipitated crude product was 
collected by filtration, which was recrystallized from hot 










CDCl3): δ 13.65 (s, 1H), 7.73 (d, 1H, J = 3.2 Hz), 7.59 (d, 1H, J = 3.2 Hz), 4.93 (d, 
2H, J = 1.9 Hz), 3.83 (s, 3H), 3.65 (t, 1H, J = 2.7 Hz). 13C NMR (125 MHz, CDCl3): δ 
165.2, 152.2, 145.4, 145.3, 129.0, 121.1, 113.9, 79.2, 78.3, 63.8, 56.6. HRMS-ESI: 




To a EtOH (150 mL) solution of 1d (4.0 g, 15.08 
mmol), iron (3.4 g, 60.3 mmol) and acetate acid 
(15 mL) were added. The mixture was heated 
under reflux for 2 hours. After cooling, the 
solvent was evaporated and the residue was 
dissolved with CH2Cl2 and washed with water. 
The organic layer was dried over Na2SO4. Evaporation of the solvent gave the amine 
product used for the next step reaction without purification. A solution of 1f (4 g, 16.5 
mmol) in SOCl2 (9 mL) was heated at reflux for 2 hours. After removal the SOCl2, the 
amine product and DIEA (6.5 mL, 37.5 mmol) in dry CH2Cl2 (100 mL) were added to 
the residue. The reaction was allowed to proceed for 4 h. After washing with HCl 
solution and aqueous sat. NaHCO3, the organic layer was dried over Na2SO4. The 
residue was recrystallized from methanol to give the pure product 1g as a white solid. 
Yield: 5.61 g, 79 %. 1H NMR (500 MHz, CDCl3): δ 10.48 (s, 1H), 8.56 (d, 1H, J = 
3.2 Hz), 8.05 (d, 1H, J = 3.4 Hz), 7.61 (d, 1H, J = 3.4 Hz), 7.23 (d, 1H, J = 3.2 Hz), 
4.80 (d, 2H, J = 2.5 Hz), 4.74 (d, 2H, J = 2.5 Hz), 4.03 (s, 3H), 3.94 (s, 3H), 3.89 (s, 
3H), 2.60 (t, 1H, J = 2.5 Hz), 2.55 (t, 1H, J = 2.7 Hz). 13C NMR (125 MHz, CDCl3): δ 
165.4, 160.9, 153.4, 153.3, 145.6, 144.7, 144.0, 133.5, 129.7, 123.8, 122.0, 115.8, 
112.2, 111.8, 78.1, 77.0, 76.9, 75.8, 64.6, 62.7, 56.7, 56.4, 52.4. HRMS-ESI: 
















To a EtOH (40 mL) solution of 1g (1.76 g, 
3.75 mmol), iron (1.05 g, 18.75 mmol) and 
acetate acid (4 mL) were added. The 
mixture was heated under reflux for 4 
hours. After cooling, the solvent was 
evaporated and the residue was dissolved 
with CH2Cl2 and washed with water. The 
organic layer was dried over Na2SO4. Evaporation of the solvent gave the amine 
product used for the next step reaction without purification. A solution of 1f (1 g, 4.13 
mmol) in SOCl2 (2.1 mL) was heated at reflux for 2 hours After removal the SOCl2, 
the amine product and DIEA (1.6 mL, 9.38 mmol) in dry CH2Cl2 (70 mL) were added 
to the residue. The reaction was allowed to proceed for 4 h. After washing with HCl 
solution and aqueous sat. NaHCO3, the organic layer was dried over Na2SO4. The 
residue was recrystallized from methanol to give the pure product 1h as a white solid. 
Yield: 1.91 g, 75 %.1H NMR (500 MHz, CDCl3): δ 10.37 (s, 2H), 8.62 (d, 1H, J = 3.3 
Hz), 8.53 (d, 1H, J = 3.3 Hz), 8.08 (d, 1H, J = 3.3 Hz), 7.65 (d, 1H, J = 3.3 Hz), 7.52 
(d, 1H, J = 3.3 Hz), 7.23 (d, 1H, J = 3.3 Hz), 4.82 (d, 2H, J = 2.5 Hz), 4.80 (d, 2H, J = 
2.3 Hz), 4.76 (d, 2H, J = 2.5 Hz), 4.07 (s, 3H), 3.95 (s, 3H), 3.93 (s, 3H), 3.90 (s, 3H), 
2,60 (t, 1H, J = 2.3 Hz), 2.56 (t, 2H, J = 2.5 Hz). 13C NMR (125 MHz, CDCl3): δ 
165.5, 162.4, 160.9, 154.6, 153.5, 153.5, 145.4, 144.6, 143.8, 141.8, 133.8, 132.8, 
129.6, 126.7, 123.8, 122.1, 116.0, 112.2, 112.0,111.6, 111.5, 78.2, 78.0, 77.1, 76.9, 
76.0, 75.8, 64.6, 63.4, 62.6, 56.8, 56.4, 56.4, 52.4. HRMS-ESI: calculated for 



















To a EtOH (15 mL) solution of 1h (1 g, 
1.34 mmol), iron (0.3 g, 5.35 mmol) and 
acetate acid (1.5 mL) were added. The 
mixture was heated under refluxed for 4 
hours. After cooling, the solvent was 
evaporated and the residue was dissolved 
with CH2Cl2 and washed with water. The organic layer was dried over Na2SO4. 
Evaporation of the solvent gave the amine product used for the next step reaction 
without purification. A solution of 1f (447 mg, 1.61 mmol) in SOCl2 (2 mL) was 
heated at reflux for 2 hours. After removal the SOCl2, the amine product and DIEA 
(0.57 mL, 3.35 mmol) in dry CH2Cl2 (50 mL) were added to the residue. The reaction 
was allowed to proceed for 4 h. After washing with HCl solution and aqueous sat. 
NaHCO3, the organic layer was dried over Na2SO4. The residue was recrystallized 
from methanol to give the pure product 1i as a white solid. Yield: 0.87 g, 65 %. 1H 
NMR (500 MHz, d6-DMSO): δ 10.54 (s, 1H), 10.46 (s, 1H), 10.39 (s, 1H), 8.32 (d, 
1H, J = 2.9 Hz), 8.24 (d, 1H, J = 2.8 Hz), 8.07 (d, 1H, J = 2.8 Hz), 7.77 (d, 1H, J = 
3.0 Hz), 7.67 (d, 1H, J = 3.0 Hz), 7.37 (d, 1H, J = 2.9 Hz), 7.33 (d, 1H, J = 3.0 Hz), 
7.11 (d, 1H, J = 3.0 Hz), 4.98 (d, 2H, J = 1.7 Hz), 4.89 (br, 4H), 4.85 (d, 2H, J = 1.7 
Hz), 3.93 (s, 3H), 3.92 (s, 3H), 3.90 (s, 3H), 3.88 (s, 3H), 3.81 (s, 3H), 3.69 (t, 1H, J = 
1.7 Hz), 3.63 (q, 2H, J = 1.7 Hz), 3.61 (t, 1H, J = 1.7 Hz). 13C NMR (125 MHz, 
d6-DMSO): δ 165.8, 163.4, 163.1, 153.9, 153.7, 153.2, 153.1, 144.7, 144.6, 144.1, 
143.9, 143.1, 134.0, 133.5, 133.0, 132.9, 128.1, 127.6, 124.8, 121.1, 114.1, 113.6, 
112.9, 112.8, 112.4, 111.5, 111.0, 110.8, 79.7, 79.4, 79.4, 79.4, 79.1, 79.1, 79.1, 78.8, 
64.5, 63.6, 63.4, 62.9, 57.1, 56.5, 56.5, 53.0. HRMS-ESI: calculated for 





















To a EtOH (5 mL) solution of 1i (0.2 g, 
0.23 mmol), iron (0.1 g, 1.83 mmol) and 
acetate acid (0.5 mL) were added. The 
mixture was heated under refluxed for 4 
hours. After cooling, the solvent was 
evaporated and the residue was dissolved 
with CH2Cl2 and washed with water. The 
organic layer was dried over Na2SO4. Evaporation of the solvent gave the amine 
product used for the next step reaction without purification. A solution of 1f (67 mg, 
0.28 mmol) in SOCl2 (1 mL) was heated at reflux for 2 hours. After removal the 
SOCl2, the amine product and DIEA (0.1 mL, 0.58 mmol) in dry CH2Cl2 (20 mL) 
were added to the residue. The reaction was allowed to proceed for 4 h. After washing 
with HCl solution and aqueous sat. NaHCO3, the organic layer was dried over Na2SO4. 
The residue was recrystallized from methanol to give the pure product 1j as a white 
solid. Yield: 0.1 g, 41 %. 1H NMR (500 MHz, d6-DMSO): δ 10.50 (s, 1H), 10.48 (s, 
1H), 10.45 (s, 1H), 10.42 (s, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 8.20 (s, 1H), 8.07 (s, 1H), 
7.76 (s, 1H),7.67 (s, 1H), 7.37 (s, 1H), 7.35 (s, 1H), 7.29 (s, 1H), 7.11 (s, 1H),4.97 (s, 
2H), 4.90 (s, 6H), 4.85 (s, 2H), 3.93 (s, 6H), 3.92 (s, 3H), 3.90 (s, 3H), 3.85 (s, 3H), 
3.80 (s, 3H), 3.67 (s, 1H), 3.64 (s, 3H), 3.61 (s, 1H). 13C NMR (125 MHz, d6-DMSO): 
δ 164.7, 162.7, 162.4, 162.3, 162.0, 152.9, 152.8, 152.7, 152.2, 152.1, 143.7, 143.6 
143.1, 142.9, 142.3, 141.9, 133.0, 132.4, 132.4, 132.0, 131.9, 127.2, 127.2, 126.6, 
123.8, 120.1, 113.1, 112.6, 112.4, 111.5, 111.4, 110.5, 110.0, 109.7, 78.7, 78.5, 78.4, 
78.4, 78.1, 78.1, 77.8, 63.5, 62.5, 62.5, 62.3, 61.9, 56.1, 55.5, 51.9. HRMS-ESI: 
























To a EtOH (93 mL) and THF (31 mL) 
solution of 1j (1 g, 0.93 mmol), iron (0.32 
g, 5.58 mmol) and acetate acid (9.3 mL) 
were added. The mixture was heated under 
refluxed for 4 hours. After cooling, the 
solvent was evaporated and the residue 
was dissolved with CH2Cl2 and washed 
with water. The organic layer was dried 
over Na2SO4. Evaporation of the solvent 
gave the amine product used for the next step reaction without purification. The amine 
product was dissolved in dioxane (50 mL) to which 1 M NaOH (4 mL, 4 mmol) was 
added. The mixture was stirred under room temperature for overnight and then 
neutralized by 1 M HCl until the pH value was around 7. The mixture was extracted 
with CH2Cl2 and the organic extract was dried over Na2SO4. After removal the solvent, 
the residue was dissolved in dry CH2Cl2 (100 mL), BOP (1.24 g, 2.78 mmol) and 
DIEA (0.64 mL, 3.71 mmol) were added. The reaction was stirred in room 
temperature for 12 hours. The reaction was washed with HCl solution, aqueous sat. 
NaHCO3. After removal of the solvent, the residue was recrystallized in hot methanol 
to give the product 1k, three-step total yield: 400 mg, 42.5 %. 1H NMR (300 MHz, 
d6-DMSO): δ 11.07 (s, 5H), 8.53 (d, 5H, J = 3.2 Hz), 7.45 (d, 5H, J = 3.1 Hz), 4.93 (s, 
10H), 4.05 (s, 15H), 3.66 (s, 5H). 11.06 (s, 5H). 13C NMR (75 MHz, d6-DMSO): δ 
160.9, 153.6, 141.1, 133.2, 125.3, 110.3, 109.0, 78.4, 78.3, 63.5, 55.5. HRMS-ESI: 
calculated for [M]-(C55H44N5O15)-: m/z 1014.2839, found: m/z 1014.2814.  
 
tert-Butyl (3-hydroxypropyl)carbamate (1l) 
Compound 3-aminopropan-1-ol (0.3 mol, 30 mL) was 



























triethylamine (0.45 mol, 62.8 mL) was added. By cooling in an ice bath, Boc 
anhydride (0.33 mol, 75.9 mL) was added into the mixture. Reaction mixture was 
allowed to stir at room temperature for 12 hours. In an ice bath, 1 M HCl was added 
drop wise until no bubbling was observed. After removal the solvent, the residue was 
dissolved in DCM, washed with water (30 mL *2), and dried over anhydrous Na2SO4. 
Removal of DCM in vacuo gave the product 1l as colorless liquid. Yield: 46.7 g, 89%. 
1H NMR (500 MHz, CDCl3): δ 5.16 (s, 1H), 3.70 (s, 1H), 3.56 (q, 2H, J = 5.8 Hz), 
3.16 (q, 2H, J = 5.92 Hz), 1.58 (m, 2H), 1.34 (s, 9H). 13C NMR (500 MHz, CDCl3): δ 
157.0, 79.6, 59.2, 37.0, 32.8, 28.3. HRMS-ESI: calculated for [M+Na]+(C8H17NNaO3): 
m/z 198.1105, found: m/z 198.1101. 
 
tert-Butyl (3-azidopropyl)carbamate(1m) 
Compound 1l (2.9 mmol, 0.50 g) was dissolved in 3 mL of 
THF, to which triethylamine (5.8 mmol, 0.8 mL) was added. 
This reaction was carried under  nitrogen atomsphere and 
cooled to 0ºC in an ice bath. Methanesulfonyl chloride (5.8 mmol, 0.45 mL) was 
added dropwise into the reaction mixture over 30 minutes. Reaction mixture was 
warmed gradually to room temperature and stirred overnight. 50 mL water was added 
into the reaction mixture and to which sodium bicarbonate (3.05 mmol, 0.255 g) and 
sodium azide (7.25 mmol, 0.471 g) were added. THF was removed in vacuo, and 
under nitrogen protect environment, reaction mixture was heated under reflux 
overnight. Extraction was done with ethyl acetate, organic layer was washed with 1 M 
HCl, and dried over anhydrous Na2SO4. Removal of EA in vacuo gave 1m as 
yellowish liquid. Yield: 0.39 g, 67%.1H NMR (300 MHz, CDCl3); δ 5.32 (s, 1H), 3.47 
(t, 2H, J = 5.9 Hz), 3.06 (q, 2H, J = 6.2 Hz), 1.54 (m, 2H), 1.27 (s, 9H). 13C NMR 
(500 MHz, CDCl3): δ 155.9, 79.4, 66.7, 49.0, 29.2, 28.3. HRMS-ESI: calculated for 







Compound 2-(2-aminoethoxy)ethanol (0.3 mol, 30 mL) was 
dissolved in acetone/water (1/1, 100 mL), to which 
triethylamine (0.45 mol, 62.8 mL) was added. By cooling in an ice bath, Boc 
anhydride (0.33 mol, 75.9 mL) was then added to the mixture. Reaction mixture was 
allowed to stir at room temperature for 12 hours. In an ice bath, 1 M HCl was added 
drop wise until no bubbling was observed. After removal the solvent, the residue was 
dissolved in DCM, washed with water (30 mL *2), and dried over anhydrous Na2SO4. 
Removal of DCM in vacuo gave the product 1n as colorless liquid. Yield: 57.6 g, 
93%. 1H NMR (300 MHz, CDCl3): δ 5.21 (s, 1H), 3.68 (q, 2H, J = 4.3 Hz), 3.53 – 
3.49 (m, 4H), 3.28 (q, 2H, J = 5.2 Hz), 2.97 (s, 1H), 1.38 (s, 9H). 13C NMR (500 MHz, 
CDCl3): δ 156.1, 79.4, 72.2, 70.2, 61.6, 40.4, 28.3. HRMS-ESI: calculated for 
[M+Na]+ (C9H19NNaO4): m/z 228.1216, found: m/z 228.1206. 
tert-Butyl (2-(2-azidoethoxy)ethyl)carbamate(1o) 
Compound 1n (2.44 mmol, 0.50 g) was dissolved in 3 mL of 
THF, to which triethylamine (4.88 mmol, 0.7 mL) was 
added. This reaction was carried under  nitrogen atomsphere and cooled to 0ºC in an 
ice bath. Methanesulfonyl chloride (4.88 mmol, 0.38 mL) was added dropwise into 
the reaction mixture over 30 minutes. Reaction mixture was warmed gradually to 
room temperature and stirred overnight. 50 mL water was added into the reaction 
mixture and to which sodium bicarbonate (2.56 mmol, 0.215 g) and sodium azide (6.1 
mmol, 0.397 g) were added. THF was removed in vacuo, and under nitrogen protect 
environment, reaction mixture was heated under reflux overnight. Extraction was 
done with ethyl acetate, organic layer was washed with 1 M HCl, and dried over 
anhydrous Na2SO4. Removal of EA in vacuo gave 1o as yellowish liquid. Yield: 0.33 
g, 58% 1H NMR (300 MHz, CDCl3): δ 4.93 (s, 1H), 3.62 (t, 2H, J = 4.9 Hz), 3.52 (t, 
2H, J = 3.9 Hz), 3.36 (t, 2H, J = 5.1 Hz), 3.30 (q, 2H, J = 5.3 Hz), 1.42 (s, 9H). 13C 
NMR (500 MHz, CDCl3): δ 155.9, 79.0, 70.1, 69.7, 50.5, 40.2, 28.2. HRMS-ESI: 















Ethyl 1-(prop-2-yn) -5-(tert-butoxycarbonylamino)-4-oxo-1,4-dihydropyridine-3- 
carboxylate (1w) 
Compound 1t (8.05 mmol, 3.00g) was dissolved in 250 mL 
of THF, to which 10% Pd/C (0.30 g, 10%) was added. 
balloon was installed. The mixture was stirred at 45oC for 2 
days under H2 atmosphere . Reaction mixture was filtered to 
obtain a grey residue containing both deprotective product 
1u and Pd/C. This residue is used directly for next step. 
Compound 1u (6.52 mmol, 1.84g) was dissolved in 250 mL of anhydrous acetone, to 
which anhydrous K2CO3 (13.04 mmol, 1.81 g) and 3-bromoprop-1-yne (6.52 mmol, 
0.58 mL) were added. The mixture was heated under reflux for 4 hours. Reaction 
mixture was filtered, and solvent was removed in vacuo. The residue was dissolved in 
DCM, washed with water, and dried over anhydrous Na2SO4. Removal of DCM in 
vacuo gave the crude product, which was subjected to column purification (ethyl 
acetate/hexane=1/1) to yield the pure product 2c as a white solid. Yield: 1.54 g, 74%. 
1H NMR (500 MHz, CDCl3): δ 8.38 (s, 1H), 8.25 (s, 1H), 7.87 (s, 1H), 4.68 (d, J = 
2.5 Hz, 2H), 4.30 (q, 2H), 2.81 – 2.59 (m, 1H), 1.54 – 1.42 (s, 9H), 1.35 (t, J = 7.0 Hz, 
3H). 13C NMR (125 MHz, CDCl3): δ 167.3, 164.6, 152.7, 141.2, 133.2, 122.6, 113.9, 
81.1, 74.9, 60.9, 47.1, 28.2, 14.3. HRMS-ESI: calculated for [M+Na]+ 












Compound 1i (2 g, 2.3 mmol) was 
dissolved in dioxane and H2O (100 mL, 
v/v 1/1) mixture solution, and 1 M KOH 
(4.6 mL) and KCl (3.4 g, 46 mmol) were 
added in to the mixture. This reaction 
was stirred at room temperature for 12 
hours, then 1 M HCl was added to 
neutralize the mixture to pH value 3. The 
mixture was extracted with CH2Cl2(100 mL * 3). The organic extracts were dried over 
Na2SO4 and concentrated under reduced pressure to produce the acid product. This 
acid (200 mg, 0.23 mmol)was dissolved in SOCl2 (2 mL) and stirred 2 hours under 
reflux. Then the excess SOCl2 was removed in vacuo to produce the chloride product. 
Compound 1w (74 mg, 0.23 mmol) was treated with HCl dioxane solution for 12 
hours at room temperature and the solvent was removed in vacuo to to produce the 
amine product 1y. To the solution of chloride product in dry CH2Cl2, the mixture of 
1y and DIEA (0.16 mL, 0.93 mmol) was added. This reaction was allowed to proceed 
for 12 hours, after washing with HCl solution, aqueous sat. NaHCO3 and Brine, the 
organic layer was dried over Na2SO4. The residue was recrystallized from methanol to 
give the pure product 1za as a white solid. Yield: 137 mg, 57 %. 1H NMR (500 MHz, 
d6-DMSO): δ 10.82 (s, 1H), 10.51 (s, 1H), 10.50 (s, 1H), 10.44 (s, 1H), 9.08 (d, 1H, J 
= 2.1 Hz), 8.49 (d, 1H, J = 2.0 Hz), 8.29 (d, 1H, J = 2.7 Hz), 8.24 (d, 1H, J = 2.8 Hz), 
8.08 (d, 1H, J = 2.9 Hz), 7.74 (d, 1H, J = 3.1 Hz), 7.64 (d, 1H, J = 3.0 Hz), 7.41 (d, 
1H, J = 3.2 Hz), 7.37 (d, 1H, J = 3.0 Hz), 7.30 (d, 1H, J = 3.0 Hz), 5.12 (d, 2H, J = 
1.8 Hz), 4.96 (d, 2H, J = 1.9 Hz), 4.89 (m, 6H), 4.21 (q, J = 7.1 Hz, 2H), 3.94 (s, 3H), 
3.93 (s, 3H), 3.91 (s, 3H), 3.88 (s, 3H), 3.80 (s, 3H), 3.67 – 3.60 (m, 4H), 1.25 (t, J = 
7.1 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 167.2, 164.3, 163.6, 163.5, 162.2, 154.0, 
153.8, 153.7, 153.0, 144.6, 144.6, 143.9, 143.5, 143.5, 142.9, 133.7, 133.4, 133.2, 
133.0, 132.2, 126.4, 126.2, 121.0, 114.3, 114.1, 113.7, 113.4, 112.6, 111.4, 111.2, 
110.7, 78.8, 77.9, 64.5, 63.7, 63.6, 63.4, 60.6, 57.1, 56.6, 56.5, 56.5, 46.5, 14.7. 

























To a EtOH (2 mL) and THF (2 mL) 
solution of 1za (150 mg, 0.14 mmol), iron 
(40 mg, 0.71 mmol) and acetate acid (0.2 
mL) were added. The mixture was heated 
under refluxed for 4 hours. After cooling, 
the solvent was evaporated and the residue 
was dissolved with CH2Cl2 and washed 
with water. The organic layer was dried 
over Na2SO4. Evaporation of the solvent 
gave the amine product used for the next step reaction without purification. The amine 
product was dissolved in dioxane (10 mL) to which 1 M NaOH (1 mL, 1 mmol) was 
added. The mixture was stirred under room temperature for overnight and then 
neutralized by 1 M HCl until the pH value was around 7. The mixture was extracted 
with CH2Cl2 and the organic extract was dried over Na2SO4. After removal the solvent, 
the residue was dissolved in dry CH2Cl2 (30 mL), BOP (188 mg, 0.423 mmol) and 
DIEA (0.1 mL, 0.564 mmol) were added. The reaction was stirred in room 
temperature for 12 hours. The reaction was washed with HCl solution, aqueous sat. 
NaHCO3. After removal of the solvent, the residue was recrystallized in hot methanol 
to give the product 1zb, three-step total yield: 35 mg, 25%. 1H NMR (500 MHz, 
CDCl3): δ 13.18 (s, 1H), 11.59 (s, 1H), 11.38 (s, 1H), 11.19 (s, 1H), 11.15 (s, 1H), 
9.20 (s, 1H), 8.67 (m, 3H), 8.61 (d, 2H, J = 2.5 Hz), 7.56 (s, 3H), 7.51 (s, 1H), 6.94 (t, 
1H, J = 6.2 Hz), 5.94 (d, 2H, J = 5.5 Hz), 4.81 (s, 8H), 4.11 (s, 3H), 4.08 (s, 6H), 4.05 
(s, 3H), 2.57 (s, 4H). 13C NMR (126 MHz, CDCl3): δ 201.73, 170.18, 162.43, 162.14, 
162.10, 161.93, 161.87, 155.05, 154.90, 154.75, 142.25, 141.84, 141.38, 141.30, 
138.90, 134.04, 133.99, 133.89, 133.78, 132.19, 125.68, 125.51, 124.94, 124.19, 























77.04, 76.79, 76.00, 75.88, 63.31, 63.24, 63.04, 62.86, 56.40. HRMS-ESI: calculated 
for [M+Na]+ (C53H42N6O14Na): m/z 1009.2651, found: m/z 1009.2626. 
 
Compound 9a 
Compound 1k (50 mg, 0.05 mmol) was 
dispersed in 25 mL THF solvent. To this 
solution, DIEA (0.168 mL, 1 mmol), 
Copper (I) iodide (10mg, 0.05 mmol) and 
linker 1 (150 mg, 0.75 mmol) were added 
in order. The mixture was stirred at 35 ºC 
for 2 days. After removal the solvent, the 
residue was dissolved in CH2Cl2 (5 mL). 
The product was further purified by 
preparative TLC plate(ethyl acetate: 
CH2Cl2: MeOH=2:1:0.1). One kind of white solid was obtained. Yield: 22mg, 22%. 
1H NMR (500 MHz, CDCl3): δ 10.96 (s, 5H), 8.66 (d, 5H, J = 2.5 Hz), 7.88 (s, 5H), 
7.56 (d, 5H, J = 2.5 Hz), 5.30 (s, 10H), 4.98 (s, 5H), 4.48 (t, 10H, J = 6.3 Hz), 4.07 (s, 
15H), 3.20 (br, 10H,), 2.15 (t, 10H, J = 7.0 Hz ), 1.46 (s, 45H). 13C NMR (125 MHz, 
CDCl3): δ161.9, 156.2, 155.8, 143.5, 140.9, 133.6, 125.9, 123.5, 111.3, 111.0, 79.6, 
63.5, 62.5, 47.7, 37.4, 30.7, 28.4. HRMS-ESI: calculated for 
[M+Na]+(C95H125N25NaO25)+: m/z 2038.9038, found: m/z 2038.9171.   
Compound 10a 
Compound 1k (50 mg, 0.05 mmol) was 
dispersed in 25 mL THF solvent. To this 
solution, DIEA (0.168 mL, 1 mmol), 
Copper (I) iodide (10mg, 0.05 mmol) and 
linker 2 (173 mg, 0.75 mmol)were added 





















































for 2 days. After removal the solvent, the residue was dissolved in CH2Cl2 (5 mL). 
The product was further purified by preparative TLC plate(ethyl acetate: CH2Cl2: 
MeOH=2:1:0.1). One kind of white solid was obtained. Yield: 31mg, 30%. 1H NMR 
(500 MHz, CDCl3): δ 10.93 (s, 5H), 8.68 (d, 5H, J = 3.2 Hz), 7.88 (s, 5H), 7.58 (d, 5H, 
J = 3.2 Hz), 5.32 (s, 10H), 4.94 (s, 5H), 4.58 (t, 10H, J = 5.1 Hz), 4.03 (s, 15H), 3.88 
(t ,10H, J = 5.1 Hz), 3.53 (t, 10H, J = 5.1 Hz), 3.30 (br, 10H), 1.42 (s, 45H). 13C NMR 
(125 MHz, CDCl3): δ 162.0, 156.0, 155.9, 143.3, 140.9, 133.6, 125.9, 124.2, 111.3, 
111.0, 79.4, 70.4, 69.1, 63.5, 62.5, 50.3, 40.3, 28.4. HRMS-ESI: calculated for 
[M]+(C100H135N25O30)+: m/z 2165.9710, found: m/z 2165.9812.  
Compound 9 
To the solution of 9a (50mg, 0.025mmol) 
in CH2Cl2 (5 mL), trifluoroacetic acid (5 
mL) was added. The mixture was stirred at 
room temperature for overnight. Then the 
solvents were removed in vacuo and the 
residue was recrystallized by ether to 
produce product 9 as yellow solid. Yeild: 
35mg, 70%. 1H NMR (500 MHz, 
d4-MeOD): δ 8.42 (s, 5H), 8.25 (s, 5H), 
7.43 (s, 5H), 5.30 (s, 10H), 4.60 (s, 10H), 
4.05 (s, 15H), 3.05 (s, 10H), 2.34 (s, 10H). 13C NMR (125 MHz, d4-MeOD): δ 163.2, 
156.8, 144.9, 142.4, 134.7, 126.9, 125.8, 112.4, 111.5, 65.0, 63.1, 48.4, 38.2, 29.2. 































To the solution of 10a (50mg, 0.024mmol) 
in CH2Cl2 (5 mL), trifluoroacetic acid (5 
mL) was added. The mixture was stirred at 
room temperature for overnight. Then the 
solvents were removed in vacuo and the 
residue was recrystallized by ether to 
produce product 10 as yellow solid. Yeild: 
30mg, 58%.1H NMR (500 MHz, 
d4-MeOD): δ 8.65 (s, 5H), 8.24 (s, 5H), 
7.58 (d, 5H, J = 2.85 Hz), 5.31 (s, 10H), 4.70 (t, 10H, J = 4.95 Hz), 4.10 (s, 15H), 
3.98 (t, 10H, J = 5 Hz), 3.72 (t, 10H, J = 4.90 Hz), 3.14 (t, 10H, J = 5 Hz). 13C NMR 
(125 MHz, d4-MeOD): δ 161.7, 155.4, 143.2, 141.0, 133.2, 125.2, 125.0, 111.1, 110.1, 
69.1, 66.5, 63.7, 61.6, 49.9, 39.1. HRMS-ESI: Calculated for [M]2+ (C75H97N25O20)2+: 
m/z 833.8671, found: m/z 833.8658. 
 
7.3 Experimental section of side chain helical compounds 
L1-L5 
7.3.1 General remarks 
All the reagents were obtained from commercial suppliers and used as received 
unless otherwise noted. The organic solutions from all liquid extractions were dried 
over anhydrous Na2SO4 for a minimum of 15 minutes before filtration. Reactions 
were monitored by thin-layer chromatography (TLC) on silica gel pre-coated glass 
plate (0.225 mm thickness, 60F-254, E. Merck). Flash column chromatography was 
performed using pre-coated 0.2 mm silica plates from Selecto Scientific. Chemical 

























model J-810 CD spectrophotometer. ITC experiments were obtained using iTC200 
Microcalorimenter. Mass spectra were obtained using the Instrumentation includes 
Finnigan MAT95XL-T and Micromass VG7035. 1H NMR spectra were recorded on 
Bruker ACF-300 (300 MHz) and ACF500 (500 MHz) spectrometers. The solvent 
signal of CDCl3 was referenced at δ = 7.26 ppm, d6-DMSO was referenced at δ = 2.50 
ppm and d4-methanol was referenced at δ = 1.94 ppm. Coupling constants (J values) 
are reported in Hertz (Hz). 1H NMR data are recorded in the order: chemical shift 
value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), 
number of protons that gave rise to the signal and coupling constant, where applicable. 
13C spectra were proton-decoupled and recorded on Bruker ACF-300 (300 MHz) and 
ACF500 spectrometers (500 MHz). The solvent, CDCl3 was referenced at 77 ppm and 
d6-DMSO at 39.5 ppm. CDCl3 (99.8% deuterated) and d6-DMSO (99.8%-Deuterated) 
were purchased from Aldrich and used without further purification. d4-methanol 
(99.8% deuterated) was purchased from Cambridge Isotope Laboratories, Inc. and 
used without further purification. 
7.3.2 Experimental Procedures and Compound Characterizations of 
ligands L1-L5 
Compound La 
Compound 1d (26.5 mg, 0.1 mmol) was 
dispersed in 15 mL THF solvent. To this solution, 
DIEA (0.068 mL, 0.4 mmol), Copper (I) iodide 
(0.4mg, 0.002 mmol) and compound 1o (69 mg, 
0.3 mmol) were added in order. The mixture was 
stirred at 35 ºC for 2 days. After removal the solvent, the residue was dissolved in 
CH2Cl2 (5 mL). The product was further purified by preparative TLC plate(ethyl 
acetate: Hexane = 1:1). One kind of yellow oil La was obtained. Yield: 49mg, 98%. 












4.87 (s, 1H), 4.57 (s, 2H), 3.95 (s, 6H), 3.85 (s, 2H), 3.50 (s, 2H), 3.29 (s, 2H), 1.43 (s, 
9H). 13C NMR (75 MHz, CDCl3): δ 164.43, 155.83, 153.19, 146.98, 145.54, 128.00, 
124.20, 121.77, 114.61, 79.37, 70.24, 68.88, 64.29, 62.64, 52.79, 50.31, 40.05, 28.27. 




Compound 1g (46.8 mg, 0.1 mmol) was 
dispersed in 15 mL THF solvent. To this 
solution, DIEA (0.136 mL, 0.8 mmol), Copper 
(I) iodide (0.8mg, 0.004 mmol) and compound 
1o (138 mg, 0.6 mmol) were added in order. 
The mixture was stirred at 35 ºC for 2 days. 
After removal the solvent, the residue was 
dissolved in CH2Cl2 (5 mL). The product was further purified by preparative TLC 
plate(ethyl acetate: CH2Cl2 = 2:1). One kind of yellow oil Lb was obtained. Yield: 
76mg, 82%. 1H NMR (500 MHz, CDCl3): δ 10.46 (s, 1H), 8.52 (d, 1H, J = 3.0 Hz), 
8.04 (d, 1H, J = 3.2 Hz), 7.85 (s, 1H), 7.84 (s, 1H), 7.62 (d, 1H, J = 2.9 Hz), 7.22 (d, 
1H, J = 3.0 Hz), 5.28 (s, 2H), 5.23 (s, 2H), 4.96 (s, 2H), 4.55 (t, 4H, J = 4.7 Hz), 4.01 
(s, 3H), 3.91 (s, 3H), 3.88 (s, 3H), 3.86 – 3.80 (m, 4H), 3.49 (b, 4H), 3.27 (s, 4H), 
1.40 (s, 18H). 13C NMR (126 MHz, CDCl3): δ 165.49, 161.03, 155.94, 154.13, 154.04, 
145.22, 144.67, 143.75, 143.46, 142.42, 133.37, 129.58, 124.34, 124.05, 123.84, 
121.75, 115.59, 111.93, 111.64, 79.37, 70.34, 69.05, 68.98, 64.61, 62.70, 62.44, 52.45, 
50.37, 50.30, 40.17, 28.36. HRMS-ESI: Calculated for [M+Na]+ (C41H56N10O15Na)+: 
m/z 951.3819, found: m/z 951.3858. 
 
Compound Lc 


















solution, DIEA (0.204 mL, 1.2 mmol), Copper (I) iodide (1.2mg, 0.006 mmol) and 
compound 1o (207 mg, 0.9 mmol) were added in order. The mixture was stirred at 35 
ºC for 2 days. After removal the solvent, 
the residue was dissolved in CH2Cl2 (5 
mL). The product was further purified by 
preparative TLC plate(ethyl acetate: 
CH2Cl2 = 3:1). One kind of yellow oil Lc 
was obtained. Yield: 108 mg, 78%. 1H 
NMR (300 MHz, CDCl3): δ 10.37 (s, 1H), 
10.36 (s, 1H), 8.59 (s, 1H), 8.49 (s, 1H), 8.05 (s, 1H), 7.84 (s, 3H), 7.65 (s, 1H), 7.49 
(s, 1H), 7.21 (s, 1H), 5.28 (s, 4H), 5.24 (s, 2H), 4.94 (s, 3H), 4.55 (s, 6H), 4.04 (s, 3H), 
3.97 – 3.78 (m, 15H), 3.49 (s, 6H), 3.27 (s, 6H), 1.40 (s, 27H). 13C NMR (75 MHz, 
CDCl3): δ 165.46, 162.34, 162.23, 160.97, 155.85, 155.18, 154.20, 154.07, 145.01, 
144.54, 143.46, 143.32, 142.29, 141.50, 133.61, 132.71, 129.43, 126.62, 124.27, 
123.99, 123.72, 121.77, 115.66, 111.89, 111.61, 111.38, 111.33, 79.32, 70.29, 68.98, 
68.92, 64.51, 63.38, 62.63, 62.55, 62.35, 52.38, 50.33, 50.24, 40.11, 28.29. 
HRMS-ESI: Calculated for [M+Na]+ (C61H83N15O21Na)+: m/z 1384.5780, found: m/z 
1384.5802. 
Compound Ld 
Compound 1i (87.5 mg, 0.1 mmol) was 
dispersed in 15 mL THF solvent. To this 
solution, DIEA (0.272 mL, 1.6 mmol), 
Copper (I) iodide (1.6 mg, 0.008 mmol) 
and compound 1o (276 mg, 1.2 mmol) 
were added in order. The mixture was 
stirred at 35 ºC for 2 days. After removal 
the solvent, the residue was dissolved in 
CH2Cl2 (5 mL). The product was further purified by preparative TLC plate(ethyl 






































1H NMR (500 MHz, CDCl3): δ 10.34 (s, 1H), 10.24 (s, 1H), 10.17 (s, 1H), 8.57 (s, 
1H), 8.49 (s, 1H), 8.47 (s, 1H), 8.03 (s, 1H), 7.87 (m, 3H), 7.66 (s, 1H), 7.48 (d, 2H, J 
= 6.6 Hz), 7.21 (s, 1H), 5.26 (m, 8H), 5.00 (b, 4H), 4.56 (s, 8H), 4.06 (s, 3H), 3.90 (m, 
20H), 3.50 (s, 8H), 3.27 (s, 8H), 1.40 (s, 36H). 13C NMR (126 MHz, CDCl3): δ 165.56, 
162.56, 161.27, 155.98, 155.29, 155.24, 154.33, 154.13, 145.03, 144.62, 143.56, 
143.46, 143.37, 143.26, 142.34, 141.56, 141.52, 133.67, 133.05, 132.74, 129.75, 
126.74, 126.67, 124.42, 124.17, 124.12, 123.79, 121.84, 115.65, 112.16, 111.88, 
111.74, 111.57, 111.52, 111.18, 79.35, 77.38, 77.13, 76.87, 70.34, 69.05, 68.98, 64.61, 
63.42, 63.36, 62.71, 62.58, 62.41, 62.35, 52.47, 50.39, 50.29, 40.19, 28.37. 




Compound 1j (107.7 mg, 0.1 mmol) was 
dispersed in 15 mL THF solvent. To this 
solution, DIEA (0.34 mL, 2.0 mmol), 
Copper (I) iodide (2 mg, 0.01 mmol) and 
compound 1o (345 mg, 1.5 mmol) were 
added in order. The mixture was stirred 
at 35 ºC for 2 days. After removal the 
solvent, the residue was dissolved in 
CH2Cl2 (5 mL). The product was further 
purified by preparative TLC plate(ethyl acetate). One kind of yellow oil Le was 
obtained. Yield: 138 mg, 62%. 1H NMR (500 MHz, CDCl3); δ 10.36 (s, 1H), 10.29 (s, 
1H), 10.10 (s, 1H), 10.00 (s, 1H), 8.60 (s, 1H), 8.52 (s, 3H), 8.06 (s, 1H), 7.89 (s, 3H), 
7.87 (s, 2H), 7.66 (s, 1H), 7.49 (s, 3H), 7.23 (s, 1H), 5.30 (s, 8H), 5.26 (s, 2H), 4.97 (b, 
5H), 4.57 (s, 10H), 4.08 (s, 3H), 3.98 (s, 5H), 3.93 (s, 3H), 3.91 – 3.74 (m, 16H), 3.52 
(s, 10H), 3.29 (s, 10H), 1.42 (s, 45H). 13C NMR (126 MHz, CDCl3): δ 165.29, 162.74, 



























143.52, 143.42, 143.35, 143.31, 142.34, 141.64, 141.51, 133.70, 133.04, 132.99, 
132.80, 129.74, 126.95, 126.82, 126.69, 124.38, 124.16, 123.65, 121.87, 115.71, 
114.06, 112.08, 111.83, 111.60, 111.37, 79.38, 70.37, 69.07, 68.99, 64.62, 63.45, 
63.30, 62.72, 62.49, 62.39, 53.46, 52.32, 50.31, 40.20, 28.38. HRMS-ESI: Calculated 
for [M+Na]+ (C101H137N25O33Na)+: m/z 2250.9703, found: m/z 2250.9707. 
 
Compound L1 
To the solution of La (mg, mmol) in CH2Cl2 
( mL), trifluoroacetic acid ( mL) was added. The 
mixture was stirred at room temperature for 
overnight. Then the solvents were removed in 
vacuo and the residue was recrystallized by ether 
to produce product L1 as yellow solid. Yeild: mg, 96 %.1H NMR (500 MHz, CDCl3): 
δ 8.14 (s, 2H), 7.89 (s, 1H), 7.59 (s, 1H), 7.52 (s, 1H), 5.16 (s, 2H), 4.56 (s, 2H), 3.91 
(s, 3H), 3.89 (s, 3H), 3.86 (s, 2H), 3.68 (s, 2H), 3.14 (s, 2H). 13C NMR (126 MHz, 
CDCl3): δ 164.65, 153.26, 147.00, 145.54, 128.11, 124.69, 122.05, 114.60, 69.11, 
66.66, 64.34, 62.50, 52.90, 50.13, 39.39. HRMS-ESI: Calculated for [M]+ 
(C16H22N5O7)+: m/z 396.1514, found: m/z 396.1522. 
 
Compound L2 
To the solution of Lb (mg, mmol) in CH2Cl2 
( mL), trifluoroacetic acid ( mL) was added. The 
mixture was stirred at room temperature for 
overnight. Then the solvents were removed in 
vacuo and the residue was recrystallized by ether 
to produce product L2 as yellow solid. Yeild: mg, 
96 %. 1H NMR (500 MHz, d4-MeOD): δ 8.40 (s, 1H), 8.19 (s, 2H), 7.91 (s, 1H), 7.73 






















3.89 (s, 3H), 3.72 (s, 4H), 3.14 (s, 4H). 13C NMR (126 MHz, d4-MeOD): δ 165.77, 
161.77, 154.19, 153.94, 144.89, 144.85, 144.03, 143.22, 142.54, 133.15, 129.88, 
125.08, 124.85, 124.10, 121.31, 114.62, 111.83, 111.44, 69.17, 66.47, 63.95, 62.14, 
62.08, 61.67, 51.80, 49.93, 39.12. HRMS-ESI: Calculated for [M+Na]+ 
(C31H40N10O11Na)+: m/z 751.2770, found: m/z 751.2754. 
 
Compound L3 
To the solution of Lc (mg, mmol) in 
CH2Cl2 ( mL), trifluoroacetic acid ( mL) 
was added. The mixture was stirred at 
room temperature for overnight. Then the 
solvents were removed in vacuo and the 
residue was recrystallized by ether to 
produce product L3 as yellow solid. Yeild: 
mg, 80 %. 1H NMR (500 MHz, d4-MeOD): δ 8.43 (s, 1H), 8.29 (s, 1H), 8.23 (s, 3H), 
7.86 (s, 1H), 7.76 (s, 1H), 7.43 (s, 1H), 7.22 (s, 1H), 5.32 (s, 2H), 5.24 (2, 2H), 5.23 (s, 
2H), 4.69 (s, 6H), 4.05 (s, 3H), 3.96 (s, 9H), 3.94 (s, 3H), 3.91 (s, 3H), 3.73 (s, 6H), 
3.16 (s, 6H). 13C NMR (126 MHz, d4-MeOD): δ 165.76, 162.83, 162.18, 154.75, 
154.10, 153.89, 144.81, 144.58, 143.80, 143.24, 142.57, 133.39, 132.62, 130.20, 
126.54, 125.12, 124.89, 123.95, 121.13, 114.35, 112.35, 111.51, 110.88, 69.12, 66.47, 
65.52, 63.79, 62.84, 62.12, 62.07, 61.54, 51.67, 49.89, 39.11. HRMS-ESI: Calculated 
for [M+Na]+ (C46H59N15O15Na)+: m/z 1084.4207, found: m/z 1084.4261. 
Compound L4 
To the solution of Ld (mg, mmol) in 
CH2Cl2 ( mL), trifluoroacetic acid ( mL) 
was added. The mixture was stirred at 
room temperature for overnight. Then the 
































residue was recrystallized by ether to produce product L4 as yellow solid. Yeild: mg, 
70 %. 1H NMR (500 MHz, d4-MeOD): δ 8.38 (s, 1H), 8.31 (s, 1H), 8.25 (m, 5H), 7.86 
(s, 1H), 7.71 (s, 1H), 7.37 (s, 1H), 7.35 (s, 1H), 7.16 (s, 1H), 5.30 (s, 2H), 5.21 (s, 6H), 
4.69 (s, 8H), 4.04 (s, 3H), 3.97 (s, 14H), 3.90 (s, 3H), 3.89 (d, 3H), 3.74 (s, 8H), 3.17 
(s, 8H). 13C NMR (126 MHz, d4-MeOD): δ 165.63, 162.86, 162.68, 161.99, 154.84, 
154.15, 153.90, 144.79, 144.45, 143.68, 143.18, 142.57, 142.27, 141.97, 133.38, 
132.95, 132.62, 130.10, 126.53, 126.34, 125.15, 124.92, 123.74, 121.28, 114.49, 
112.18, 111.61, 111.41, 110.88, 110.43, 69.11, 65.49, 63.82, 63.08, 62.11, 61.56, 
51.66, 49.87, 39.09. HRMS-ESI: Calculated for [M+Na]+ (C61H78N20O19Na)+: m/z 
1417.5644, found: m/z 1417.5647.  
 
Compound L5 
To the solution of Le (mg, mmol) in 
CH2Cl2 (mL), trifluoroacetic acid ( mL) 
was added. The mixture was stirred at 
room temperature for overnight. Then the 
solvents were removed in vacuo and the 
residue was recrystallized by ether to 
produce product L5 as yellow solid. Yeild: 
mg, 62 %. 1H NMR (500 MHz, d4-MeOD): 
δ 8.37 (s, 1H), 8.31 (s, 2H), 8.24 (s, 6H), 
7.88 (s, 1H), 7.70 (s, 1H), 7.37 (m, 3H), 7.17 (s, 1H), 5.30-5.21 (m, 10H), 4.68 (s, 
10H), 4.09 – 3.90 (m, 22H), 3.84 – 3.67 (m, 16H), 3.17 (s, 10H). 13C NMR (126 MHz, 
d4-MeOD): δ 165.35, 163.08, 162.79, 162.06, 154.85, 154.16, 153.90, 144.85, 144.43, 
143.81, 143.19, 142.54, 142.35, 142.05, 133.35, 132.89, 132.57, 130.21, 126.79, 
126.62, 126.46, 125.12, 124.93, 123.73, 121.31, 114.48, 112.29, 111.88, 111.54, 
110.94, 110.56, 69.12, 66.47, 63.92, 63.06, 62.98, 62.91, 62.09, 62.05, 61.56, 51.56, 
49.87, 39.10. HRMS-ESI: Calculated for [M]2+ (C76H99N25O23)2+: m/z 864.8667, 
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